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ABSTRACT 
Estrogen-containing hormone therapy (HT) is approved for treatment of 
symptoms associated with menopause by the Food and Drug Administration. A common 
estrogen used in HT is 17β-estradiol (E2). Rodent models of menopause, and some 
clinical work as well, suggest a cognitively-beneficial role of E2. However, as of the 
2017 statement released by the North American Menopause Society, HT is not currently 
advised for use as cognitive therapy in healthy, menopausal women, given that the data 
so far from existing clinical studies are not yet definitive. Indeed, the delivery of E2 
treatment can be optimized to yield more consistent results on cognitive function, 
particularly considering that exogenously administered E2 gets rapidly metabolized and 
cleared from the body. Further, E2-containing HT must include a progestogen if 
prescribed to women with a uterus to oppose its undesired uterine stimulating effects, 
such as increased endometrial hyperplasia and cancer risks. Studies have shown that the 
addition of a progestogen to E2 treatment can attenuate the effects of E2 on cognition and 
brain variables associated with cognitive function. Thus, a brain-specific delivery 
platform of E2 treatment that would minimize the hormone’s effects in the periphery 
while maintaining the beneficial cognitive effects is desirable. To achieve this goal, my 
dissertation work bridged two distinct scientific fields – behavioral neuroendocrinology 
and polymeric drug delivery – with the overarching aim of targeting the delivery of E2 to 
the brain to achieve maximal cognitively-beneficial effects with minimal undesired 
uterine stimulation. This aim was addressed via three distinct delivery strategies: 1) 
combining E2 with a cognitively-beneficial progestogen, 2) encapsulating E2 in 
polymeric nanoparticles, and 3) solubilizing E2 using cyclodextrins for intranasal 
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administration. Findings revealed that although all E2-containing treatments increased 
uterine horn weights, a marker of uterine stimulation, in middle-aged ovariectomized rats, 
some E2 treatment formulations yielded memory improvements, others were neutral in 
their effects on memory, and some impaired memory. Together, data from this 
dissertation set the stage for targeted E2 delivery research to optimize the cognitive 
therapeutic effects of E2 in the context of menopause while minimizing peripheral 
burden, leading to translationally relevant clinical implications for women’s health. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
This chapter was submitted, and has undergone peer-review, as a chapter for the book 
entitled “Estrogens and Memory: Basic Research and Clinical Implications” for Oxford 
University Press, in May, 2018 titled: 
Ovarian hormones, cognition, and reproductive aging: applications and 
implications for translating preclinical endocrine brain research to the clinic 
A.V. Prakapenka, V.L. Peña, H.A. Bimonte-Nelson 
 
Contribution: I was the first author for the submitted book chapter, and the two co-
authors were Veronica L. Peña and Heather A. Bimonte-Nelson. I played a heavy role 
both in the writing as well as the editing stages of this chapter. Sections of the chapter 
were edited to fit the context of this dissertation. 
 
Introduction 
Hormones matter. In the last two decades, there has been an increasing number of 
studies addressing the impact of sex hormones on behaviors other than those related to 
reproduction. Indeed, the field of behavioral endocrinology has clearly demonstrated that 
hormones impact more than sex behaviors. Sex steroids such as estrogens, progesterone, 
and androgens have extensive and powerful effects on the body and exert both permanent 
and transient effects on innumerable systems, including the central nervous system. 
Animal scientific studies from the mid-20th century showing that sex steroids play an 
integral role in development and regulation of the brain and behavior (e.g. Beach and 
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Holz-Tucker, 1948; Phoenix et al., 1959; Davis et al., 1979) set the stage for detailed 
evaluation of the wide-reaching effects of sex steroid hormones on a multitude of systems 
and functions. Scientists have built upon this classic framework using clever, creative, 
and innovative approaches and tools to systematically investigate independent and 
interactive brain-behavioral effects of sex steroids (Bimonte, Mack, Stavnezer, & 
Denenberg, 2000; Fitch, Cowell, Schrott, & Denenberg, 1991; Williams, Barnett, & 
Meck, 1990). Researchers studying hormone effects on the brain and its functions have 
utilized animal models to methodically assess and control for biological and behavioral 
functions that are difficult to directly evaluate in human research studies. Systematic 
experiments in animal models have provided critical information regarding hormone-
brain-behavior interactions. This interdisciplinary, systems work has spanned molecular 
to behavioral foci, with knowledge increasing in breadth and depth with every passing 
year.  
Growing evidence now shows that there is an impressive array of cognitive 
behaviors and neurobiological mechanisms impacted by sex steroids, and this 
information has important real-world, translational applications and implications. For 
example, it is now well established that both males and females undergo endocrine 
changes as they age. In women, the 40’s are a critical time in which age-related endocrine 
changes begin, as this period is marked by perimenopause-related irregular fluctuations 
of ovarian hormones and a transition to the postmenopause-related hormone nadir. These 
mid-life menopause-related changes coalesce with symptoms that can be broad and 
multi-system related, which greatly impacts health and quality of life. Women often opt 
to take hormone therapy to combat menopause-associated symptoms such as hot flashes, 
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osteoporosis, vaginal dryness, sleep disturbances, and changes in mood and cognition 
(NAMS, 2014). Thus, a considerable focus of behavioral endocrinology research has 
been to address questions related to hormone therapy, such as whether to take hormone 
therapy, and if so, what doses should be taken and when, and whether estrogen should be 
taken alone or with a progestogen. The more information researchers glean regarding the 
wide-reaching effects of menopause and hormone therapy on cognition, the more 
researchers have recognized that there is so much more to learn. It can be argued that 
every animal and human study involving ovarian hormone loss and hormone therapy has 
resulted in more questions, and has taught scientists that they must respect, value, and 
embrace the massive and diverse impact that sex hormones have on the brain and its 
functioning. Specifically, estrogens are thought to play a large role in hippocampal-
dependent memory, and this role is impacted by multiple factors, including age at 
treatment initiation, treatment duration, type of hormone, dose of hormone, route of 
administration, and period of time between the loss of circulating ovarian hormones and 
hormone treatment initiation. This chapter aims to summarize key discoveries in the field 
of translational behavioral endocrinology, focusing on work using animal models to 
understand menopause and estrogen-including hormone therapies, and intends to provide 
vital background for developing delivery strategies to optimize estrogen’s role on 
cognitive function while minimizing estrogen’s peripheral burden.  
 
Estrogens 
In mammals, all naturally occurring steroid hormones are derived from the parent 
molecule, cholesterol. Estrogens are a class of steroid hormones that include 
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endogenously occurring hormones such as estrone (E1), 17β-estradiol (E2), and estriol 
(E3), their hydroxylated metabolites (e.g., 2-methoxyestradiol) and glucuronide and 
sulfate conjugates (e.g., estrone sulfate), and synthetic estrogens (e.g., ethinyl estradiol) 
(Kuhl, 2005; Lobo, 2007; Mattison, Karyakina, Goodman, & LaKind, 2014). Throughout 
this chapter, E2 will always refer to 17β-estradiol if specified within the cited paper, 
otherwise the estrogen will be referred to using the term provided in the cited paper. 
Table 1 summarizes the current U.S. Food and Drug Administration (FDA) approved 
estrogens for menopausal hormone therapy, along with their corresponding brand name 
and route of administration (U.S. FDA’s Office of Women’s Health, 2015). As seen in 
the table, the most common routes of administration for FDA-approved menopausal 
estrogen-based hormone therapy are oral (pill), transdermal (gel, spray, and patch), and 
local vaginal administration (vaginal ring, cream, and tablet). When assessing total 
circulating estrogen concentrations, using E2 as an example, there is typically only ~1-
2% of free E2 available for activity at target tissue sites (D. C. Anderson, 1974; Kuhl, 
2005). The rest of the total circulating E2 is bound to either sex hormone binding 
globulin or to albumin, decreasing the hormone’s bioavailability (Lobo, 2007). Local 
application of estrogens via the vaginal route is considered to have little to no systemic 
effects, minimizing undesired estrogen exposure to peripheral organs as compared to 
alternate routes; however, following vaginal administration, there is evidence that 
estrogens can indeed enter systemic circulation (Labrie et al., 2009). For instance, E2 
blood serum levels, measured via mass spectrometry assays 24 hours after one week of 
daily vaginal cream application (25 μg Vagifem or 1 g Premarin), were elevated by about 
5-fold during the 24 hours following administration (Labrie et al., 2009). These data, 
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showing an increase from 3 pg/ml to 17 pg/ml in E2 concentration, demonstrate that local 
vaginal administration can increase systemic E2 (Labrie et al., 2009). Typical E2 
circulating levels for a postmenopausal woman are < 20 pg/ml (Kuhl, 2005). Thus, these 
findings raise the question of whether the observed increase in E2 concentration 
following local administration is enough to produce undesired systemic side effects. Both 
oral and transdermal routes of administration produce levels of serum E2 that are over 20 
pg/ml, which is higher than the levels found in postmenopausal women (Kuhl, 2005). The 
oral route of administration achieves a cyclic pattern of circulating E2 levels in women, 
as it is typically administered on a daily basis, and the transdermal route of 
administration produces more tonic circulating levels of E2 in women, as the hormone 
slowly enters circulation through absorption throughout the day for several days. With 
oral administration, E2 is immediately susceptible to first-pass metabolism, whereby E2 
undergoes intestinal and hepatic conversion into estrogen metabolites and conjugates that 
are less potent compared to E2. E2 and the estrogen metabolites and conjugates then 
either enter the bile pool for enterohepatic circulation or enter the bloodstream (Kuhl, 
2005; Ruoff & Dziuk, 1994). The transdermal route of administration circumvents first-
pass metabolism of E2. With transdermal administration, E2 diffuses through the skin 
layers (stratum corneum, epidermis, and dermis) and then enters the bloodstream (Kuhl, 
2005). Due to individual differences in metabolism (for oral) and rate of absorption (for 
transdermal), there are large inter- and intra- patient differences in circulating E2 
concentrations and therapeutic effects of E2-based hormone therapy for menopause 
(Kuhl, 2005; Kuhnz, Gansau, & Mahler, 1993; Lobo, 2007). Additionally, high doses of 
E2, as high as ~1-2 mg E2/day for oral delivery and ~2-10 mg E2 for a four-day 
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transdermal patch (reportedly achieving ~50 μg circulating E2/day concentration), are 
required to overcome the barriers of oral and transdermal delivery and achieve desired 
therapeutic effects (Kuhl, 2005; Lees & Stevenson, 2001; Reginster et al., 1997). Thus, 
the route of administration can heavily dictate systemic circulation and activity of E2, and 
therefore, the hormone’s potential for therapeutic effects. 
Additionally, estrogens vary in efficacy as well as potency, as measured by each 
hormone’s binding affinity to estrogen receptor α and estrogen receptor β. These two 
estrogen receptors are nuclear receptors that vary greatly in individual distribution and 
expression throughout the body (Kuhl, 2005; Kuiper et al., 1997). Among the naturally 
occurring estrogens, E2 has the strongest affinity to both estrogen receptors α and β, 
followed by E1 and then E3 (Kuhl, 2005; Kuiper et al., 1997). Some synthetic estrogens 
have markedly stronger affinity to the estrogen receptors than E2, such as ethinyl 
estradiol, which has a relative binding affinity of 190% to estrogen receptors compared to 
the 100% relative binding affinity of E2 (Blair et al., 2000). Estrogens that are derived 
from the urine of pregnant mares, called conjugated equine estrogens (CEE), are the 
estrogens present in Premarin (PREgnant MARe urINe), used primarily for menopausal 
hormone therapy (Lobo, 2007). CEE includes at least 10 different known estrogens, with 
the highest content as estrone sulfate (50%) and equilin sulfate (20-25%), and to a lesser 
amount the sulfate esters of 17α-estradiol, 17β-dihydroequilin, 17α-dihydroequilin, 
equilenin, 17β-dihydroequilenin, 17α-dihydroequilenin, Δ8,9-dehydroestrone, and E2 
(Bhavnani, 2003; Bhavnani & Stanczyk, 2014; Kuhl, 2005; Lobo, 2007). Studies suggest 
that the relative binding affinity of each estrogen component in CEE to estrogen receptors 
in order from highest to lowest is: 17β-dihydroequilin, E2, 17β-dihydroequilenin, 17α-
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dihydroequilin, E1, 17α-dihydroequilenin, 17α-estradiol, Δ8,9-dehydroestrone, equilenin, 
and equilin (Bhavnani, 2003; Lobo, 2007). Since all of the known estrogens in CEE are 
derived from equine sources, the majority of these estrogens are not naturally endogenous 
to women. Indeed, of the estrogens present in CEE, only E1 sulfate, E2 sulfate, and 17α-
estradiol sulfate are endogenous to women (Kuhl, 2005; Lobo, 2007). Because estrogen 
receptors are found widely throughout the body and the brain, including brain areas 
important for cognition, such as the hippocampus, basal forebrain, and the cortex (Eyster, 
2016; Kuhl, 2005; Mitra et al., 2003; Pérez, Chen, & Mufson, 2003), different clinically-
prescribed estrogens may have distinct effects on various systems and their functions; the 
scope of this understanding includes not only reproductive domains, but also cognition 
and other aspects of brain functioning.  This knowledge can aid in developing targeted 
estrogen-based formulations for the treatment of symptoms associated with menopause, 
and is important when considering other estrogen-containing prescriptions such as 
hormone-based contraceptives.    
 
Female reproductive aging: Hormonal changes across lifespan  
The hypothalamic-pituitary-gonadal (HPG) axis refers to the interplay between 
the hypothalamus, the pituitary, and the gonads to aid in development as well as 
regulation of multiple systems in the body, including the reproductive system. Increases 
in specific hormones released from each of these structures sends feedback information to 
each other to either increase (positive feedback) or decrease (negative feedback) the 
production and release of other hormones, as nicely evidenced in the role of the HPG in 
the reproductive cycle. Prior to discussing the effects of estrogens on spatial memory in 
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rodent models of menopause, it is important to understand the reproductive hormone 
changes across the lifespan of women and female rodents. Although the majority of 
observed changes in the hormonal milieu across a normal reproductive cycle in women 
and female rodents are similar (Figure 1), there are distinct species differences in the way 
the cycles change with age that must be considered when interpreting results related to 
reproductive senescence and estrogen-based hormone therapy in rodent models of 
reproductive aging. In this section, the changes in HPG axis signaling across a 
reproductive cycle and with aging in both humans and rodents are addressed. 
 
Women: Menstrual cycle 
The reproductive cycle in women is termed the menstrual cycle and lasts about 28 
days. The average age of menarche, defined as the first menstruation or shedding of the 
uterine lining, for women in the U.S. is 12.8 years, which marks her first complete 
menstrual cycle (Kronenberg et al., 2008). Throughout the duration of the menstrual 
cycle, changes in circulating levels of ovarian hormones occur that reflect the maturation 
and release of an egg from the ovaries, as well as preparation of the uterus for 
fertilization. In the ovaries, immature eggs are contained within ovarian follicles. At the 
start of the menstrual cycle, during the follicular phase, gonadotropin releasing hormone 
(GnRH) is synthesized and released from the hypothalamus, which signals the anterior 
pituitary gland to produce and release follicle stimulating hormone (FSH). FSH 
stimulates growth of ovarian follicles, resulting in maturation of the egg contained within 
a dominant follicle, as well as increased proliferation of granulosa cells. As the egg 
matures, these granulosa cells start releasing estrogens in gradually increasing amounts 
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until a threshold is reached. Increasing estrogen levels prepare the uterus for pregnancy 
by stimulating growth of the endometrial lining. Additionally, androgen-producing theca 
cells surround the developing follicle and granulosa cells, and contribute to the estrogen 
surge by aromatizing androgens to estrogens (Magoffin, 2005). Once the estrogen 
threshold is reached, positive feedback mechanisms signal GnRH from the hypothalamus 
to initiate a burst release of luteinizing hormone (LH) from the anterior pituitary gland, 
and the consequent induction of ovulation (ovulatory phase). Typically, one egg is 
released from one mature follicle within one menstrual cycle. After ovulation, the 
menstrual cycle enters the luteal phase, where a corpus luteum is formed from the follicle 
of the just-released egg. The corpus luteum releases progesterone, and to a lesser extent 
estrogens, to prime the uterus for fertilization. If the egg becomes fertilized, then the 
outer part of the zygote starts developing into the placenta and the inner part of the zygote 
starts developing into the fetus; the placenta produces progesterone in addition to 
multiple other hormones, peptides, and growth factors to aid in fetal development 
(Kronenberg et al., 2008). If the egg is not fertilized, then the negative feedback from 
increasing levels of progesterone and estrogen results in a decline in GnRH, LH, and FSH 
levels, in turn resulting in atrophy of the corpus luteum. As the corpus luteum 
degenerates, it becomes the non-hormone producing corpus albicans, leading to a 
decrease in progesterone and estrogen levels. The uterine lining is then shed via 
menstruation (menstrual phase). Negative feedback from low levels of progesterone and 
estrogen to the hypothalamus and anterior pituitary re-starts the cycle, yielding increasing 
levels of GnRH released from the hypothalamus and increasing levels of FSH released 
from the anterior pituitary.  
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Rodent: Estrous cycle 
The reproductive cycle of the female rodent, the estrous cycle, is similar to that of 
a woman’s menstrual cycle in many ways, although it is much shorter, lasting only 4-5 
days in standard laboratory rats and mice (Freeman, 2006; Haim, Shakhar, Rossene, 
Taylor, & Ben-Eliyahu, 2003). Comparable to the follicular, ovulatory, luteal, and 
menstrual phases of the menstrual cycle, there are four phases in the estrous cycle that 
signify ovarian follicle maturation and, thus, changes in circulating hormone levels: 
diestrus, proestrus, estrus, metestrus (Goldman, Murr, & Cooper, 2007; Koebele & 
Bimonte-Nelson, 2016; S. E. Mennenga & Bimonte-Nelson, 2015; Westwood, 2008). For 
ease of discussion here, the diestrus phase will be considered as marking the start of the 
estrous cycle. During diestrus, GnRH is released from the hypothalamus, signaling FSH 
release from the anterior pituitary gland to subsequently stimulate ovarian follicle growth 
(Freeman, 2006). As the eggs mature within the growing follicles, granulosa cells 
proliferate and release estrogens, which start preparing the uterine horns for pregnancy. 
The theca cell layer forms around the developing follicles and proliferating granulosa 
cells, releasing androgens that can then get metabolized into estrogens. Next, the animal 
enters the proestrus phase, where a high estrogen level threshold is reached and GnRH 
induces a burst release of LH from the anterior pituitary gland, prompting ovulation 
(Freeman, 2006; Haim et al., 2003). In the proestrus phase, development of the 
endometrial lining within the uterine horns progresses in preparation for fertilization. The 
proestrus phase is typically a short phase, lasting less than 24 hours. To produce litters of, 
on average, 8 pups in mice and 13 pups in rats, multiple eggs are released from mature 
follicles in one cycle (e.g.; Pritchett-Corning et al., 2009). The completion of ovulation 
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starts the estrus phase, which is marked by comparatively high, but decreasing, estrogen 
levels. The final phase, metestrus, is characterized by high progesterone and low estrogen 
levels released from the corpora lutea formed from the remaining follicles of the just-
released eggs (Freeman, 2006). If the eggs are fertilized, then placentas will form and 
continue to produce progesterone as the zygotes develop. If the eggs are not fertilized, 
then the increasing levels of progesterone and estrogen will lead to negative feedback to 
the anterior pituitary and hypothalamus, triggering a decline in GnRH as well as LH and 
FSH levels, along with atrophy of the corpora lutea. As the estrous cycle starts over, the 
corpora lutea degenerates into corpora albicans and the uterine lining is reabsorbed, 
rather than shed as in women. Subsequent low levels of progesterone and estrogens will 
negatively feed back to the anterior pituitary and the hypothalamus, and the estrous cycle 
will start again with the release of increasing GnRH and FSH levels from the 
hypothalamus and anterior pituitary, respectively. Unlike in women, it is possible for 
female rodents to enter a state of pseudopregnancy after receiving sufficient vaginal 
stimulation. A pseudopregnant rodent will not have fertilized eggs, but the presence of 
the corpora lutea will be prolonged due to prolactin release from the pituitary, resulting in 
sustained levels of high progesterone and low estrogens (Stocco, Telleria, & Gibori, 
2007; Westwood, 2008). 
 
Women: Menopause 
 The transition to menopause, the point at which menstruation ceases, begins as 
early as 40 years of age. Women will typically complete the transition to menopause at an 
average age of 52 years (NAMS, 2012, 2014). The transition period to menopause is 
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often referred to as the perimenopausal state. This transition period varies greatly 
between women, but it may last up to 10 years and is associated with irregular menstrual 
cycles as well as significant fluctuations in circulating ovarian hormone levels and 
accelerated follicular depletion (Burger, Hale, Dennerstein, & Robertson, 2008; Harlow 
& Paramsothy, 2011; Richardson & Nelson, 1990). Menopause is primarily driven by 
follicular depletion, which can alter normal functioning of the HPG axis (NAMS, 2014). 
At menopause, the ovarian follicle reserve is depleted, resulting in cessation of the 
menstrual cycle; menopause is consequently characterized by a marked decrease in the 
production and release of circulating ovarian hormones, including estrogens and 
progesterone (NAMS, 2014). Menopause is confirmed retrospectively after one year 
without menses (NAMS, 2014). The predominant circulating ovarian-derived hormones 
after menopause are androgens, and the predominant circulating estrogen is estrone, 
much of which is released from the adrenal cortex (Lobo, 2007; Vermeulen, 1976). 
Circulating levels of LH and FSH increase in response to the disrupted feedback from the 
hypothalamus and the anterior pituitary following low levels of estrogens and 
progesterone.   
 
Rodent: Estropause  
 Age-related reproductive senescence in the female rodent is termed estropause. 
Whereas the onset of menopause is mainly dictated by a decrease in follicle reserve, 
estropause is primarily governed by intrinsic alterations in the HPG axis (S. E. Mennenga 
& Bimonte-Nelson, 2015; Wise, 1982). An assessment of circulating hormone profiles of 
estradiol, progesterone, LH, and FSH, and of the median eminence profile of luteinizing 
  
13 
hormone releasing hormone (LHRH), in proestrus middle-aged rats compared to 
proestrus young rats, showed that before the pre-ovulatory LH surge, young and middle-
aged rats had similar hormone profiles (Wise, 1982). However, middle-aged rats had 
lower LHRH, estradiol, and progesterone levels prior to ovulation relative to young rats, 
and the LH surge in middle-aged rats was temporally delayed compared to that of young 
rats (Wise, 1982). These data suggest that as aging ensues in the rat, the function and 
responsiveness of the HPG axis slows down or is otherwise disrupted, altering 
communication with the ovary.  
 A female rodent in estropause is chronically anovulatory and exhibits either 
moderate circulating estrogen levels and low progesterone levels reflective of a persistent 
estrus phase, or low estrogen and high progesterone circulating levels reflective of a 
repetitive pseudopregnancy state (S. E. Mennenga & Bimonte-Nelson, 2015; Westwood, 
2008). Eventually, many female rodents enter a state of anestrus which is marked by low 
circulating levels of estrogens and progesterone (S. E. Mennenga & Bimonte-Nelson, 
2015; Westwood, 2008). Of note, the terms anestrus and persistent diestrus are often used 
interchangeably in the literature; in this chapter, this phase will be referred to as anestrus. 
A longitudinal study evaluating reproductive senescence in female rats as they progressed 
from young adulthood (4 months old) to aged (18-22 months old) revealed a trend of 
irregular cycles during the transition between normal to senescent reproductive states, 
with rats entering either persistent estrus followed by irregular cycles and sometimes 
anestrus, or entering immediately into anestrus (LeFevre & McClintock, 1988). LH and 
FSH levels during estropause can differ depending on whether an animal is in persistent 
estrus, repetitive pseudopregnancy, or an anestrus state (Huang, Steger, Bruni, & Meites, 
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1978). For example, aged rats in the persistent estrus state have higher FSH levels than 
aged rats in either anestrus or repetitive pseudopregnancy states, and higher FSH levels 
than young proestrus and estrus rats (Huang et al., 1978). FSH levels in anestrus and 
repetitive pseudopregnant aged rats are lower than those of young rats in proestrus or 
estrus cycle phases (Huang et al., 1978). LH levels are similar between aged rats in 
persistent estrus and young rats in proestrus or estrus (Huang et al., 1978). LH levels are 
also similar between aged rats in repetitive pseudopregnancy and young rats in diestrus 
(Huang et al., 1978). Interestingly, in mice, both LH and FSH levels are reportedly higher 
in aged mice compared to young normally cycling C57BL/6 mice (Parkening, Collins, & 
Smith, 1980).   
 
Animal models of menopause  
Animal models of menopause have been used for decades in preclinical 
experiments to study the endocrine system and changes thereof. Despite the reproductive 
senescence differences mentioned above between rodents and humans, animal models 
have provided tremendous insight into hormone-brain-behavior interactions. In the 
rodent, much like in the human, the endocrine system contains a vast and complex milieu 
of hormone interactions whose tight regulation provides a homeostatic environment. As 
discussed above, the circulating ovarian hormone profile differs between reproductively 
senescent women and female rodents. In a menopausal woman, there is a marked 
decrease in circulating ovarian hormone levels of estrogens and progesterone, and 
androgens become the predominant circulating ovarian hormones; in an estropausal 
rodent, most animals exhibit either consistently moderate levels of estrogens with low 
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levels of progesterone, or low levels of estrogens with high levels of progesterone. Due to 
these distinct differences, several types of rodent menopause models have been 
developed to mimic the trajectory and hormone profile of menopause as closely as 
possible (Figure 2). These models allow for systematic preclinical evaluations of 
menopause and menopausal hormone therapies on normal system functions, including, 
but not limited to, brain functions such as cognition. It should be noted, however, that no 
model of menopause in rodents is flawless, and indeed no animal model can be truly 
perfect. Each model discussed herein provides certain advantages, alongside some 
drawbacks, for experimental designs aimed at understanding how the ever-changing 
ovarian hormone profile across a female’s reproductive lifespan impacts cognitive 
function.  
 
Ovary intact 
 The ovary intact rodent model is useful in studying and understanding the impact 
of hormone fluctuations across the normal reproductive cycle on the brain and its 
functions (Stackman et al., 1997; Quinlan et al., 2010; Woolley and McEwen, 1992; 
Spencer et al., 2010; Warren et al., 1995). For instance, the classic study by Woolley and 
McEwen (1992) showed that rats in proestrus, the estrous phase with the highest E2 
levels, exhibited an increased density of synapses on dendritic spines in the hippocampal 
CA1 region compared to rats in estrus, the estrous phase in which E2 levels are lower. 
Long-term potentiation, the leading molecular model of memory formation, is enhanced 
during proestrus relative to estrus in rats (Warren, Humphreys, Juraska, & Greenough, 
1995). Of note, however, there are important caveats to investigating how circulating 
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ovarian hormones alter the brain and its functions in ovary intact rodents. Although this 
model allows changes across the estrous cycle to be observed, such as alterations in 
hippocampal microstructure and function, the fluctuations in numerous ovarian hormones 
across the cycle make it difficult to decipher the specific hormone responsible for a given 
effect. Moreover, exogenously administering hormones to a gonadally-intact animal in 
which hormones are actively cycling can dysregulate the naturally functioning endocrine 
system, further complicating the interpretation of which particular hormone/s modulate or 
drive an observed effect. However, there are creative ways to get around these 
limitations. For example, in a series of studies, Woolley and McEwen combined estrous 
cycle data with add-back exogenous administration in the ovariectomy (Ovx) rodent 
model to parse the contributions of E2 and progesterone. In the Ovx model, discussed in 
detail below, the main source of circulating ovarian hormones – the ovaries – are 
surgically removed. Specific hormone/s of interest can be added back to this ‘blank’ 
circulating gonadal hormone milieu to examine their direct effects. It is important to keep 
in mind that even with Ovx, ovarian hormones (e.g., progesterone and E2) can still be 
produced in other tissues such as the brain (Micevych and Sinchak, 2008; Kretz et al., 
2004, Tuscher et al., 2016). Nevertheless, the Ovx model is an effective method to 
investigate hormone effects on learning and memory specific to a circulating ovarian 
hormone milieu of interest. In this manner, Woolley and McEwen were able to show that 
following the loss of circulating ovarian hormones, spine density in the hippocampal 
CA1 region gradually decreased after Ovx (C S Woolley & McEwen, 1993). Acute 
exogenous administration of an estrogen, estradiol benzoate, 3 days after Ovx 
temporarily increased spine density in the hippocampal CA1 region compared to Ovx 
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controls, peaking at 2-3 days following injection (C S Woolley & McEwen, 1993). 
However, acute exogenous administration of progesterone following estradiol 
administration produced a transient increase in spine density in the hippocampal CA1 
region during the first 6 hours, followed by a sharp decline, as compared to estradiol 
alone (C S Woolley & McEwen, 1993). Further, blocking progesterone receptors during 
proestrus in ovary-intact rats attenuated the spine density loss seen from proestrus to 
estrus (Woolley and McEwen, 1993). These results indicate that progesterone is critical 
for the natural recession of E2-induced spine growth. Thus, these scientists more 
specifically isolated the contributions of estradiol and progesterone by using the ovary 
intact rodent model to uncover structural changes in the hippocampus across the estrous 
cycle, and cleverly assimilated this novel information with the Ovx model to determine 
how each hormone drives these effects.   
Ovary intact middle-aged or aged rodents are not often used to model the 
neurobehavioral effects of estrogen-based hormone therapy in menopause because 
estropause is driven by HPG axis dysregulation, whereas menopause is driven by the 
depletion of ovarian follicle supplies. The dissimilar circulating ovarian hormone profiles 
in estropause and menopause must be acknowledged and accounted for when using an 
ovary intact model to address questions regarding the effects of hormone therapies at 
reproductive senescence. However, of note, ovary intact middle-aged and aged rodents do 
provide an important model of HPG axis dysregulation, which can be used to gain 
insights into how changes in HPG axis function impact systemic functions, including 
cognition. Indeed, numerous scientists have effectively used ovary-intact aging rodents as 
a model, and have dedicated their life’s work to understanding the mechanisms driving 
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menopause, such as the role of HPG axis function (Downs & Wise, 2009; Kermath & 
Gore, 2012; Morrison, Brinton, Schmidt, & Gore, 2006; Wise, 1982). 
 
Bilateral ovariectomy (Ovx)  
Ovx is the classic technique in rodents used to observe effects of ovarian hormone 
loss. Ovaries in rodents, much like in humans, are bilaterally located in the peritoneal 
cavity. In rodents, one ovary is connected to each end of a bifurcated uterine horn, which 
acts as the uterus (Figure 2). During bilateral Ovx, the ovaries, oviducts (which are akin 
to the fallopian tubes in women), and uppermost tips of the uterine horns are ligated and 
excised (Hiroi et al., 2016; Koebele & Bimonte-Nelson, 2016; M. E. Olson & Bruce, 
1986). With the removal of the ovaries, there is an abrupt cessation of the estrous cycle 
and a drop in endogenous circulating ovarian hormones (e.g. estrogens, progesterone, and 
androgens), creating a ‘blank’ circulating hormonal slate, although some ovarian 
hormones can still be produced in other tissues (e.g., the brain), to which hormones of 
interest can exogenously be added back to systematically assess the effects of factors 
such as dose, route, and/or duration of treatment administration on various system 
functions. This model has allowed for tremendous discovery in the field of behavioral 
neuroendocrinology because bilateral Ovx not only produces a drastic decrease in 
circulating ovarian hormone levels, but also an increase in FSH and LH levels similar to 
those seen in menopausal women after surgical removal of ovaries (oophorectomy). By 
the age of 60, more than one third of women in the U.S. undergo hysterectomy surgery, 
which is the removal of the uterus; an estimated 600,000 women in the U.S. undergo 
hysterectomy surgeries each year, half of which are accompanied by oophorectomy 
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(Whiteman et al., 2008). Oophorectomy and hysterectomy often occur together, a trend 
that has increased over time (Lowder et al., 2010). Typically, women undergo 
oophorectomy to combat ovary-related abnormalities such as onset of ovarian cancer 
(Asante et al., 2010; Erekson, Martin, & Ratner, 2013), reduction of the risk for breast 
cancer development (J. E. Olson, Sellers, Iturria, & Hartmann, 2004), and treatment for 
symptoms occurring with severe premenstrual syndrome (Cronje, Vashisht, & Studd, 
2004). As such, bilateral Ovx is considered a fitting technique for modeling surgical 
menopause, as it removes the main source of endogenous ovarian hormones in a manner 
similar to oophorectomy. Thus, Ovx provides an excellent model for methodically 
examining the effects of both surgical menopause and effects of specific hormone therapy 
regimens on cognition. 
A major benefit of the Ovx model is that it allows researchers to delve into 
questions regarding the window of opportunity theory for efficacy of menopausal 
hormone therapies. The window of opportunity theory posits that there is a critical period 
after ovarian hormone loss in which hormone therapy can have the most beneficial 
therapeutic effect on the brain and cognition (Linda A Bean et al., 2015; J. M. Daniel, 
Witty, & Rodgers, 2015; Maki, 2013; W. A. Rocca, Grossardt, & Shuster, 2011; M. 
Singh, Simpkins, Bimonte-Nelson, & Brinton, 2013). Evidence in support of this theory 
comes from studies showing that if initiation of hormone therapy is delayed well after the 
onset of menopause in women or Ovx in rats, then the beneficial effects of estrogen 
treatments on cognition in both humans (Rocca et al., 2010, 2011) and rats (Jill M. 
Daniel, Hulst, & Berbling, 2006; R. B. Gibbs, 2000) are attenuated. In one such study, 
middle-aged Ovx rats received tonic subcutaneous E2 treatment immediately following 
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Ovx surgery, or 5 months after Ovx surgery (Daniel et al., 2006). Findings from this 
study revealed that E2 treatment immediately following Ovx resulted in better spatial 
working memory compared to vehicle controls, whereas E2 treatment initiated 5 months 
following Ovx yielded no difference in spatial working memory compared to vehicle 
controls (Jill M. Daniel et al., 2006). Another study showed that rats receiving acute E2 
treatment after prolonged hormone deprivation following Ovx (~10 weeks) exhibited 
decreased apical spine density in the CA1 region of the hippocampus compared to rats 
receiving exogenous intermittent E2 treatment beginning about a week after Ovx 
(McLaughlin, Bimonte-Nelson, Neisewander, & Conrad, 2008). Of note, both of these E2 
treatment regimens increased apical spine density in the CA1 region of the hippocampus 
relative to vehicle control (McLaughlin et al., 2008). Collectively, these findings suggest 
that there is diminished sensitivity of hippocampal morphology and mnemonic efficacy 
to E2 treatment following delayed onset of estrogen treatment. The Gibbs laboratory 
further elaborated on the critical window of opportunity theory by proposing a 
cholinergic basis for the theory. Their behavior findings were consistent, demonstrating 
that while E2 replacement directly after, or 3 months after, Ovx improved spatial working 
memory in middle-aged rats, E2 replacement 10 months after Ovx did not show 
improvements in spatial working memory (R. B. Gibbs, 2000). Moreover, findings from 
several studies showed a detrimental impact of Ovx on cholinergic neurons of the basal 
forebrain in rats, and a decrease in E2’s ability to oppose this impact as a function of both 
age and time since the loss of ovarian hormones (R.B. Gibbs, 2010; R B Gibbs, 1998). 
Taken together, research using the Ovx model in rodents has provided an important 
method of testing the validity of the window of opportunity theory and the putative 
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neurobiological mechanisms underlying this window. Importantly, this work has 
illustrated that the timing of exogenous hormone treatment initiation following loss of 
circulating ovarian hormones greatly impacts its efficacy in tests of spatial learning and 
memory. 
The Ovx rodent model also allows researchers to systematically address the 
question of whether age of menopause onset affects cognitive function. Although the 
average age of menopause is 52 years, the age of menopause onset varies greatly 
(typically from 40 to 58 years of age) (NAMS, 2014), yet little is known about whether 
age of onset impacts cognitive function. This issue is just beginning to be investigated. 
One study showed that there are varying cognitive effects of early versus late menopause 
in women, independent of hormone therapy; women who underwent menopause later in 
life (between 51-63 years of age) performed better on the Mini-Mental State Exam 
(MMSE), a common test used to assess global cognitive function, than women who 
underwent menopause earlier in life (between 16-40 years of age) (McLay, Maki, & 
Lyketsos, 2003). Another study demonstrated that women who underwent menopause at 
or before 40 years of age were impaired in verbal fluency and visual memory tasks 
compared to women who underwent menopause after 50 years of age (Ryan et al., 2014). 
The Ovx rodent model has been effectively used to systematically determine the impact 
of age of ovarian hormone loss on cognition, as well as the cognitive response to 
exogenous hormone treatment, discussed in detail later in this chapter. 
Regarding limitations, it is important to note that the Ovx rodent model is a binary 
all-or-nothing model. That is, the cessation of circulating ovarian hormones is abrupt 
after surgical removal of the ovaries, much like turning off an electrical switch. In 
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contrast, ovarian hormone loss with menopause in women is a gradual process that occurs 
against a backdrop of natural aging. Thus, the Ovx model alone does not provide an 
opportunity to investigate the effects on system functions with the natural transition to 
menopause and despite closely modeling surgical menopause, Ovx is not translationally 
representative of the transitional natural menopause that most women will experience 
(Whiteman et al., 2008). In general, most women will experience transitional menopause, 
with the transition phase lasting up to 10 years prior to the onset of menopause with 
associated irregular fluctuations of circulating ovarian hormone levels as well as several 
undesired symptoms (Burger et al., 2008; Harlow & Paramsothy, 2011). Thus, an 
informative additional model of menopause would allow for investigation of changes 
across the transitional period of natural menopause and subsequent effects of menopausal 
hormone therapy. 
 
Unilateral ovariectomy (ULO)   
To circumvent the disadvantage of the abrupt loss of circulating ovarian 
hormones seen with the Ovx rodent model, researchers have developed clever 
alternatives to design models of menopause that allow the endocrine system to function at 
partial capacity. Instead of bilaterally removing both ovaries, one ovary alone can instead 
be removed for unilateral ovariectomy (ULO). The ULO model presents an interesting 
variant of the Ovx model (Figure 2). Six hours after ULO was performed in 2-3 month 
old rats experiencing metestrus at the time of surgery, there was a surge in FSH levels in 
plasma, a characteristic of menopausal status in women, as well as in the pituitary (Otani 
& Sasamoto, 1982). Plasma FSH markedly increased within 6 hours, plateaued at 12 
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hours, and dropped to normal levels by 24 hours following surgery, compared to 
bilaterally ovary intact rats, whereas plasma LH levels did not differ from bilaterally 
ovary intact rats (Otani & Sasamoto, 1982). FSH in the pituitary also showed a 
significant increase after 6 hours that persisted until the animals were in proestrus when 
compared to bilaterally ovary intact rats. This surge in both plasma and pituitary FSH 
was also seen when ULO surgery was performed during the diestrus phase (Otani & 
Sasamoto, 1982). The ULO animals exhibited approximately double the largest measured 
follicles compared to those of bilaterally ovary intact rats, likely due to the FSH rise 
(Otani & Sasamoto, 1982). The FSH increase is believed to occur as a compensatory 
mechanism for the loss of one ovary, which the authors posited was due to a lack of 
inhibin-like substances (Otani & Sasamoto, 1982). In women, unilateral oophorectomy 
has been shown to impact relative risk of dementia. Hysterectomy alone increased the 
risk of dementia or cognitive impairment, an effect that was further increased with the 
addition of unilateral oophorectomy, with an even greater elevation in risk when 
hysterectomy was combined with bilateral oophorectomy (Walter A. Rocca, Grossardt, 
Shuster, & Stewart, 2012). Collectively, these findings indicate that unilateral removal of 
an ovary provides a translationally-relevant model of hormonal changes during 
menopause, and could provide meaningful insights into the putative altered risk of 
cognitive change with natural and/or surgical menopause.  However, this model has 
been very infrequently used in behavioral neuroendocrinology, so little is known about 
its effects on cognition and brain function in rodents.  
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4-vinylcyclohexene diepoxide (VCD)  
Given that the majority of women will undergo transitional menopause, it is 
noteworthy that an animal model has been developed that recapitulates the natural, 
transitional menopause that women typically experience. In women, menopause is 
induced by follicular depletion, which accelerates in the decade preceding menopause 
(Richardson & Nelson, 1990). Humans and rodents have four different types of ovarian 
follicles: primordial, primary, secondary, and antral follicles, which mature during the 
follicular phase of the female cycle (Koebele & Bimonte-Nelson, 2016; Kronenberg et 
al., 2008). Within each cycle, a follicle progresses from primordial to primary, to 
secondary, and to antral, after which it becomes preovulatory, and a mature egg is 
released from the ovary (Koebele & Bimonte-Nelson, 2016; Kronenberg et al., 2008). In 
rodents, 4-vinylcyclohexene diepoxide (VCD), a metabolite of vinylcyclohexene (VCH), 
induces ovarian follicular depletion via accelerated atresia of primordial and primary 
ovarian follicles, while leaving the ovaries intact (Flaws et al., 1994; Springer et al., 
1996; Kao et al., 1999; Hoyer et al., 2001). If VCD treatment is initiated before the 
rodents undergo estropause, a form of reproductive senescence ensues that is remarkably 
similar to that of women who undergo transitional menopause. Follicular depletion can 
be induced in mice (Kao et al., 1999; L. P. Mayer, Devine, Dyer, & Hoyer, 2004) and in 
rats (Kao et al., 1999; Loretta P. Mayer et al., 2002) via a series of intraperitoneal 
injections of VCD. More recently, protocols have included oral consumption of food bait 
containing a combination of VCD and triptolide (Dyer et al., 2013). Triptolide is a type of 
herbal Chinese medicine synthesized from Trypterygium wilfordii, also known as the 
thunder god vine, which is known to accelerate follicular depletion (Dyer et al., 2013). 
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The most commonly utilized doses of VCD to date are 80 mg/kg/day or 160 mg/kg/day 
via intraperitoneal injection for a total of 15 days. These two doses and regimens are 
effective at depleting ovarian follicles with reduced incidence of health concerns in rats 
and mice compared to other tested doses and regimens of VCD injections (Acosta et al., 
2010; Acosta, Mayer, Talboom, Tsang, et al., 2009; Koebele et al., 2017; Thompson et 
al., 2005). Compared to vehicle controls, rats receiving daily intraperitoneal injection of 
80 mg/kg VCD for 30 days showed evidence of initial primordial and primary follicle 
depletion (Loretta P. Mayer et al., 2002). By 60 days after the first VCD injection, 
growing follicles started to deplete, and by 120 days after the first VCD injection, antral 
follicles started to deplete (Loretta P. Mayer et al., 2002). In a study evaluating 30, 60, 
120, 240, and 360 post-initial VCD injection day timepoints, rats showed heightened 
levels of FSH relative to controls by 120 days after the first VCD injection, and levels 
remained elevated until 360 days after VCD initiation (Loretta P. Mayer et al., 2002). Of 
note, the VCD model achieves follicular depletion and elevated FSH levels within 4 
months of treatment initiation, and the transition to menopause in women can take up to a 
decade which is akin to about 4.6 months in a rat (Richardson and Nelson, 1990; 
Sengupta, 2013). On the other hand, if rats were given a single bolus of VCD, there was 
growth, rather than depletion, of primary follicles compared to controls (Borman et al., 
1999). One interpretation of these findings is that the first response to VCD is protective 
in nature; however, this effect is not yet completely understood. 
It is critical to note that there are differences in the effects of VCD/VCH treatment 
between mice and rats. Mice are far more sensitive to VCH-induced follicular depletion, 
which researchers believe is because mice have a greater capability to metabolize VCH to 
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VCD (Hoyer et al., 2001; Hoyer & Sipes, 2007; Kappeler & Hoyer, 2012). In rats, VCH 
results in little-to-no follicular depletion following treatment at the doses tested thus far, 
and therefore, VCD is considered the bioactive form of the compound in both rats and 
mice (Hoyer et al., 2001; Hoyer & Sipes, 2007). Mice also seem to be more responsive to 
VCD than rats. In one of the first studies comparing VCD treatment in mice versus rats, 
an 80 mg/kg intraperitoneal injection of VCD for 12 days resulted in greater overall 
primordial and primary follicular loss in mice than in rats compared to age-matched 
species-specific controls (Kao et al., 1999). In the same study, VCD-treated mice also 
showed earlier primordial follicular loss, beginning on day 8 of injections, whereas VCD-
treated rats did not show significant primordial follicular loss until day 10 (Kao et al., 
1999). However, once primordial follicular loss was detected, the rate of primordial 
follicular loss remained similar across both species, indicating that both species lost 
follicles at a comparable rate (Kao et al., 1999). 
In mice that have received VCD, as with women undergoing transitional 
menopause, plasma gonadotropin (LH and FSH) levels increased, and plasma 
progesterone levels decreased, relative to mice that received vehicle; E2 levels became 
undetectable via radioimmunoassay (L. P. Mayer et al., 2004). Thus, since 
androstenedione levels only decreased by about one-third, the hormone profile of VCD-
treated mice became androstenedione-rich, a characteristic which is similar in 
postmenopausal women (L. P. Mayer et al., 2004). Underscoring that VCD-treated 
ovaries can yield androgens, cells taken from the ovaries of VCD-treated mice could be 
induced in culture to produce androstenedione (L. P. Mayer et al., 2004). Research 
utilizing the VCD rat model showed that when compared to ovary-intact vehicle-treated 
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sham rats, VCD-treated rats showed increased levels of circulating FSH, and no 
differences in circulating LH and androstenedione levels, at subject sacrifice which 
occurred 141 days after the first VCD injection (Acosta et al., 2009a). Taken together, the 
VCD-induced rise in gonadotropins, coupled with an androstenodione-rich milieu, 
supports the tenet that the VCD rodent model is a translationally viable model of 
transitional menopause with the noted caveat that all models have their strengths and 
weaknesses. Indeed, although the VCD rodent model represents many aspects of the 
alterations in ovarian follicles and circulating hormone profiles occurring with 
transitional menopause, there are precautions and complexities of this model that must be 
considered. For instance, VCD is a chemical utilized in the creation of epoxy and other 
industrial byproducts (Chhabra, 1989). As such, its exogenous administration to rodents 
may lead to undesired effects, which, in turn, may inadvertently impact behavioral 
outcomes (Chhabra, 1989). Recent research has revealed that oral VCD given daily for 
28 days can increase oxidative stress in the liver and kidneys, as well as elevate 
circulating and liver inflammatory factors, in male and female rats (Amos Olalekan 
Abolaji et al., 2016). Further investigation showed that oral VCD given daily for 28 days 
can also increase oxidative stress in the ovaries and uterine horns, raise apoptosis and 
inflammatory factors in the ovaries, as well as result in hormone dysregulation, in young-
adult female rats (Amos O. Abolaji et al., 2016). The authors propose that these effects 
may be mechanisms through which VCD induces ovarian follicular depletion (Amos O. 
Abolaji et al., 2016). Nonetheless, these unintentional effects may confound the 
interpretation of the impact of ovarian hormone loss and hormone therapy on various 
brain and behavioral outcomes in VCD-treated rodents. 
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In conclusion, this section has discussed the strengths and weaknesses of several 
menopause models.  One must choose carefully when selecting a menopausal model. 
Although all currently available rodent models of reproductive senescence offer 
opportunities for precise hormone manipulation, especially when combined with 
pharmacological manipulations or hormone-variant knock outs, for example, each has 
caveats that must be taken into account when interpreting results regarding the impact of 
menopause and hormone therapy on system functions, including cognition. Of note, all 
recapitulate enough key aspects of menopause to allow researchers to directly study the 
complexities of hormone interactions across reproductive aging. In preclinical research, 
strictly regimented experimental study designs can be conducted with proper control and 
randomization. Indeed, animal models are an important step in gaining a better 
understanding of the intricacies and implications of hormonal changes across the lifespan, 
and can provide the vital foundational knowledge necessary to stimulate innovative 
research which translates to the clinic.   
 
Spatial memory  
The hippocampus is a brain region involved in the formation of spatial memories, 
which are memories regarding one’s environment and orientation in space (Leutgeb et al., 
2005; O’Keefe & Dostrovsky, 1971; Rosenzweig, Redish, Mcnaughton, & Barnes, 2003). 
Numerous behavioral maze tasks have been developed to assess hippocampal-dependent 
spatial memory processing in rodents. These testing paradigms evaluate a rodent’s ability 
to learn to navigate in the maze and remember one or multiple locations of reward in an 
environment that provides abundant cues located outside of the maze (extra-maze). 
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Spatial memory tasks can be designed to test either short-term or long-term memory. 
Short-term memory, whereby information is either updated and/or manipulated, is termed 
working memory (Baddeley, 2003; H. A. Bimonte-Nelson, Daniel, & Koebele, 2015; 
Olton & Papas, 1979). Long-term memory, whereby information remains constant over a 
long period of time, is termed reference memory (H. A. Bimonte-Nelson et al., 2015; 
Olton & Papas, 1979). Here, several of the commonly used tasks to assess these memory 
types are defined. For instance, in the Morris water maze (MWM) task, an animal must 
learn to find a submerged escape platform in a round tub filled with opaque water using 
spatial extra-maze cues that are placed throughout the testing room. Although the start 
location varies across trials and days, the platform location remains constant throughout 
testing, thus, this task tests spatial reference memory. Another task, the radial arm maze 
(RAM) was originally developed to test spatial working memory (Olton & Samuelson, 
1976). The wheel-shaped apparatus consists of a circular central platform from which 8, 
12, or 17 arms radiate.  Each arm is baited at the end with a hidden cup in which food or 
water is placed for food- or water-restricted rodents to find. The maze is surrounded by 
extra-maze cues that animals can use to navigate. Once located, food and water rewards 
are not replaced, so the optimal strategy is to visit each arm only once. Because rodents 
do not enter the arms in the same sequence each day, this task tests spatial working 
memory. The RAM has been modified over the years to test both spatial reference and 
working memory simultaneously by baiting only half the arms with food (Olton & Papas, 
1979). Because the same arms remain unbaited throughout trials and days, animals 
should never enter them; this information remains constant – these arms never have food, 
and thus, these arms assess spatial reference memory. In contrast, re-entries into 
  
30 
previously entered arms within a day are considered tests of spatial working memory 
because information must be updated – the previously entered arms no longer contain 
bait. More recently, a water-escape version of the RAM has been developed that merges 
the response-reinforcement contingencies of the MWM with the ability to measure spatial 
working and reference memory of the RAM (Bimonte & Denenberg, 1999; Hyde, 
Hoplight, & Denenberg, 1998). The water version of the RAM task is utilized in a similar 
manner; however, it is not reliant on appetitive reinforcement for the completion of the 
maze. For this task, typically an 8-arm tub is filled with opaque water and the ends of 
some arms contain an escape platform hidden underneath the surface of the water. The 
animal is trained to find the location of the hidden platform(s); once a platform is located, 
it is removed for the rest of that testing day. Thus, animals must update and remember the 
location/s from which they have already escaped. As in the dry-land RAM, optimal 
performance is obtained when animals use extra-maze cues for spatial navigation. Spatial 
reference and working memory are tested in the same way as the land RAM, with the 
platforms replacing baited food or water as the navigational target. The delayed-match-
to-position (DMP) maze is used to test spatial working memory and recent memory, 
which is the short term retention of information, but does not involve the manipulation of 
information as does working memory. In this water-escape task, one out of many arms 
(this can vary in number, depending on the maze) contains a hidden platform, the location 
of which remains the same within a day, but varies across days. Similar to other water-
escape maze tasks, the maze is filled with opaque water and is located in a room with 
numerous spatial cues that can be utilized for spatial navigation. The first trial is 
considered the information trial, in which the animal learns where the platform location is 
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for that day. The animal must return to the correctly platformed spatial location for the 
remainder of that day. This requires an animal to update the information regarding the 
platform location across days. Trial 2 is considered the working memory trial since 
information must be updated from the prior day. The remainder of the trials within that 
same day are not considered working memory, but are considered recent memory, since 
nothing is being updated but short term retention must occur to solve the task 
successfully. This task can also utilize food reward in a dry walk-through maze, such as 
the classic T-maze (three perpendicular arms in the shape of a T) and Y-maze (three non-
perpendicular arms in the shape of a Y). Here, as in the water-escape DMP version, the 
reinforcer is alternated (e.g., the platform arm is alternated in the water-escape version 
and the baited arm is alternated in the dry-land version). A delay period between trials for 
any of these tasks can be implemented to test for spatial memory retention. Additional 
details on the mazes and the maze protocols can be found in The Maze Book: Theories, 
Practice, and Protocols for Testing Rodent Cognition (H. A. Bimonte-Nelson, 2015a). 
 
Chronic estrogen therapy and spatial memory  
The abrupt decrease in circulating ovarian hormone levels after Ovx in young 
adult or middle-aged animals is often associated with compromised spatial learning and 
memory (Bimonte & Denenberg, 1999; Feng, Cheng, & Zhang, 2004; R. B. Gibbs & 
Johnson, 2008; Alicja L Markowska & Savonenko, 2002; Talboom, Williams, Baxley, 
West, & Bimonte-Nelson, 2008). Although estrogen supplementation can benefit 
cognition after Ovx, the learning and memory effects of estrogen-based hormone therapy 
are largely dependent on type of estrogen used. In addition, preclinical studies examining 
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the role of estrogens in spatial memory reveal multiple other factors that profoundly 
impact the efficacy of estrogen treatment. These include type of menopause model used, 
cyclic versus tonic administration, age at treatment initiation (young adult: 4-8 months, 
middle-aged: 11-14 months, and aged: >17 months), and timing of supplementation 
relative to length of prior hormone loss.   
 
CEE and its equine-specific components 
As previously mentioned, CEE are the hormones used in the name brand 
Premarin, a hormone therapy formulation prescribed to menopausal women to manage 
symptoms associated with menopause. A handful of preclinical studies have addressed 
the effects of CEE on cognitive function using rodent models, with a focus on how CEE 
dose, administration regimen, and type of menopause influences CEE’s cognitive effects. 
Overall, studies suggest that CEE treatment in Ovx middle-aged rats can have a 
beneficial effect on spatial working memory, spatial reference memory, and delayed 
retention of spatial memory (Acosta, Mayer, Talboom, Zay, et al., 2009; E. Engler-
Chiurazzi et al., 2011). Moreover, following behavioral testing, CEE-induced changes in 
the transcription of genes in the hippocampus that are involved in cognitive function and 
plasticity were found, providing biological plausibility for the impact of CEE on spatial 
memory (E. Engler-Chiurazzi et al., 2011). The Bimonte-Nelson laboratory has 
administered cyclic subcutaneous injections (2 days on and 2 days off) of 10 μg CEE/day, 
20 μg CEE/day, or 30 μg CEE/day to middle-aged Ovx rats for 18 days prior to behavior 
testing; the treatment regimen was continued until behavior testing was completed 
(Acosta, Mayer, Talboom, Zay, et al., 2009). The 20 μg CEE/day dose was chosen based 
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on the clinically used daily 0.625 mg CEE dose in Premarin, adjusting for differences in 
average body weight of a middle-aged woman and rat; of note, this dose was used in the 
Women’s Health Initiative Memory Study (WHIMS) (Shumaker et al., 2003). Compared 
to the vehicle-treated control group, all CEE-treated groups exhibited enhanced spatial 
reference memory on the MWM task, and improved spatial working memory during the 
acquisition phase of the DMP plus maze task (Acosta, Mayer, Talboom, Zay, et al., 
2009). In addition, the 30 μg CEE/day group also exhibited enhanced spatial localization 
of the platform location on the MWM relative to the vehicle control group (Acosta, 
Mayer, Talboom, Zay, et al., 2009). The beneficial cognitive effects of the 30 μg 
CEE/day (2 days on and 2 days off) treatment regimen were recently replicated in a study 
assessing young adult Ovx rats of a different strain (Sprague-Dawley, versus the 
previously used Fischer-344) on the water RAM and DMP plus maze tasks (Hiroi et al., 
2016). Evaluating effects in a different strain is important, as the two strains inherently 
have different genetic backgrounds as do people, thus suggesting that these findings on 
estrogenic cognitive effects may be generalized to a genetically diverse population within 
a species. Additional evidence suggests that CEE-mediated memory performance is 
dependent on CEE dose. In one experiment, tonic CEE was administered to middle-aged 
Ovx rats via a subcutaneous osmotic pump which released CEE at doses based on the 
same calculations as Acosta et al (2009b), adjusting for body weight for the daily 0.625 
mg CEE dose in Premarin. This design resulted in low, medium, and high CEE groups of 
12 μg CEE/day, 24 μg CEE/day, and 36 μg CEE/day, respectively (E. Engler-Chiurazzi 
et al., 2011). The low CEE dose impaired spatial reference memory performance in the 
MWM task, as well as impaired spatial working memory performance in the DMP plus 
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maze task, when compared to the vehicle control group (E. Engler-Chiurazzi et al., 2011). 
The high CEE dose enhanced spatial memory retention in the water RAM following a 4 
hour delay, and the two higher CEE doses (statistically combined) improved spatial 
memory retention in the DMP plus maze following a 6 hour delay, relative to the vehicle 
control group (E. Engler-Chiurazzi et al., 2011). Interestingly, an assessment of the 
circulating E1:E2 ratio for all CEE treated rats revealed a negative correlation between 
the E1:E2 ratio and working memory errors; indeed, as the ratio of E1:E2 increased, 
animals in this study tended to exhibit better working memory performance (E. Engler-
Chiurazzi et al., 2011). The results indicated that when circulating E2 was present, high 
circulating E1 could be cognitively beneficial. Important findings from the Galea 
laboratory, wherein adult Ovx rats were administered daily subcutaneous injections of 10 
μg CEE/day or 20 μg CEE/day, demonstrated that both the 10 μg and the 20 μg CEE/day 
doses impaired spatial working and reference memory on the land RAM (Barha & Galea, 
2013). Spatial working and reference memory impairment due to the cyclic (daily) low 
CEE dose used here is consistent with the spatial working and reference memory 
impairment of the tonic low CEE dose evidenced in Engler-Chiurazzi et al (2011). The 
collected findings indicate that the age of the rats at CEE treatment, and whether CEE 
administration is cyclic or tonic, impacts efficacy on cognition. Cyclic CEE injections (2 
days on/2 days off) with a break in between administration tended to enhance spatial 
memory on the MWM, water RAM, and DMP plus maze tasks in young adult and 
middle-aged Ovx rats; whereas, tonic CEE released through osmotic pumps at similar 
doses in middle-aged Ovx rats resulted in more variable efficacy, yielding impaired, null, 
or enhanced effects on spatial memory that had greater dependence on CEE dose. More 
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frequent injections (e.g., daily) of CEE in adult Ovx rats impaired spatial memory on the 
land RAM; of note, this daily injection regimen could yield tonic-like effects due to 
accumulation of the sesame oil/hormone substrate at the injection tissue sites.  
Background hormone milieu also impacts cognitive efficacy of CEE treatment, as 
the type of menopause model used to evaluate the cognitive impact of CEE can markedly 
affect the direction of the outcome. In a study comparing Ovx and VCD models of 
menopause, menopause type before giving CEE hormone therapy was methodically 
manipulated. Female rats underwent either Ovx to model surgical menopause, or VCD to 
model transitional menopause incorporating gradual follicular depletion and retention of 
follicle-deplete ovaries, followed by 2 days on/2 days off 30 μg CEE/day subcutaneous 
injections at middle-age (Acosta et al., 2010). In comparison to respective vehicle 
controls, CEE treatment in Ovx rats enhanced, whereas CEE treatment in VCD rats 
impaired, spatial working and reference memory on the water RAM (Acosta et al., 2010). 
Additionally, following implementation of an 8-hour delay on the DMP plus maze task, 
CEE treatment did not impact spatial memory retention in VCD rats, but CEE treatment 
improved spatial memory retention in Ovx rats (Acosta et al., 2010). These data indicate 
that CEE has contrasting effects on spatial learning and memory that are dependent on 
whether the animal underwent surgical versus transitional menopause. With Ovx, there is 
an abrupt and complete loss of ovarian follicles and circulating ovarian hormone levels, 
whereas with VCD, there is a transitional decrease in ovarian follicles and in some 
circulating ovarian hormone levels over time. Thus, the effects on the brain and cognitive 
function may be different as a function of abrupt versus gradual change in ovarian 
hormone profile. Moreover, androstenedione is the predominant circulating ovarian 
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hormone in the VCD, but not the Ovx, model of menopause. The presence of 
androstenedione can also play a role in the cognitive effects of estrogen-based hormone 
therapy. Indeed, research has shown in multiple replicate studies that increasing 
circulating levels of androstenedione in VCD rodents are correlated with worse cognitive 
performance (Acosta et al., 2010; Acosta, Mayer, Talboom, Tsang, et al., 2009; B. W. 
Camp et al., 2012). Interestingly, blocking the conversion of androstenedione to E1 
rescued the cognitive impairment seen with androstenedione treatment (Sarah E. 
Mennenga, Koebele, et al., 2015), indicating that E1 may be a contributing factor in the 
impairment observed when levels of circulating androstenedione are high. 
The known estrogens in CEE, including sulfate ester forms of E1, E2, 17α-
estradiol, equilin, 17β-dihydroequilin, 17α-dihydroequilin, equilenin, 17β-
dihydroequilenin, 17α-dihydroequilenin, and ∆8,9-dehydroestrone, have varied 
functional and neuroprotective effects (Bhavnani, 2003; Bhavnani & Stanczyk, 2014; 
Brinton, Proffitt, Tran, & Luu, 1997; Talboom et al., 2010; Zhao & Brinton, 2006). These 
equine estrogens differ in binding affinity to estrogen receptors, which may contribute to 
the variation in their functional effects (Bhavnani, 2003; Lobo, 2007). For instance, in 
vitro analysis of these 10 estrogens in cultured basal forebrain neurons showed that eight 
of the estrogens, 17α-estradiol, E2, equilin, 17α-dihydroequilin, equilinen, 17α-
dihydroequilenin, 17β-dihydroequilenin, and ∆8,9-dehydroestrone, had neuroprotective 
effects as measured by the ability to decrease glutamate excitotoxicity-induced damage to 
the neuronal plasma membrane (Zhao & Brinton, 2006). However, when examined for 
neuroprotective effects against damage induced by β-amyloid25-35, only E2, E1, and ∆8,9-
dehydroestrone were protective against the associated decrease in intracellular ATP 
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(Zhao & Brinton, 2006). Additionally, greater neuroprotective effects were observed 
following co-administration of E2 plus equilin, E2 plus ∆8,9-dehydroestrone, and equilin 
plus ∆8,9-dehydroestrone against decline in intracellular ATP compared to glutamate 
treatment alone, and in relation to individual administration of E2, equilin, or ∆8,9-
dehydroestrone (Zhao & Brinton, 2006). Several preclinical studies have aimed to 
decipher the effects of various equine estrogens in CEE on spatial memory using animal 
models. The effects of tonic subcutaneous administration of Δ8,9-dehydroestrone or 
equilin, two CEE components not naturally found in women, in middle-aged Ovx rats 
were compared (Talboom et al., 2010). These two components were selected because 
they had been previously shown by the Brinton laboratory to have consistent and potent 
neuroprotective effects in vitro relative to the other equine estrogens in CEE (Zhao & 
Brinton, 2006). It was found that Δ8,9-dehydroestrone treatment enhanced spatial 
reference, working, and recent memory compared to vehicle control treatment, and that 
equilin treatment had no effect on spatial memory (Talboom et al., 2010). The lack of 
beneficial cognitive effects of equilin treatment is not consistent with its neuroprotective 
effects in culture. Together, these findings suggest that although in vitro studies can yield 
insight into the neuroprotective effects of estrogens, efficacy might not necessarily 
translate to behavioral outcomes in vivo. However, it is important to keep in mind that the 
cell culture work directly induced cell damage via glutamate or β-amyloid25-35, whereas 
the animal work did not model cytotoxicity or a disease state as the pre-treatment model; 
rather, the Ovx rat model was utilized.  This variation in study design could explain, in 
part, the divergent outcomes of the same estrogens.  
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Estrone (E1) 
Evidence suggests that E1 may also impact cognitive function and brain health. In 
postmenopausal women, the primary circulating estrogen is E1 (Lobo, 2007). Circulating 
E2 can be metabolized into E1 and vice versa, and the affinity of E1 for estrogen 
receptors is lower than E2 (Kuhl, 2005). Interestingly, as discussed in greater detail 
above, there is a relationship between the ratio of circulating E1 to E2 and cognition, 
whereby higher E1:E2 is associated with enhanced maze scores (E. Engler-Chiurazzi et 
al., 2011). Because the sulfate ester of E1 comprises roughly 50% of the CEE that is used 
in menopausal hormone therapy (Bhavnani, 2003; Bhavnani & Stanczyk, 2014; Lobo, 
2007), it is important to understand the effects of E1 on cognition. 
Several studies have examined the cognitive effects of E1 alone. The Galea 
laboratory first examined the effects of one single subcutaneous injection of 0.3 μg, 1 μg, 
or 10 μg of E1 in adult Ovx rats 30 minutes prior to contextual fear conditioning (Barha, 
Dalton, & Galea, 2010). Although no dose of E1 enhanced contextual fear conditioning, 
1 μg E1 impaired memory relative to vehicle controls (Barha et al., 2010), suggesting a 
detrimental effect of this dose. Similarly, a tonic subcutaneous dose of 2.6 μg/day, 4 
μg/day, or 8 μg/day of E1 in Ovx middle-aged rats was subsequently compared, and it 
was found that the 8 μg E1/day dose impaired spatial working memory and retention on 
the DMP plus maze task compared to vehicle controls, whereas the lower doses had no 
effects on memory (E. B. Engler-Chiurazzi et al., 2012). The Galea laboratory also 
investigated the effects of daily E2 (10 μg) or E1 (10 μg) treatment for 20 days on spatial 
reference memory (as tested on the MWM) as well as hippocampal neurogenesis and 
activation in adult Ovx rats (McClure, Barha, & Galea, 2013). Although they found no 
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treatment differences in spatial reference memory, E2 treatment yielded higher, and E1 
treatment yielded lower, cell survival levels in the dentate gyrus of the hippocampus 
relative to controls (McClure et al., 2013). Taken together, these studies indicate that both 
chronic and isolated-acute E1 treatment regimens can impair spatial or hippocampal-
mediated cognitive performance on a dose-dependent basis in a surgical menopause 
background as modeled in Ovx rats, with differential effects on the hippocampus with E1 
versus E2 treatments. Additional studies are needed to fully understand the effects of 
exogenously administered E1, as well as circulating E1 levels, on memory, including 
how varied E1:E2 ratios impact the brain and its functioning.  
 
17β-estradiol (E2) 
E2 is the most potent naturally circulating estrogen in mammals, and it is also a 
component in several hormone therapy formulations. E2 is the most widely studied 
estrogen in preclinical studies; thus, there are numerous studies addressing the role of E2 
in spatial learning and memory. Many of these studies indicate that E2 treatment 
enhances spatial memory in Ovx young and middle-aged rats when tested on the MWM 
(Heather A. Bimonte-Nelson, Francis, Umphlet, & Granholm, 2006; Lowry, Pardon, 
Yates, & Juraska, 2010; Talboom et al., 2008) and on the water and land versions of the 
RAM (Bimonte & Denenberg, 1999; Jill M Daniel, Fader, Spencer, & Dohanich, 1997; V 
N Luine, Richards, Wu, & Beck, 1998; Rodgers, Bohacek, & Daniel, 2010). However, 
although the overall consensus in the field seems to be that E2 is beneficial to memory, 
the story does not appear to be so straightforward. As with CEE, multiple factors impact 
whether exogenous E2 treatment will yield beneficial, null, or detrimental effects on 
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hippocampal memory. These factors include, but are not limited to, the dose, regimen, 
and age of E2 administration, as well as the time between Ovx and E2 administration 
(Barha & Galea, 2010; Heather A. Bimonte-Nelson et al., 2006; Jill M. Daniel et al., 
2006; Frick, 2009; R. B. Gibbs, 2000; Alicja L Markowska & Savonenko, 2002; 
Talboom et al., 2008). 
Rodent studies evaluating the effects of E2 on cognitive and brain function 
indicate that these effects are dose-dependent (for review: Barha and Galea, 2010; Frick, 
2010). One study found, for example, that tonic subcutaneous administration of 0.25 mg 
E2, but not 0.50 mg E2, via 60-day release pellets in middle-aged Ovx rats enhanced 
spatial reference memory on the MWM (Heather A. Bimonte-Nelson et al., 2006). 
Additionally, in adult Ovx rats, a single subcutaneous injection of 0.3 μg E2 enhanced 
contextual fear conditioning, whereas 1.0 μg or 10.0 μg E2 impaired contextual fear 
conditioning, relative to controls (Barha et al., 2010). The age at E2 administration can 
also play a role in the effect of E2 on spatial memory. Indeed, in young and middle-aged 
Ovx rats, tonic subcutaneous E2 treatment enhanced spatial reference memory on the 
MWM, but had no effect in aged Ovx rats (Talboom et al., 2008).  
Another important factor to consider is that E2 administration regimen can 
influence the direction of E2’s impact on cognitive function. For example, relative to 
vehicle controls, tonic E2 treatment enhanced spatial working memory in aged Ovx rats 
only when the animals were primed with cyclic E2 subcutaneous injections (Alicja L 
Markowska & Savonenko, 2002). In another study evaluating middle-aged Ovx rats, 
cyclic E2 injections (bi-weekly), and low dose tonic E2 implants, but not high dose tonic 
E2 implants, enhanced spatial reference memory on the MWM compared to vehicle 
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controls (Heather A. Bimonte-Nelson et al., 2006). A study evaluating aged Ovx mice on 
the water RAM found that three months of continuous E2 (injections every day) did not 
impact spatial reference and working memory, and intermittent E2 (injections every 4 
days) impaired spatial reference memory and tended to impair spatial working memory, 
as compared to vehicle controls (Gresack & Frick, 2006). In addition, accumulating 
research suggests that there are significant effects of the critical window of opportunity, 
the period of time between ovarian hormone loss and initiation of hormone treatment 
administration, which can influence E2-induced cognitive efficacy. For example, a study 
of middle-aged rats from the Gibbs laboratory provides a clear illustration of this point. 
Specifically, E2 treatment initiated immediately or 3 months following Ovx enhanced 
spatial working memory on a DMP task, whereas E2 treatment initiated 10 months 
following Ovx had no effect on memory (R. B. Gibbs, 2000). In another study, middle-
aged Ovx rats that received E2 treatment immediately following Ovx surgery exhibited 
better spatial working memory in the land RAM, whereas those that received E2 
treatment 5 months following Ovx surgery did not show a benefit, compared to controls 
(Jill M. Daniel et al., 2006). Collectively, the abundant preclinical work systematically 
evaluating E2 treatment effects on spatial cognition suggests that E2 can play a beneficial 
role in cognition. However, as illustrated above, multiple factors may render the efficacy 
of E2 null or detrimental. 
 
Synthetic estrogens  
 Synthetic estrogens are commonly used in both contraceptive and menopausal 
hormone therapy formulations. Preclinical studies of these estrogens provide additional 
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support that multiple factors surrounding estrogen treatment administration can influence 
estrogens’ effects on spatial learning and memory. Ethinyl estradiol has been evaluated 
for both dose and administration regimen effects in the rodent Ovx model. For example, 
the Bimonte-Nelson laboratory recently assessed two doses of tonic, subcutaneous 
ethinyl estradiol administration in young adult Ovx rats on the spatial water RAM and 
MWM; the high ethinyl estradiol dose (0.3 μg/day) impaired spatial working memory on 
the water RAM relative to vehicle controls and a low ethinyl estradiol dose (0.125 
μg/day), but did not affect spatial reference memory on the MWM (Sarah E. Mennenga, 
Gerson, Koebele, et al., 2015). Moreover, in another study, the effects on spatial memory 
of cyclic subcutaneous ethinyl estradiol in doses of 0.125 μg/day, 0.18 μg/day, or 0.3 
μg/day in young adult Ovx rats were tested (Sarah E. Mennenga, Gerson, Koebele, et al., 
2015). Consistent with previous studies, the 0.3 µg/day dose impaired spatial working 
memory in the water RAM relative to vehicle, 0.125 μg/day, and 0.18 μg/day (Sarah E. 
Mennenga, Gerson, Koebele, et al., 2015). All three cyclic ethinyl estradiol treatments 
impaired spatial reference memory on the MWM task (Sarah E. Mennenga, Gerson, 
Koebele, et al., 2015). Others have also tested the effects on spatial memory of another 
E2 synthetic analog, estradiol benzoate, using the rodent Ovx model. The lowest 
subcutaneous injection dose of 0.32 μg estradiol benzoate/day enhanced spatial working 
memory in the land RAM compared to vehicle controls, whereas the higher doses of 1 
μg/day and 5 μg/day impaired spatial working memory compared to vehicle controls 
(Holmes, Wide, & Galea, 2002). Another study administered tonic low or high doses of 
estradiol benzoate via subcutaneous silastic capsules, resulting in estradiol plasma levels 
of ~40 pg/ml or  >200 pg/ml, respectively, to young, middle-aged, and aged Ovx rats 
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(Foster, Sharrow, Kumar, & Masse, 2003). Results showed an age by dose interaction for 
retention on a spatial discrimination task (Foster et al., 2003), such that enhanced 
retention scores were exhibited for the vehicle-treated young rats, low estradiol benzoate-
treated middle-aged rats, and high estradiol benzoate-treated aged rats; retention scores 
were not impacted for low or high estradiol benzoate-treated young rats, vehicle or high 
estradiol benzoate-treated middle-aged rats, and vehicle or low estradiol benzoate-treated 
aged rats (Foster et al., 2003). Thus, there is evidence indicating that, similar to natural 
estrogens, synthetic estrogens can also impact learning and memory. Although there is 
limited work done in this research domain, results thus far suggest that the directionality 
of the cognitive impact of synthetic estrogens is governed not only by the type of 
synthetic estrogen, but also by experimental factors such as age, treatment dose, and 
treatment regimen.   
 In summary, preclinical research spanning the last three decades has revealed a 
great deal regarding exogenous treatment with estrogens and subsequent effects on 
spatial memory. It is now understood that estrogens do modulate spatial memory, 
although several factors impact the directionality of these estrogenic effects, including the 
type, dose, duration, and frequency of estrogen treatment, as well as the age and memory 
type evaluated. However, the picture is not yet complete, and replication and extension of 
many of the existing studies are needed. Additional research is required to determine the 
critical factor variants driving the decision points to dictate whether a woman should start 
estrogen therapy, and if so, when – for example, during the transition to menopause or 
postmenopause, immediately following or after a delayed period of surgical ovarian loss, 
or never unless symptoms occur – as well as what type of estrogen would be best for a 
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woman with a particular circulating hormone background milieu. It is possible that there 
is an estrogen formulation that is yet to be created, discovered, or evaluated that would be 
beneficial in a broad range of female phenotypes, thereby yielding an optimal hormone 
therapy profile for overall women’s health during aging. Furthermore, when considering 
estrogens as hormone therapy, interactions with progestogens should be carefully 
considered. Indeed, hormone therapy is often provided as an estrogen plus progestogen 
combination formulation. The following section discusses what is currently known 
regarding progestogen, as well as estrogen plus progestogen, treatments and their effects 
on spatial learning and memory.  
 
Progestogens, and estrogen plus progestogen hormone combinations 
The term progestogens is used to describe both endogenous progesterone and 
synthetic variations of progesterone, known as progestins. Some examples of progestins 
are medroxyprogesterone acetate (MPA) and levonorgestrel (Levo), two compounds 
found in both birth control formulations and hormone therapy. When estrogens are given 
exogenously to a woman with an intact uterus, a progestogen component is necessary to 
oppose the heightened risk for developing endometrial hyperplasia and cancer with 
unopposed estrogen exposure (NAMS, 2012). The WHIMS indicated that CEE plus 
MPA combination hormone therapy did not have beneficial effects on cognition, 
especially if deficiencies in cognitive abilities were present prior to initiation of treatment 
(Espeland et al., 2004; Rapp et al., 2003; Resnick et al., 2006; Shumaker et al., 2003). 
Specifically, exogenous administration of the CEE plus MPA hormone combination in 
postmenopausal women 65 years or older did not enhance cognition compared to 
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exogenous administration of a placebo (Rapp et al., 2003). Furthermore, a clinically 
meaningful increase in risk for cognitive decline was observed for postmenopausal 
women taking this combination hormone therapy (Rapp et al., 2003). Postmenopausal 
women taking CEE plus MPA had twice the risk for developing probable dementia, and 
were not protected against mild cognitive impairment, compared to those taking a 
placebo (Shumaker et al., 2003). There is evidence that the MPA component of hormone 
therapy is detrimental to the brain and its functioning. For example, in vitro MPA 
treatment was not neuroprotective, and when combined with E2, MPA attenuated the 
neuroprotective effects of E2 against glutamate toxicity (Nilsen & Brinton, 2002). The 
Bimonte-Nelson laboratory has demonstrated that MPA can impair spatial working 
memory in both middle-aged and aged Ovx rats, and that this effect may be non-
reversible, as cognitive impairments continued even when MPA treatment was stopped 
for 4 months prior to behavior testing and circulating MPA levels were not detectable 
(Braden et al., 2010, 2011). The Kronos Early Estrogen Prevention Study (KEEPS) 
included an ancillary study, the Cognitive and Affective Study (KEEPS-Cog), to address 
global cognitive function in women within 6-36 months of their last menstrual period 
taking CEE or E2 hormone therapy in combination with micronized progesterone. Given 
the timing of treatment to menopause, this study evaluated women ranging from the late 
menopausal transition to early postmenopause (Gleason et al., 2015). Neither 
combination hormone therapy regimens benefitted or impaired cognition over a four-year 
period compared to placebo treatment, although the CEE/micronized progesterone 
combination improved some depression and anxiety measures (Gleason et al., 2015). 
Although this study would seem to suggest little cognitive benefit of CEE/micronized 
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progesterone and E2/micronized progesterone, preclinical studies examining clinically-
relevant hormone combination treatments, although largely focusing on E2 rather than 
CEE, suggest that the addition of a progestogen component to an estrogen treatment can 
impact E2-induced beneficial cognitive effects. Outcomes seem to be heavily influenced 
by the type of estrogen and type of progestogen utilized, as well as the behavioral or 
neurobiological outcome examined. These findings are further elaborated upon below. 
 
Progesterone 
Accumulating evidence suggests that the addition of progesterone to a cognitively 
efficacious E2 treatment regimen can attenuate or obviate E2-induced benefits, although 
these effects depend on numerous variables, including, but not limited to, mode of E2 and 
progesterone administration, as well as progesterone dose. The Bimonte-Nelson 
laboratory found that in middle-aged Ovx rats, the addition of tonic progesterone (2 
subcutaneous pellets with 200 mg released over 60 days) to cyclic E2 (10 µg 
subcutaneous injection every other week) or to tonic low dose E2 (subcutaneous pellet 
with 0.25 mg released over 60 days) attenuated E2-induced beneficial effects on spatial 
reference memory on the MWM (Heather A. Bimonte-Nelson et al., 2006). Indeed, the 
cyclic E2 plus tonic progesterone, and the tonic low dose E2 plus tonic progesterone, 
combination treatments resulted in spatial reference memory that was comparable to age-
matched vehicle controls; in contrast, cyclic E2 alone and low dose tonic E2 alone 
treatments enhanced spatial reference memory (Heather A. Bimonte-Nelson et al., 2006). 
Not all studies show that progesterone attenuates the benefits of estrogens, however. For 
example, in middle-aged Ovx rats, tonic progesterone and E2 combined (both via 
  
47 
subcutaneous implant for 28 days) enhanced spatial reference memory on the MWM in a 
manner similar to that of acute E2 alone (16.67 μg E2/kg subcutaneous injections for two 
days) and tonic E2 alone (subcutaneous E2 implant for 28 days) relative to controls 
(Markham, Pych, & Juraska, 2002). Moreover, Gibbs showed that when Ovx was 
performed at middle-age, rats receiving tonic E2 treatment immediately after Ovx, tonic 
E2 treatment 3 months after Ovx, or cyclic E2 plus progesterone treatment 3 months after 
Ovx, exhibited enhanced spatial working memory in the DMP task compared to Ovx rats 
receiving control treatment (R. B. Gibbs, 2000). Interestingly, spatial working memory in 
middle-aged rats receiving cyclic E2 plus progesterone treatment starting 10 months after 
Ovx was not different from that of non-hormone treated controls (R. B. Gibbs, 2000). 
These findings show that cyclic E2 plus progesterone combination treatment can be 
cognitively beneficial with the appropriate parameters. They support the existence of a 
critical window of opportunity following the loss of circulating ovarian hormones during 
which exogenously administered ovarian hormones can have potentially beneficial 
cognitive effects.  
Additional studies utilizing acute E2 and progesterone combination hormone 
treatment further highlight the complexities of the cognitive effects of these two 
hormones. The Frick laboratory has shown that, in young Ovx mice, a single bolus 
intraperitoneal injection of progesterone (10 mg/kg or 20 mg/kg) given immediately after 
training improved non-spatial object recognition memory consolidation tested 48 hours 
later compared to vehicle-treated controls (L. L. Harburger, Pechenino, Saadi, & Frick, 
2008). Similarly, effects were observed in young Ovx mice after dorsal hippocampal 
infusion of 0.01, 0.1, or 1 µg/µl progesterone (Fortress, Heisler, & Frick, 2015; P.T. Orr, 
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Rubin, Fan, Kent, & Frick, 2012; Patrick T Orr, Lewis, & Frick, 2009). Intraperitoneal 
injections of progesterone also enhanced object recognition memory consolidation in 
middle-aged and aged Ovx mice in a dose-dependent manner (Lewis, Orr, & Frick, 
2008). A 20 mg/kg dose of progesterone also enhanced spatial reference memory 
consolidation in the MWM among aged Ovx mice, but no dose of progesterone affected 
memory in this task among middle-aged or young Ovx mice (L. L. Harburger et al., 
2008; Lewis et al., 2008), suggesting a potentially important influence of aging on the 
ability of progesterone to regulate spatial reference memory. On the other hand, the 
Bimonte-Nelson laboratory has shown that progesterone (0.7 mg/day via daily 
subcutaneous injection) administered for 13 days before testing impaired spatial working 
memory on the water RAM in middle-aged Ovx rats when compared to vehicle-treated 
controls (B. Blair Braden et al., 2015), indicating that spatial working memory is 
sensitive to chronic progesterone treatment. In aged Ovx mice, when paired with acute 
E2 (0.2 mg/kg via intraperitoneal injection) treatment, the high dose progesterone (20 
mg/kg via acute intraperitoneal injection) eliminated the beneficial effects of E2 on 
spatial reference memory in the MWM (Lauren L. Harburger, Bennett, & Frick, 2007). 
The low dose of progesterone (10 mg/kg via acute intraperitoneal injection) did not 
significantly attenuate the beneficial effects of E2 (Lauren L. Harburger et al., 2007). 
This research demonstrates that the progesterone dose can influence progesterone and 
estrogen/progesterone combination treatment outcomes for cognition.  
Studies on E2 plus progesterone hormone treatments have also examined impacts 
on neurobiological mechanisms thought to relate to cognitive function. The Bimonte-
Nelson laboratory has demonstrated that the addition of progesterone attenuated the E2-
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induced increase in neurotrophin protein levels. Specifically, tonic E2 (subcutaneous 
pellet with 1.5 mg/60 days) treatment in aged Ovx rats increased brain derived 
neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in the entorhinal 
cortex, a brain region involved in spatial memory, compared to age-matched Ovx 
controls (H. A. Bimonte-Nelson, Nelson, & Granholm, 2004; Steffenach, Witter, Moser, 
& Moser, 2005). The addition of tonic progesterone (2 subcutaneous pellets with 200 
mg/60 days) obviated these E2-induced increases, whereby neurotrophin levels in the 
entorhinal cortex following E2 plus progesterone treatment did not differ from those 
observed in age-matched Ovx controls (H. A. Bimonte-Nelson et al., 2004). Progesterone 
may reduce the beneficial effects of E2 on memory by interfering with the biochemical 
effects of E2. For example, dorsal hippocampal activation of the extracellular signal-
regulated kinase/mitogen activated protein kinase (ERK/MAPK) signaling cascade, 
particularly the ERK2 isoform of ERK, is necessary for E2 (administered via acute 
intraperitoneal injection or acute intracerebroventricular infusion in the dorsal third 
ventricle) to enhance object recognition memory consolidation in young Ovx mice 
(Fernandez et al., 2008; L. L. Harburger, Saadi, & Frick, 2009). Interestingly, dorsal 
hippocampal infusion of progesterone has a biphasic effect on ERK2 activation whereby 
ERK2 activation increased 5 minutes, but decreased 15 minutes, after infusion; blocking 
activation of ERK2 also attenuated the beneficial effects of progesterone alone on 
objection recognition consolidation memory (Orr et al., 2012). When acute 
intraperitoneal progesterone injections of 5, 10, or 20 mg/kg were given in addition to 0.2 
mg/kg E2 treatment, the E2-induced increase in dorsal hippocampal ERK2 activation was 
no longer present; this was true for all progesterone doses co-administered with E2 (L. L. 
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Harburger et al., 2009). However, only the 5 mg/kg dose of progesterone attenuated E2’s 
effects on object recognition; E2 could still enhance object recognition when co-
administered with 10 or 20 mg/kg progesterone (L. L. Harburger et al., 2009). These 
findings suggest that the memory-enhancing effects of E2 combined with the higher 
progesterone doses were not associated with ERK2 activation, at least at the same time 
point observed after E2 alone, indicating that while progesterone alters the biochemical 
effects of E2 this alteration does not necessarily mediate the memory enhancing effects of 
E2. The findings also suggest that the ratio of E2 to progesterone is important for 
behavioral outcomes such as those tested here for non-spatial memory.  
E2 plus progesterone combination hormone treatment effects have also been 
studied in the context of diet and exposure to drugs of abuse. For instance, a study testing 
the cognitive effects of methamphetamine found that Ovx rats administered chronic E2 (1 
mg/kg via daily intraperitoneal injection) or progesterone (8 mg/kg via daily 
intraperitoneal injections) showed attenuated methamphetamine-induced spatial reference 
memory deficits on the MWM (Ghazvini et al., 2016). The combination of E2 and 
progesterone, however, fully opposed the benefits of either hormone alone for these 
methamphetamine-induced impairments (Ghazvini et al., 2016). Other factors, such as 
diet and general health, can impact the manner in which E2 and progesterone interact. In 
a study in middle-aged Ovx rats investigating the interactions between dietary calcium 
intake and hormone therapy, chronic E2 treatment (10 µg every 48 hours via 
subcutaneous injections for 128 days) with or without progesterone (500 µg four hours 
before testing) enhanced learning on the land RAM only when dietary calcium was 
standard as in regular rat chow; when dietary calcium was decreased, E2 alone still 
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facilitated learning, but the combination E2 plus progesterone therapy did not (Sato et al., 
2004). These examples speak to the breadth of factors that researchers should consider 
during the scientific study of hormone therapy; with more research, it could be revealed 
that numerous factors such as diet and drug exposures are critical contributors to 
cognitive efficacy of hormone therapy.  
Another important area of research regarding the study of hormone therapy is in 
relation to neurodegenerative disease, specifically Alzheimer’s disease (AD). Some 
studies suggest that estrogens may help to improve cognition in patients with AD 
(Asthana et al., 1999, 2001; Wharton et al., 2011; Wroolie et al., 2015; for review see: 
Henderson, 2006), and to both improve cognition and reduce neuropathology in rodent 
models of AD (Amtul, Wang, Westaway, & Rozmahel, 2010; Carroll et al., 2007; 
Carroll, Rosario, Villamagna, & Pike, 2010). Using the triple transgenic mouse AD 
model (3xTg-AD), the Pike laboratory showed that tonic E2 alone treatments 
immediately after Ovx improved recent memory as tested on the Y-maze; neither tonic 
nor cyclic progesterone treatment impacted performance relative to vehicle treatment 
(Carroll et al., 2007; Carroll et al., 2010). It is unclear what impact combination 
E2/progesterone treatment has on this novelty memory task in the triple transgenic AD 
mouse model, as tonic progesterone did not reverse E2’s beneficial effects in the first 
study (Carroll et al., 2007), but did reverse E2’s effects in the second study (Carroll et al., 
2010). Of note, when progesterone was administered cyclically instead of tonically, it did 
not reverse E2’s cognitive enhancements (Carroll et al., 2010), indicating that tonic 
versus cyclic mode of administration might impact outcome of combination hormone 
therapy, at least in this AD mouse model. Two key markers for AD-like neuropathology 
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in the AD mouse model are increased levels of ß-amyloid accumulation and increased 
hyperphosphorylation of the tau protein. In both studies, E2 treatment decreased ß-
amyloid accumulation compared to controls, whereas the combination of E2 plus tonic 
progesterone treatment was ineffective (Carroll et al., 2007; Carroll et al., 2010), and the 
combination of E2 plus cyclic progesterone treatment maintained the E2-induced 
decrease in ß-amyloid accumulation (Carroll et al., 2010). Further, E2 plus tonic 
progesterone (Carroll et al., 2007; Carroll et al., 2010), as well as E2 plus cyclic 
progesterone (Carroll et al., 2010), decreased hyperphosphorylated tau, even though E2 
alone had either a null effect (Carroll et al., 2007) or beneficial effect (Carroll et al., 
2010) on hyperphosphorylated tau. Collectively, findings from these studies indicate that 
the regimen of progesterone treatment, either cyclic or tonic, may influence cognitive 
function and expression of neuropathological hallmarks in rodent models of AD, 
although relationships between these neuropathological markers and cognition remain 
unclear. 
 
Synthetic progestins 
The implications of the findings from the WHIMS brought new light to the 
investigation of the complexities in combination hormone therapy, including, but not 
limited to, its effects on cognitive function. MPA alone treatment has been shown by the 
Bimonte-Nelson and other laboratories to impair spatial and novelty memory in ages 
ranging from young adulthood to late middle age in the rat (B. B. Braden et al., 2011; B. 
Blair Braden et al., 2017, 2010; Okojie & Oyekunle, 2014). Although the effect of MPA 
alone has proven to be robust, cognitive effects from combination E2/MPA studies are 
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still not fully understood. Some research suggests that the combination of E2 and MPA 
can be beneficial for cognitive performance. One study investigated the effects of chronic 
oral E2 (47 µg/kg/day via drinking water), cyclic oral E2 (47 µg/kg/day via drinking 
water) given three out of every four days, and chronic oral E2 plus tonic MPA (1.5 mg 
via a 90 day subcutaneous pellet) in rats that received Ovx (Chisholm & Juraska, 2012). 
Ovx occurred at 12-13 months old, hormone treatment began immediately after, and 
behavior testing was initiated at 17-18 months old (Chisholm & Juraska, 2012). The 
chronic oral E2 plus MPA combination enhanced learning of a T-maze alternation task 
compared to Ovx rats receiving vehicle only, chronic oral E2 only, or cyclic oral E2 only 
(Chisholm & Juraska, 2012). This beneficial effect of combined E2/MPA hormone 
treatment may be specific to a task such as the alternation test used in the study, as 
animals can use a variety of navigational strategies to solve the task. Remarkably, 
research has demonstrated that the proestrus phase of the estrous cycle (high circulating 
estrogens) biases female rats towards hippocampal-based navigation strategies, while the 
estrus phase (low circulating estrogens) biases female rats towards non-hippocampal-
based navigation strategies (Korol et al., 2004). Further research has demonstrated that 
progesterone in combination with estradiol benzoate can shift rats towards non-
hippocampal navigation strategies (Korol and Pisani, 2015). Indeed, when a spatial task 
was utilized, the same chronic oral E2 plus tonic MPA combination treatment impaired 
performance, at similar experimental timeframes. Specifically, Ovx rats given the 
E2/MPA combination exhibited a greater swim distance on the MWM compared to those 
given chronic oral E2 only or cyclic oral E2 only (Lowry et al., 2010). Together, 
experiments evaluating MPA alone are uniform in showing consistent cognitive 
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impairments at a broad range of ages. The cognitive outcome of adding MPA to E2 
treatment seems to be mediated, in part, by type of memory examined; for a spatial 
memory task, the combination E2/MPA treatment impaired cognitive function compared 
to E2 alone, whereas for a task that is ambiguous in its spatiality, the combination 
E2/MPA treatment enhanced cognitive function relative to E2 alone.   
Ethinyl estradiol and Levo are clinically available in combination for oral 
contraceptive use; however, they are discussed here because they could potentially be 
used for menopausal hormone therapies (individually or together), and there is a 
population of women who utilize oral and other hormonal contraceptives during the 
transition to menopause. To my knowledge, there has been only one preclinical study 
investigating the impact of chronic ethinyl estradiol and Levo in combination on 
cognition. This study demonstrated that three weeks of daily subcutaneous treatment with 
low doses of either ethinyl estradiol (10 µg subcutaneous injection) or Levo (20 µg 
subcutaneous injection) alone, or a low dose ethinyl estradiol and Levo combination 
(10:20 µg), impaired non-spatial novel object recognition memory in young ovary intact 
rats compared to vehicle treatment (Simone et al., 2015). High dose treatment of ethinyl 
estradiol (30 µg) alone improved memory compared to controls on the same task, 
whereas high dose Levo (60 µg) and high dose ethinyl estradiol plus Levo combination 
(30:60 µg) treatments had no effect compared to control treatment (Simone et al., 2015). 
Thus, when the treatment doses were high, the addition of Levo to the cognitively 
beneficial ethinyl estradiol attenuated the effects of ethinyl estradiol on non-spatial 
memory. When tested on a novel context recognition task, assessing spatial memory, 
only the low dose Levo (20 µg) alone treatment resulted in improved memory compared 
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to vehicle controls (Simone et al., 2015). This beneficial cognitive effect of Levo alone 
treatment was replicated in two separate studies from the Bimonte-Nelson laboratory, 
where tonic treatment and cyclic treatment with Levo in middle-aged Ovx rats enhanced 
spatial working memory on the water RAM (B. Blair Braden et al., 2017; Prakapenka et 
al., 2018). Interestingly, the beneficial effects of Levo were not maintained when 
combined with E2. Indeed, both E2 and Levo enhanced spatial working memory on the 
water RAM when they were each given alone, but did not yield benefits on spatial 
working memory when given together (Prakapenka et al., 2018). Levo is one of the only 
synthetic progestins tested to date in preclinical models that exhibits some beneficial 
cognitive effects. These beneficial effects occurred in both young ovary-intact and 
middle-aged Ovx rats. Further systematic experimental evaluations identifying potential 
impacts of Levo in combination with clinically-utilized estrogens, including naturally 
occurring and synthetic versions, will help elucidate whether there is a broader efficacy 
for this clinically relevant hormone combination, potentially providing a wider range of 
hormone therapy combination options for menopausal women.  
 
Conclusions 
Preclinical investigations are vital to understanding the role of estrogen-
containing hormone therapy, including as a sole treatment and as estrogenic plus 
progestogenic hormone therapy combinations. Using representative rodent models of 
menopause, such basic science research can yield great insight into how these treatments 
impact the brain and its functions, including cognition. These models provide unique 
opportunities to directly manipulate multiple factors implicated in clinically-relevant 
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exogenous hormone treatments to achieve the goal of understanding how hormones 
impact system functions, and to optimize regimens. Indeed, rodent studies of the 
behavioral and neurobiological effects of hormones highlight the intricate complexities 
governing the roles of ovarian hormones, and their combinations, in cognitive function. 
Although preclinical research suggests that estrogen-based hormone therapies can benefit 
cognition following the loss of circulating ovarian hormones, these findings are heavily 
dependent on study design and the specific factors addressed within a study. That one can 
rigorously control experimental designs with animal models has allowed researchers to 
methodically and systematically test effects of varied hormone exposures after different 
types of ovarian hormone loss. Results have indicated that the effects of estrogens on 
cognitive and brain function are reliant on a myriad of factors, including type of estrogen 
used, estrogen dose, route of administration, age at treatment, type of menopause model, 
and time of treatment initiation in relation to hormone deprivation history. Interactions 
between ovarian hormones, specifically those between estrogens and progestogens, and 
between different types of estrogens, differentially affect cognitive function. Again, 
several factors govern these interactions, such as the ratio between estrogen and 
progestogen treatment, the specific type of estrogen or progestogen utilized, as well as 
other treatment regimen variables. Furthermore, rodent studies reveal additional 
complexities when interpreting specific effects of estrogen-based hormone therapies on 
cognition, such as diet or history of drug abuse.  
Bridging preclinical and clinical research is critical to translating findings from 
bench to bedside to result in discoveries that will truly impact women’s health. One of the 
most critical ways to facilitate translation is to ensure that preclinical findings are noted 
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and utilized as being a liaison to bridge and drive clinical study design, and also that 
purposeful efforts are made to methodically evaluate potentially important clinical 
therapies and factors as directly as possible in preclinical studies. This includes using 
animal models to test hormone therapy individual components and combinations as used 
in women, encompassing effects mapped on to the timepoints relative to age and 
menopause status as closely as possible. While there are strengths and weaknesses to 
every preclinical model, acknowledging these caveats while still aiming to optimize 
translation is key to successful scientific discovery and translation across species. 
Overall, using these strategies can aid in clarifying the effects of menopausal hormone 
therapy on the many systems and functions important for women’s overall health, and 
can potentially lead to the development of targeted hormone therapies aimed at 
optimizing the quality of life for women experiencing symptoms associated with 
menopause. Of further note, collaborative efforts will be critical to broadening and 
extending understanding of the multi-dimensional effects of ovarian hormone loss and 
replacement, including work spanning natural and synthetic therapeutic options. 
Engaging a consortium of experts extending outside of the behavioral 
neuroendocrinology field is the optimal strategy to facilitate the mapping of hormone 
neuromechanism pathways that might impact brain functioning, including cognition. 
Subsequently, once potential pathways and associated targets are identified, scientists can 
engineer with the help of novel tools such as brain- or receptor- targeted delivery 
platforms to administer hormones to desired foci of interest in order to achieve optimal 
therapeutic efficacy. As the decades have passed and research has shed light on the many 
systems impacted by hormones, it has been learned that factors that were once considered 
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nuances of a hormone effect are, in fact, clear drivers of these effects. For continued 
progress in the field of translational behavioral neuroendocrinology, research must 
continue to discover, acknowledge, and respect these complexities, and push forward 
with a multi-pronged approach using classic techniques complimented by innovative and 
novel methods. Purposeful collaborative efforts between clinicians and basic scientists 
will break barriers and ultimately translate findings to yield optimal hormone therapy 
efficacy and outcomes for successful cognitive and brain aging in women. 
 
Goals of this dissertation 
The overarching goal of this dissertation work was to approach optimization of E2 
treatment, whereby maximal beneficial cognitive effects with minimal peripheral 
stimulation, particularly at the uterine horns, would be achieved, utilizing several distinct 
drug delivery strategies. The rat model of surgical menopause, Ovx, was implemented 
across all studies, and the same timeline between Ovx, treatment, and behavioral battery 
initiation was utilized. The first strategy was to evaluate an E2 plus progestogen hormone 
combination treatment that contained the cognitively-beneficial E2 plus a cognitively-
beneficial progestogen. Chapter 2 examined the impact of subcutaneously administered 
E2 plus Levo hormone combination treatment on spatial learning and memory, as well as 
on uterine stimulation. Then, Chapter 3 further evaluated the effect of subcutaneously 
administered E2 plus Levo hormone combination treatment on spatial learning and 
memory, as well as on uterine stimulation, as a function of clinically relevant E2 to Levo 
dose ratios. The second strategy was to encapsulate E2 in polymeric nanoparticles to 
harness the sustained release, decreased metabolism, and potential for tissue-specific 
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targeting delivery advantages following agent encapsulation in nanoparticles. Chapter 4 
assessed the cognitive effects of E2 encapsulated poly (lactic-co-glycolic) acid (PLGA) 
nanoparticles relative to blank PLGA nanoparticles and relative to free E2, provided that 
blank PLGA and the sesame oil vehicle for free E2 did not differ in cognitive outcomes. 
Additionally, impact on uterine horn stimulation was evaluated. The third approach 
combined both route of administration as well as addition of an agent carrier delivery 
strategies to target the delivery of E2 to the brain, but minimize its delivery to the uterine 
horns. Specifically, intranasal administration of E2 was implemented to achieve greater 
brain-to-uterine horn delivery relative to the subcutaneous route of administration, and 
cyclodextrins were used to solubilize E2 as well as to increase the delivery of E2 to brain 
regions involved in cognition relative to free E2. Thus, Chapter 5 addressed the impact of 
intranasal administration of E2 on spatial learning and memory as well as uterine horn 
stimulation following either free E2 intranasal treatment or an E2-cyclodextrin intranasal 
treatment that yielded greatest uptake in the dorsal hippocampus. Chapter 6 summarized 
the findings from the studies evaluating the three delivery approaches outlined above, 
provides limitations of these studies, as well as takeaways and future directions. 
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CHAPTER 2 
17β-ESTRADIOL PLUS A COGNITIVELY-BENEFICIAL PROGESTOGEN, 
LEVONORGESTREL 
 
This chapter was published in Neurobiology of Aging in January, 2018, and was titled:  
Contrasting effects of individual versus combined estrogen and progestogen 
regimens as working memory load increases in middle-aged ovariectomized rats: 
one plus one does not equal two 
A.V. Prakapenka, R. Hiroi, A.M. Quihuis, C. Carson, S. Patel, C. Berns-Leone, C. Fox, 
R.W. Sirianni, H.A. Bimonte-Nelson 
 
Contribution: I am the first author of this document and was the primary graduate student 
principal investigator on this project. Under the mentorship of Heather A. Bimonte-
Nelson and Rachael W. Sirianni, I designed and carried out the study with the assistance 
of our laboratory teams. I am the first-author for the manuscript, and I received great help 
from my co-authors in carrying out the study as well as editing the manuscript.  
 
Introduction 
Menopause, defined as the cessation of menses for at least one year, is marked by 
a reduction in levels of ovarian hormones, including estrogens and progesterone. This 
decrease in circulating levels of ovarian hormones can lead to the onset of several undesired 
physiological symptoms, including hot flashes, vaginal atrophy, and osteoporosis (Al-Safi 
& Santoro, 2014; NAMS, 2014). In women, several domains of memory performance, as 
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well as focus and concentration, are also sensitive to changes in ovarian hormone levels, 
and have been associated with menopausal status (Maki, 2012). The presence and severity 
of these symptoms vary amongst women, and these symptoms can greatly impact a 
woman’s quality of life; as a result, some women choose to take hormone therapy to 
ameliorate their symptoms. Thus, it is imperative to acquire a thorough understanding of 
how alterations in levels of ovarian hormones, and exogenously administered hormones, 
impact issues associated with menopause, such as changes in memory. Moreover, 
elucidating the roles of ovarian hormone loss and hormone therapies on the brain and its 
functions could lead to novel hormone therapy options that are tailored to alleviating 
specific symptoms associated with menopause. 
17β-estradiol (E2) is the most potent, naturally circulating estrogen in mammals, 
and it is commonly used as the estrogenic component in hormone therapy for menopause. 
As early as the 1950s, studies have suggested a beneficial role of estrogens in cognitive 
and related molecular processes of the central nervous system (e.g., Bimonte and 
Denenberg, 1999; Caldwell and Watson, 1952; Komnenich et al., 2013; Matsumoto et al., 
1985; Singh et al., 1995; Woolley and McEwen, 1993). Today, there are an extensive array 
of studies aimed at understanding the effects of E2 on learning and memory in humans as 
well as in animal models (Frick, 2015; Koebele & Bimonte-Nelson, 2015; Korol & Pisani, 
2015; Maki, 2012; S. E. Mennenga & Bimonte-Nelson, 2013; Sherwin, 2006). The 
ovariectomy (Ovx) model in rodents, whereby the primary source for circulating ovarian 
hormones, the ovaries, are surgically removed, provides a low circulating ovarian hormone 
profile or a ‘blank hormonal slate’. Although some ovarian hormones (e.g., E2 and 
progesterone) can also be synthesized in the brain (Kretz et al., 2004; Micevych & Sinchak, 
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2008; J. J. Tuscher et al., 2016), the Ovx rodent model can be employed to study the 
cognitive effects of exogenously administered hormone regimens that aim to achieve a 
specific circulating hormone profile. In Ovx rats, E2 treatment enhanced cognitive 
performance on a multitude of learning and memory behavioral paradigms, such as the 
radial-arm maze (Bimonte & Denenberg, 1999; Jill M. Daniel et al., 2006; Jill M Daniel et 
al., 1997; Fader, Johnson, & Dohanich, 1999; R. B. Gibbs & Johnson, 2008; V N Luine et 
al., 1998; Rodgers et al., 2010), Morris water maze (MWM; Heather A. Bimonte-Nelson 
et al., 2006; El-Bakri et al., 2004; Feng et al., 2004; Kiss et al., 2012; Lowry et al., 2010; 
McLaughlin et al., 2008; Talboom et al., 2008), delayed match-to-position T-maze (R. B. 
Gibbs, 2000; R B Gibbs, 1999; Robert B. Gibbs, 2007; Robert B. Gibbs, Gabor, Cox, & 
Johnson, 2004; Robert B Gibbs, 2002), and object placement (Conrad, McLaughlin, 
Huynh, El-Ashmawy, & Sparks, 2012; Frye, Duffy, & Walf, 2007; Victoria N. Luine, 
Jacome, & Maclusky, 2003; McLaughlin et al., 2008).  
In the brain, E2 can modulate the MAPK/ERK pathway, which is involved in the 
formation of different memory types (Atkins, Selcher, Petraitis, Trzaskos, & Sweatt, 1998; 
Blum, Moore, Adams, & Dash, 1999; Schafe et al., 2000). When the MAPK/ERK signaling 
pathway is activated, the signal travels from a cell receptor (e.g., estrogen receptors) to the 
nucleus DNA via a sequence of proteins, including the activated extracellular signal-
regulated kinase 1 and 2 (Erk1/2) (Ciccarelli and Giustetto, 2014; Koebele and Bimonte-
Nelson, 2017; Witty et al., 2012). Research indicates that, in the dorsal hippocampus, 
MAPK/ERK activation is essential for long-term memory formation, as well as for E2-
induced beneficial effects on memory consolidation (Blum et al., 1999; L. Fan et al., 2010; 
Fernandez et al., 2008; L. L. Harburger et al., 2009). Indeed, there is increased expression 
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of activated Erk2 in the dorsal hippocampus following E2 treatment (Fernandez et al., 
2008; L. L. Harburger et al., 2009; Witty, Gardella, Perez, & Daniel, 2013). Blocking this 
E2-induced increase in Erk2 activation attenuated the beneficial cognitive effects of E2 on 
the object recognition task (L. Fan et al., 2010; Fernandez et al., 2008). E2 treatment can 
also increase the expression of neurotrophins that are associated with learning and memory, 
including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and 
neurotrophin 3 (NT-3), in regions of the brain that are involved in cognitive function (i.e. 
entorhinal cortex and hippocampus) (H. A. Bimonte-Nelson et al., 2004; Kiss et al., 2012; 
Zhou, Zhang, Cohen, & Pandey, 2005). Neurotrophins and the MAPK/ERK pathway have 
been implicated in learning and memory as well as neuroplasticity (Bechara, Lyne, & 
Kelly, 2014; Gooney, Shaw, Kelly, O’Mara, & Lynch, 2002; McGauran et al., 2008). 
Taken together, these studies highlight the significant role of E2 in cognitive function that 
is mediated through its role in several defined pathways associated with neuroplasticity 
and memory.  
For women with an intact uterus, estrogen-based hormone therapies must also 
include a progestogen component to offset the increased risk for developing endometrial 
hyperplasia and cancer following exposure to unopposed estrogens (NAMS, 2012). 
Progestogens are a class of steroid hormones, and include natural progesterone and 
progestins (synthetic progestogens), which bind to the progesterone receptor. There is 
preclinical evidence that some progestogens can also offset the cognitive benefits of E2 
(Heather A. Bimonte-Nelson et al., 2006; L. L. Harburger et al., 2009; Lauren L. Harburger 
et al., 2007; Lowry et al., 2010). For instance, studies testing combination hormone 
therapies have shown that the addition of progesterone to E2 treatment reversed the 
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enhancing cognitive effects of E2 on the spatial reference memory MWM task in Ovx 
rodents (Heather A. Bimonte-Nelson et al., 2006; Lauren L. Harburger et al., 2007; Lowry 
et al., 2010). There is also preclinical evidence that the addition of progesterone can 
attenuate E2-induced changes in several neuromolecular mechanisms in the brain that are 
essential for cognitive function. For example, in the entorhinal cortex, the E2-induced 
increases in BDNF, NGF, and NT-3 levels were obviated with the addition of progesterone 
(H. A. Bimonte-Nelson et al., 2004). In the dorsal hippocampus, progesterone in 
combination with E2 treatment attenuated the E2-induced increase in activated Erk2 
expression (L. L. Harburger et al., 2009). These findings indicate that the addition of a 
progesterone component in hormone therapy to oppose undesired E2 stimulation in the 
periphery may not be cognitively beneficial, and that it can attenuate associated E2-induced 
benefits.  
Since progesterone has low systemic bioavailability with oral and transdermal 
delivery, synthetic progestogens are often used for both contraceptive and hormone therapy 
purposes (Du, Sanchez, Kim, & Azen, 2013; Kuhl, 2005; Pickar, Bon, Amadio, Mirkin, & 
Bernick, 2015). Medroxyprogesterone acetate (MPA) is a synthetic progestogen that is 
commonly prescribed for birth control (Depo-Provera), as well as used in combination with 
an estrogen for menopausal hormone therapy. The Bimonte-Nelson laboratory found that 
exogenous treatment with MPA alone in female rats impaired cognitive function (B. B. 
Braden et al., 2011; B. Blair Braden et al., 2017, 2010). Furthermore, a study testing the 
effects of a tonic MPA and E2 hormone combination showed that subcutaneous MPA (via 
a pellet) plus oral E2 (via drinking water) treatment resulted in impaired learning on the 
MWM in middle-aged Ovx rats compared to chronic E2, chronic E2 plus progesterone, or 
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cyclic E2 (Lowry et al., 2010). Additionally, subcutaneous tonic administration of 
progesterone or of MPA in adult Ovx rats blocked the neuroprotective effects of E2 
following excitotoxic lesion with kainate (Rosario, Ramsden, & Pike, 2006). These studies 
further indicate that the role of E2 on the brain and cognitive function can be altered by the 
addition of a progestogen, and the magnitude of this effect may be governed by the type of 
progestogen administered (e.g., progesterone versus MPA).  
Research done thus far supports the hypothesis that MPA has detrimental effects 
on cognition, alone and in combination with estrogen; there are other FDA-approved 
progestogens that satisfy the uterus opposing effects that have not been cognitively 
profiled. An important goal to aid women’s health is to find a progestogen that will 
accomplish uterine protection while not imposing negative cognitive effects. 
Levonorgestrel (Levo) is a synthetic progestogen utilized in multiple contraceptives, such 
as intrauterine devices (i.e. Mirena) and emergency contraception (i.e. Plan B), as well as 
in combination with estrogens in oral birth control pills such as Lutera, Aviane, 
Seasonique, and Seasonale. In menopausal hormone therapy, Levo is combined with E2 in 
the transdermal patch, Climara Pro. The contraceptive efficacy of Levo, and of 
combination estrogen plus Levo, hormone formulations are well established. However, 
research has only just begun to address the potential effects of Levo on cognitive 
performance, and only one preclinical study has evaluated such impact in the context of 
aging. The Bimonte-Nelson laboratory has demonstrated that daily subcutaneous 
administration of 0.6 μg Levo, a dose that is equivalent to the clinically available Climara 
Pro patch when accounting for body weight, enhanced working memory performance on 
the water radial-arm maze (WRAM) relative to administration of the vehicle control in 
  
66 
middle-aged, Ovx rats (B. Blair Braden et al., 2017). This is especially exciting, as this is 
the first progestogen given chronically shown to benefit memory in a preclinical model of 
menopause. However, whether these benefits will hold when given in combination with an 
estrogen is yet to be determined. This question is critically important given the strong 
clinical use of combined regimens for menopausal hormone therapy.  
The current study examined the effect of E2 + Levo hormone combination 
treatment on cognitive function, with interpretations relative to vehicle control treatment, 
as well as relative to E2 alone and Levo alone treatments. The intent was to study these 
regimens in the context of older age and ovarian hormone loss. Thus, treatments were 
administered to middle-aged Ovx rats. The 0.6 μg Levo dose was carefully chosen based 
on prior studies that showed enhancing cognitive effects of Levo alone at this dose (B. 
Blair Braden et al., 2017); I was interested in examining whether a cognitively enhancing 
Levo dose when given alone would also enhance cognitive function when given in 
combination with E2. First, cognitive function was assessed using a battery of behavioral 
tasks to test spatial learning and memory using the WRAM (working and reference 
memory) and the MWM (reference memory), including a control behavioral task (visible 
platform). Second, following behavioral testing, activated Erk1 and Erk2 levels in brain 
regions that are involved in cognitive function were evaluated, including the frontal cortex, 
dorsal hippocampus, CA1/CA2 ventral hippocampus, entorhinal cortex, and perirhinal 
cortex. Given that the E2 and Levo regimens tested here were based on prior effects 
benefitting cognition in the Bimonte-Nelson laboratory, I hypothesized that E2 alone and 
Levo alone treatments would yield favorable cognitive effects. Because Levo is often used 
in combination with estrogens in clinical formulations, and because Levo is the first 
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progestogen shown to initiate beneficial cognitive effects when given alone in the Bimonte-
Nelson laboratory, I sought to determine whether its beneficial effects would hold when 
given combined with estrogen. Thus, here, I ask: in a surgical menopause model, will the 
combination of two cognitively-enhancing hormones result in strengthened beneficial 
effects, or in null or attenuating effects, on learning and memory performance?   
 
Methods 
Animals 
Forty middle-aged, 11-month old, Fischer-344 CDF virgin female rats from the National 
Institute on Aging, Harlan Laboratories (Indianapolis, IN) were used based on prior 
publications (B. Blair Braden et al., 2017; Chisholm & Juraska, 2012; Rodgers et al., 2010). 
Rats were pair housed on a 12-hour light/dark cycle, and food (Teklad global 18% protein 
rodent diet, Envigo) and water were ad libitum. All procedures were done with approval 
from the Arizona State University IACUC and followed the standards set by the National 
Institutes of Health. 
  
Ovariectomy (Ovx) 
All rats underwent Ovx surgery from the dorsolateral aspect under acute isoflurane 
inhalation anesthesia. Each rat was administered a single subcutaneous injection of 
Rimadyl (5 mg/kg) for pain. After dorsolateral incisions were made in the skin and 
peritoneum, a ligature was applied to the tip of each uterine horn and each ovary was 
removed. The muscle and skin were sutured (Coated VICRYL Suture, Ethicon) and rats 
were subcutaneously administered saline (2 ml) to prevent dehydration.  
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Treatment administration 
Treatment administration started 21 days after Ovx surgery, and continued until the 
end of the study (see Figure 3A for the study timeline). Rats were randomly assigned to 
receive either a daily subcutaneous injection of sesame oil as control (Vehicle, n = 10) or 
a hormone injection of 3 μg E2 (E2-Only, n = 10), 0.6 μg Levo (Levo-Only, n = 9), or a 
combination of 3 μg E2 and 0.6 μg Levo (E2 + Levo, n = 10), in 0.1 ml of sesame oil. All 
treatment injections were done between 7:00-8:00 am; behavioral tasks were initiated half 
an hour after the last treatment injection, and treatment groups were counterbalanced 
throughout the day to account for timing differences between treatment injection and 
behavioral testing. One animal from the Levo-Only group was excluded from all analyses 
due to premature death, the cause of which was not related to experimental conditions. The 
dose for Levo-Only treatment was based on published work from the Bimonte-Nelson 
laboratory where a daily subcutaneous injection of 0.6 μg of Levo enhanced performance 
on the WRAM in middle-aged Ovx rats (B. Blair Braden et al., 2017). After 20 days of 
treatment, all animals started testing on a battery of behavioral tasks to assess cognitive 
performance. The timing of treatment initiation and duration prior to behavior testing was 
methodically decided based on prior studies from the Bimonte-Nelson laboratory that have 
shown effects of hormone treatment on cognitive performance (Heather A. Bimonte-
Nelson et al., 2006; E. Engler-Chiurazzi et al., 2011; Sarah E. Mennenga, Gerson, Koebele, 
et al., 2015; Talboom et al., 2008). Throughout the span of the study, body weights were 
measured weekly to evaluate the expected increase in body weight as a result of Ovx, 
followed by the expected decrease in body weight for animals that received an estrogen-
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containing treatment (Figure 3B; Geary et al., 1994; McLaughlin et al., 2008; Mennenga 
and Bimonte-Nelson, 2013). 
 
Water radial-arm maze (WRAM) 
The first behavioral task was the win-shift WRAM used to examine spatial working 
and reference memory (H. A. Bimonte-Nelson, 2015d; Bimonte & Denenberg, 1999; B. 
Blair Braden et al., 2017; S. E. Mennenga & Bimonte-Nelson, 2015; Sarah E. Mennenga, 
Koebele, et al., 2015). WRAM testing started on day 21 of treatment administration and 
lasted for 13 days. The maze was an 8 arm apparatus, and 4 out of the 8 arms contained 
hidden platforms. Each arm’s dimensions were 38.1 cm x 12.7 cm, and platforms were 10 
cm in diameter. The maze was filled with water made opaque with nontoxic black paint 
that was kept between 18-20oC for the duration of testing, and spatial cues were set up 
around the room to aid in spatial navigation.  The room was 248 cm x 243 cm in size. 
Each subject was randomly assigned a set of platform locations, which were kept 
fixed for the duration of testing for a subject. For each trial, subjects were dropped off in 
the start arm and allowed a maximum of 3 min to find a platform; once on the platform, 
subjects remained there for 15s before being placed in a heated testing cage for a 30s inter-
trial interval (ITI). A trial was completed when a platform was found. During the ITI, the 
just-located platform was removed from the maze, and the maze water was cleaned of 
debris with a fishnet. At the end of the 30s ITI, the next trial was started. There were a total 
of 4 trials per day (one trial per platform). There was an increase in working memory load 
across trials as the memory system was increasingly taxed with the removal of each 
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additional found platform. On the last day of testing, a 6-hour delay between trials 2 and 3 
was implemented to examine delayed memory retention. 
Performance on the WRAM for each subject was determined by scoring the 
orthogonal measures of working and reference memory. Briefly, the first entry into a non-
platformed arm within a day was defined as a reference memory (RM) error. A re-entry 
into a RM (non-platformed) arm within the same day was defined as a working memory 
incorrect (WMI) error. An entry into a previously platformed arm within a day was defined 
as a working memory correct (WMC) error.  
 
Morris water maze (MWM) 
The day after WRAM testing was completed, all animals began testing on the 
MWM to evaluate spatial reference memory performance (H. A. Bimonte-Nelson, 2015b; 
Talboom et al., 2014, 2008). The MWM apparatus was a circular tub, 188 cm in diameter, 
filled with water (18-20oC) that was made opaque with nontoxic paint. One platform, 10 
cm in diameter, was submerged in the northeast (NE) quadrant of the tub. The location of 
the platform remained constant across all trials and days of testing. There were abundant 
spatial cues set up around the room to aid in spatial navigation. The room was 348 cm x 
337 cm in size. Each animal received 4 trials per day for each of the 5 testing days. The 
subject was dropped off at one of four starting locations (north, south, east, or west) at the 
start of each trial and was allowed 60s to locate the platform. The order of the drop off 
starting locations was randomized across days, but kept constant for all animals across 4 
trials within a day. Once the platform was found, the subject remained on the platform for 
15s and was then placed back into a heated cage for a 5-8 min ITI. If the platform was not 
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found within the allotted 60s trial time, the subject was led to the platform and remained 
there for 15s before being placed back into a heated cage for a 5-8 min ITI. Each rat’s swim 
path was recorded using the Ethovision tracking system (Noldus Instruments, Wageningen, 
The Netherlands), and total swim distance to the platform was analyzed. On the last day of 
testing, a probe trial was administered as an additional 5th trial to test for spatial 
localization. For the probe trial, the platform was removed and the subject was allowed to 
swim for a total of 60s after being dropped off from the furthest drop off location (west) in 
relation to where the platform was located (NE quadrant).  
 
Visible platform  
To confirm their capability to perform the procedural components of a water-escape 
task, animals were tested on the visible platform task the day after completion of MWM 
testing (Bimonte-Nelson, 2015a; Mennenga et al., 2015a, 2015c). The visible platform task 
was composed of a rectangular tub, 100 cm x 60 cm, filled with clear water kept at 18-
20oC; a black platform, 10 cm in diameter, remained 4 cm above the water surface 
throughout testing. A curtain was used to block obvious spatial cues located in the area 
distal from the maze. The room was 168 cm x 155 cm in size. There were a total of 6 trials 
per animal for the one day of testing, with a 90s maximum trial time. Once the platform 
was found, subjects were given 15s on the platform and then placed back into a heated cage 
(ITI was 5-8 min). The drop off location remained constant throughout testing, and the 
platform location was varied semi-randomly between three distinct locations.  
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Blood serum analysis 
The day after visible platform testing, animals were euthanized with isoflurane, 
starting at the regular testing time and in the same order in which they were tested. Blood 
was collected via cardiocentesis, allowed to clot at 4oC (Vacutainer 367986, Becton 
Dickinson and Company, Franklin Lakes, NJ, USA), and centrifuged at 3000 rpm for 20 
min at 4oC to obtain blood serum. Serum was stored at -20oC until analysis. Circulating E2 
and estrone levels were determined by radioimmunoassay at the Core Endocrinology 
Laboratory of the Pennsylvania State University, College of Medicine. Specifically, E2 and 
estrone levels were measured in duplicate using a double antibody liquid-phase 
radioimmunoassay (Beckman Coulter, Brea, CA) as previously reported (E. B. Engler-
Chiurazzi et al., 2012; Koebele et al., 2017; Sarah E. Mennenga, Koebele, et al., 2015). For 
the E2 assay, E2-specific antibodies were used with 125I-labeled E2 as the tracer. The E2 
assay had a functional sensitivity of 4 pg/ml. Inter-assay coefficients of variation at a mean 
level of 6 pg/ml E2 averaged 8%, and intra-assay coefficients of variation averaged 6%. 
For the estrone assay, estrone-specific antibodies were used with 125I-labeled estrone as the 
tracer. The estrone assay had a functional sensitivity of 16 pg/ml. Inter-assay coefficients 
of variation for estrone at a mean level of 90 pg/ml averaged 11%, and intra-assay 
coefficients of variation averaged 8%. 
 
Uterine horn weights 
It is known that uterine horn weight is impacted by the presence of ovarian 
hormones (e.g., Engler-Chiurazzi et al., 2012; Mennenga et al., 2015b; Westerlind et al., 
1998). To confirm complete Ovx as well as E2 exposure, and to assess whether the addition 
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of Levo impacted the expected E2-induced increases, uterine horns were inspected and 
removed at sacrifice, trimmed of visible fat, and weighed (wet weight).  
 
Brain dissection 
Immediately following cardiocentesis, the brain was rapidly dissected. The Rat 
Brain Atlas (Paxinos & Watson, 1998) was used as a reference for plate designations. The 
frontal cortex was taken from the dorsal aspect of the brain (plates 5-14). The brain was 
then cut across the coronal plane to gain access to the dorsal hippocampus (plates 33-35), 
and the CA1/CA2 ventral hippocampus, entorhinal cortex, and perirhinal cortex (plates 39-
42). Brain regions were frozen and stored at -70oC until western blot analyses. 
 
Western blots 
Activated Erk1/2 expression levels in the frontal cortex, dorsal hippocampus, 
CA1/CA2 ventral hippocampus, entorhinal cortex, and perirhinal cortex (all left 
hemisphere) were analyzed using western blots (P.T. Orr et al., 2012). Samples were 
suspended in 1:50 w/v RIPA buffer (150mm NaCl, 1% Triton X-100, 0.1% SDS, 0.5% Na 
deoxycholate, 50 mm Tris, protease inhibitor (cat# 5892791001, Millipore-Sigma), and 
phosphatase inhibitor (cat# 524625, Millipore-Sigma)), homogenized with a probe 
sonicator (Ultrasonic Processor, Cole Parmer, IL, USA), and centrifuged at 10,000 rpm for 
10 min at 4oC. The BCA protein assay (ThermoFisher Scientific, Pittsburgh, PA, USA) 
was used to determine protein concentration. Brain homogenates were run on 4-12% 
NuPAGE Bis-Tris gel using the SureLock mini-cell (Invitrogen, Carlsbad, CA, USA) and 
blotted to an Immobilon PVDF membrane. All samples were loaded at the same protein 
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concentration per brain region, and all gels were counterbalanced by treatment group, with 
a total of three gels run per brain region. The western blot was blocked in 10% non-fat milk 
for 1 hour, and incubated overnight in anti-phospho p44/p42 Erk1/2 primary antibody 
(1:2000, Cell Signaling) at 4oC. The blot was then incubated with anti-rabbit HRP (1:2000, 
Cell Signaling) for 1 hour at room temperature, and visualized using chemiluminescence 
(LumiGlo and Peroxide, Cell Signaling) in a film developer (Konica SRX-101A Film 
Processor, Tokyo, Japan). After imaging, the blot was stripped in 0.2M NaOH and re-
probed for anti-total p44/p42 Erk1/2 (1:1000, Cell Signaling). Densitometry was 
performed using ImageJ software. Activated Erk1/2 levels were expressed as 
phosphorylated Erk1/2 expression normalized to total Erk1/2 expression.  
 
Statistical analyses 
 Behavioral measures obtained from each maze were analyzed separately, using 
two-tailed tests unless otherwise specified. Alpha was set at p < 0.05 for all statistical 
analyses, and Fisher’s PLSD tests were used for post hoc analyses.  
To evaluate overall WRAM learning across all days, an omnibus repeated measures 
ANOVA was run to examine the Day main effect (days 2-12) for each of the three error 
types (WMC, WMI, and RM errors). Next, based on prior publications (H. A. Bimonte-
Nelson et al., 2015; B. Blair Braden et al., 2017), WRAM testing days were blocked into 
three blocks: Days 2-5 (Block 1), Days 6-9 (Block 2), and Days 10-12 (Block 3). Each 
block was analyzed separately using repeated measures ANOVA for each of the three error 
types, as done previously (H. A. Bimonte-Nelson et al., 2015; B. Blair Braden et al., 2017). 
To determine the effects of hormone treatment on WRAM performance, the independent 
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variable was Treatment, and the repeated measures were Trials nested within Days. In the 
case of a significant Trial x Treatment interaction, Trials 3 and 4 were analyzed separately 
to test the higher memory load trials, with Treatment as the independent variable and Days 
as the repeated measures. For the WRAM delay, each treatment group was evaluated 
separately for WMC, WMI, and RM errors using one-tailed repeated measures ANOVA 
since the delay period typically impairs performance on the WRAM, as shown in prior 
findings (B. Blair Braden et al., 2015; Hiroi et al., 2016). Specifically, to analyze 
performance following the 6-hour delay, the post-delay trials, Trials 3 and 4 on Day 13 
(delay performance) were averaged and compared to the average of the baseline trials, 
Trials 3 and 4 on Day 12 (baseline performance), as done previously (Camp et al., 2012; 
Engler Chuirazzi et al., 2011; Mennenga et al., 2015; 2014).  
 MWM Total Swim Distance data were analyzed using repeated measures ANOVA. 
The independent variable was Treatment, and the repeated measures were Trials nested 
within Days. For the probe trial, repeated measures ANOVA was used to compare Percent 
Swim Distance in the NE quadrant (the previously platformed quadrant) to the quadrant 
that was located diagonally opposite to the NE quadrant (SW, southwest) to confirm spatial 
localization of the platform location (H. A. Bimonte-Nelson, 2015b; H. A. Bimonte-Nelson 
et al., 2015). 
For the visible platform analysis, Time to Platform was analyzed using repeated 
measures ANOVA. The independent variable was Treatment and the repeated measures 
were Trials (6 trials). 
For blood serum levels of E2 (pg/ml) and estrone (pg/ml), and uterine horn weights 
(g), a one-way ANOVA was used with Treatment as the independent variable. A one-way 
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ANOVA was also used to analyze activated Erk1 and Erk2 expression in each brain region, 
with Treatment as the independent variable and activated Erk expression (phosphorylated 
Erk normalized to total Erk) as the dependent variable. To examine relationships between 
activated Erk expression and cognitive performance, Pearson r correlations were run 
between activated Erk1 and activated Erk2 expression in each brain region and WMC, 
WMI, and RM error measures for Block 1 of WRAM, the block of testing where main 
behavioral effects were seen. To account for multiple correlations, a false discovery rate 
(FDR) threshold of 0.1 was used; both uncorrected (P) and FDR-corrected (Q) statistics 
are reported (Benjamini & Hochberg, 1995).  
 
Results 
Water radial-arm maze (WRAM) 
Spatial working and reference memory performance were measured using the 
WRAM. To analyze overall learning across all days of testing, there was a main effect of 
Day for each memory measure, whereby errors decreased for WMC [F(10,35) = 7.042, p < 
0.0001], WMI [F(10,35) = 12.603, p < 0.0001; Figure 4A], and RM [F(10,35) = 8.176, p < 
0.0001] across days 2-12 of testing, demonstrating learning of the WRAM task for all three 
measures of memory (data not shown). For each memory measure, there was no significant 
Treatment x Day interaction for Days 2-12, suggesting that groups did not differ in WRAM 
learning across the entire learning curve. In Block 1, there was a main effect of Treatment 
for WMI errors [F(3,35) = 3.597, p < 0.05; Figure 4B]. Post hoc analysis of this measurement 
collapsed across all trials revealed fewer errors in the E2-Only [p < 0.05] and Levo-Only 
[p < 0.01] treatment groups relative to the Vehicle control group, while there were no 
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significant differences between the Vehicle and E2 + Levo groups. These results indicate 
that the individual hormone treatments, E2-Only and Levo-Only, enhanced WMI 
performance during task acquisition, while the combination treatment did not. 
Additionally, post hoc analyses for Block 1 for WMI revealed that the E2 + Levo group 
made more errors than the Levo-Only group [p < 0.05], demonstrating that the E2 + Levo 
hormone combination treatment impaired acquisition of the WMI measure relative to 
Levo-Only treatment; there was a marginal trend for the E2 + Levo group to make more 
errors than the E2-Only group [p < 0.1], suggesting that the E2 + Levo hormone 
combination treatment tended to impair acquisition of the WMI measure relative to E2-
Only treatment. For Block 1, there was also a significant Treatment x Trial interaction 
[F(9,105) = 2.23, p < 0.05; Figure 4C] for WMI errors. Post hoc analyses showed that E2-
Only [p < 0.01; Figure 4D], Levo-Only [Figure 4D], and E2 + Levo [p < 0.01; Figure 4D] 
treatment groups made fewer WMI errors compared to the Vehicle control group on Trial 
3, the moderate working memory load trial. On Trial 4, the highest working memory load 
trial, post hoc analyses revealed that the E2 + Levo group made more WMI errors than the 
E2-Only [p < 0.05; Figure 4E] and Levo-Only [p < 0.05; Figure 4E] groups, signifying that 
the combination hormone treatment impaired the ability to handle a high working memory 
demand relative to the groups treated with either hormone alone. Due to these divergent 
cognitive effects of the E2 + Levo treatment across trials, a post hoc decision was made to 
test the interaction between the high working memory load trials, Trial 3 and 4, and E2 + 
Levo treatment group WMI performance relative to Vehicle control. This interaction was 
indeed significant [F(1,18) = 6.67, p < 0.05], indicating that the cognitive impact of the E2 + 
Levo hormone combination treatment is modulated by demand in working memory load 
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(Figure 4F). The Treatment main effects for WMC or RM for Blocks 1, 2 and 3, and for 
WMI for Blocks 2 and 3, were not significant (data not shown).  
Following the 6-hour delay on Day 13, the Vehicle control group [F(1,9) = 4.509, p 
< 0.05] and Levo-Only group [F(1,8) = 0.5099, p < 0.05] made more WMC errors on the 
post delay trials relative to baseline trials, indicating forgetting across the delay period 
(Figure 5). E2-Only and E2 + Levo groups did not significantly differ in WMC errors for 
post delay trials compared to baseline trials (Figure 5), suggesting that these groups did not 
show significant forgetting across the delay period. No differences were seen for WMI and 
RM error measures for each treatment group on the post-delay trials relative to baseline 
trials (data not shown). 
 
Morris water maze (MWM) 
The MWM was used to evaluate spatial reference memory performance. There was 
a main effect of Day across all five days of testing, with Total Swim Distance scores 
decreasing across days [F(4,35) = 83.997, p < 0.0001; Figure 6A]. The lack of a significant 
Treatment x Day interaction indicates that the groups did not differ in learning trajectory 
across days. The Treatment main effect for swim distance to the platform was not 
significant. For the probe trial, there was a main effect of Quadrant, with a greater percent 
swim distance spent in the NE target quadrant, the previously-platformed quadrant, relative 
to the opposite, SW quadrant [F(1,35) = 246.174, p < 0.0001; Figure 6B], indicating spatial 
localization of the platform location. The lack of a significant Treatment x Quadrant 
interaction suggests that the groups did not differ in their pattern of spatial localization by 
the end of testing.  
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Visible platform 
Motor and visual competence to solve a water-escape maze task was evaluated 
using the visible platform test. There was a main effect of Trial [F(5,35) = 5.609, p < 0.0001], 
with an 8.6s average latency to the platform across trials (data not shown). During the last 
trial of testing, each animal reached the platform in under 18s, confirming the ability to 
complete a water-escape maze task. Neither the Treatment, nor the Treatment x Trial 
interaction, was significant, indicating that the groups did not differ in the ability to learn 
and perform the procedural components of a water-escape maze task.  
 
Blood serum analysis 
E2 and estrone levels in blood serum, collected at sacrifice, were analyzed. For E2 
levels, there was a main effect of Treatment [F(3,34) = 10.691, p < 0.0001], with post hoc 
analyses showing higher E2 levels for the E2-Only [p < 0.0001] and E2 + Levo [p < 0.0001] 
groups compared to the Vehicle group, as well as higher E2 levels for the E2-Only [p < 
0.0001] and E2 + Levo [p < 0.0001] groups compared to the Levo-Only group (Figure 7A). 
For estrone levels, there was a main effect of Treatment [F(3,35) = 25.014, p < 0.0001], with 
higher estrone levels for both E2-Only [p < 0.0001] and E2 + Levo [p < 0.0001] groups 
relative to the Vehicle group, as well as higher estrone levels for both E2-Only [p < 0.0001] 
and E2 + Levo [p < 0.0001] groups relative to the Levo-Only group (Figure 7B). These 
results verify systemic presence of E2 and estrone in the groups receiving exogenous E2 
treatment.  
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Uterine horn weight 
There was a main effect of Treatment [F(3,35) = 58.915, p < 0.0001] for uterine horn 
weights; higher weights were seen in the E2-Only [p < 0.0001] and E2 + Levo [p < 0.0001] 
groups compared to the Vehicle group, and higher weights were seen in the E2-Only [p < 
0.0001] and E2 + Levo [p < 0.0001] groups compared to the Levo-only group, as expected 
with estrogen exposure (Figure 7C; Engler-Chiurazzi et al., 2012; Mennenga et al., 2015b; 
Westerlind et al., 1998). There was no significant difference in uterine horn weights 
between the E2-Only group and the E2 + Levo group, suggesting that the addition of the 
currently-utilized Levo regimen to the E2 treatment did not impact the E2-induced increase 
in uterine horn weight at the time of uterine data collection.  
 
Brain analysis 
Western blots were performed to examine activated Erk1 and Erk2 expression in 
several regions of the brain that are indicated in learning and memory. There were no 
significant main effects of Treatment for activated Erk1 and Erk2 expression in the frontal 
cortex, dorsal hippocampus, CA1/CA2 ventral hippocampus, entorhinal cortex, or 
perirhinal cortex (data not shown). A correlation table summarizing the relationship 
between activated Erk1 and activated Erk2 expression in the frontal cortex and error 
measures for Block 1 of WRAM for each treatment group is presented in Table 1. After 
adjusting for multiple correlations using a set FDR threshold of 0.1, a relationship between 
cognitive performance and activated Erk2 expression was seen that was specific to animals 
treated with E2-Only, with higher levels of activated Erk2 associated with better 
performance. In particular, in the frontal cortex, there was a significant negative correlation 
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between activated Erk2 expression and Block 1 WMC errors within the E2-Only group 
[r(19) = -0.88, P < 0.001, Q < 0.1; Figure 8B], suggesting that the E2-treated animals that 
tended to have higher levels of activated Erk2 in the frontal cortex tended to make fewer 
WMC errors. In contrast to the relationship seen with E2-Only treatment, there was no 
significant correlation between activated Erk2 expression in the frontal cortex and Block 1 
WMC errors within the E2 + Levo treatment group [r(19) = 0.26, P = 0.47, Q = 0.87; Figure 
8D], suggesting that the addition of Levo obviated the E2-induced association between 
working memory performance and activated Erk2 levels in the frontal cortex. There was 
also no significant correlation between activated Erk2 expression in the frontal cortex and 
Block 1 WMC errors within the Vehicle control group [r(19) = 0.72, P =  0.02, Q = 0.28; 
Figure 8A] and within the Levo-Only treatment group [r(18) = -0.43, P = 0.25, Q = 0.87; 
Figure 8C]. There was no significant relationship between cognitive performance and 
activated Erk1 expression, nor between cognitive performance and activated Erk2 
expression, in the dorsal hippocampus, CA1/CA2 ventral hippocampus, entorhinal cortex, 
or perirhinal cortex (correlation tables not shown).  
 
Discussion 
The current study demonstrated that E2-Only and Levo-Only treatments enhanced 
working memory performance during acquisition of the WRAM, as measured by WMI 
errors collapsed across all trials, and that the combination of E2 + Levo attenuated these 
beneficial cognitive effects. In fact, at the highest demand working load (trial 4) during 
acquisition, the E2 + Levo combination impaired performance, as compared to the E2-Only 
and Levo-Only groups. Thus, even a progestin that was shown here and in prior work 
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(Braden et al., 2017) to enhance the ability to handle an increasing working memory load 
on the WRAM task when given alone, can reverse the beneficial effects of E2 at a high 
memory demand. Additionally, findings showed that there was a distinct relationship 
between activated Erk2 expression in the frontal cortex and working memory performance 
within the E2-Only treatment group, which was mitigated by the addition of Levo to the 
E2 treatment. However, Levo did not uniformly attenuate the benefits of E2. At a working 
memory load that was less demanding, the addition of Levo did not reverse the cognitive 
benefits of E2 relative to vehicle treatment, as determined by trial 3 for WMI errors on the 
WRAM. Indeed, similar to each hormone treatment given alone, the hormone combination 
treatment benefitted this moderate working memory load trial performance as compared to 
the vehicle treatment.  
Overall, the present study found that all hormone treatment groups were able to 
learn spatial working and reference memory tasks, as shown by their performance across 
all days on the WRAM (Days 1-12, collapsed across the 4 trials) and the MWM (Days 1-
5, collapsed across the 4 trials). During the acquisition phase of the WRAM (Block 1 of 
testing), when rats were initially learning the rules of the task, the E2-Only and Levo-Only 
treatment groups made fewer WMI errors across all four trials compared to the vehicle 
group, indicating that E2-Only and Levo-Only enhanced working memory performance 
during the learning phase of the task relative to control. With reference to prior publications 
testing E2 (using various regimens, doses, and rat ages), in general, results here are 
consistent with previously published findings suggesting enhanced cognitive performance 
with E2 only treatment (Bimonte & Denenberg, 1999; Jill M. Daniel et al., 2006; Jill M 
Daniel et al., 1997; Fader et al., 1999; R. B. Gibbs & Johnson, 2008; V N Luine et al., 
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1998; Rodgers et al., 2010). The results are also consistent with previously published 
findings of enhanced cognitive performance with Levo only treatment (B. Blair Braden et 
al., 2017; Simone et al., 2015). When evaluating all four trials combined, the combination 
of E2 + Levo obviated the working memory benefits of E2-Only and Levo-Only. There 
has been only one other published preclinical study testing an estrogen/Levo combination, 
whereby the synthetic estrogen ethinyl estradiol (EE) plus Levo was tested in a different 
model and behavior paradigm: the young ovary-intact rat tested in object memory (Simone 
et al., 2015). However, even with the important differences between the studies, similar 
results were reported, with the EE plus Levo hormone combination treatment attenuating 
EE-induced improvements in novel object memory and Levo-induced enhancements in 
visuospatial memory in ovary-intact young rats (Simone et al., 2015). Preclinical studies 
testing other combination hormone therapies have also shown that, in Ovx rodents, the 
addition of natural progesterone to E2 treatment can reverse the enhancing cognitive effects 
of E2 (Heather A. Bimonte-Nelson et al., 2006; Lauren L. Harburger et al., 2007; Lowry 
et al., 2010). It has also been shown that the addition of MPA to an E2 treatment resulted 
in impaired learning on the MWM compared to E2 treatment alone (Lowry et al., 2010). 
Interestingly, results from this study showed that working memory demand 
influenced the direction of hormone treatment effects on cognitive performance 
specifically during the acquisition phase of the WRAM. On Trial 3, when the working 
memory load was moderate, the E2-Only, Levo-Only, and E2 + Levo treatment groups 
made fewer WMI errors than the vehicle group, suggesting that all hormone treatments 
enhanced performance relative to control treatment during this moderate demand trial. 
However, on Trial 4, when the working memory load was highest, the E2 + Levo treatment 
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group made more WMI errors compared to E2-Only and Levo-Only treatment groups, 
revealing that this estrogen/progestin combination treatment impaired high demand 
working memory ability relative to each individual hormone treatment. This is additionally 
represented in Figure 4F, with effects clearly illustrated by the interaction between the 
moderate and the high working memory load trials (Trials 3 and 4) and Treatment (E2 + 
Levo group versus the vehicle group). Taken together, these results indicate that the 
hormones E2 and Levo impact cognitive function in a model of surgical menopause, with 
the direction of this mnemonic impact dependent on: 1) whether E2 and Levo are 
administered alone as an individual exogenous regimen, or together as a hormone 
combination exogenous regimen, and 2) cognitive demand. Each individual hormone 
regimen and the combined hormone regimen enhanced cognitive performance when the 
working memory demand was moderate; however, when the working memory demand was 
high, these two hormones in combination impaired performance compared to each 
hormone alone. These findings are in accordance with previous studies demonstrating 
distinct hormone effects across an increase in working memory demand, including with 
estrogens (Bimonte & Denenberg, 1999; Hiroi et al., 2016; Sarah E. Mennenga, Gerson, 
Koebele, et al., 2015), progestogens (B. B. Braden et al., 2011; B. Blair Braden et al., 2017, 
2015), and androgens (Bryan W. Camp et al., 2012; Sarah E. Mennenga, Koebele, et al., 
2015).  
When a 6-hour delay period was implemented for the WRAM, neither of the E2-
treated groups (E2-Only and E2 + Levo) differed in WMC errors between the post-delay 
trials and the baseline trials. This suggests that exogenous E2 treatment protected from 
delay-induced impairment in performance on working memory. Of note, the addition of 
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Levo to E2 did not reverse the protective effects of E2-Only against delay-induced 
impairment in working memory performance. However, the vehicle and Levo-Only 
treatment groups exhibited impaired performance, where they made more WMC errors on 
the post-delay trials relative to their baseline performance. Together, these findings 
demonstrate a potential protective effect of E2 on cognitive function across the delay period 
that was not seen with the vehicle and the Levo-Only treatment, regardless of whether Levo 
is on board with the E2 treatment or not. These results are consistent with previous studies 
where E2 enhanced cognitive performance following the implementation of a delay period 
(Lauren L. Harburger et al., 2007; Talboom et al., 2008). For instance, one study trained 
aged Ovx mice on the MWM and then immediately administered vehicle, E2, or E2 plus a 
low or high dose of progesterone treatment (Lauren L. Harburger et al., 2007). Following 
a 24 hour delay period, results showed that the E2 treatment enhanced performance (Lauren 
L. Harburger et al., 2007). The addition of a low dose of progesterone did not alter the 
beneficial cognitive effects of E2 on post-delay performance, but the addition of a high 
dose of progesterone attenuated the beneficial cognitive effects of E2 on post-delay 
performance (Lauren L. Harburger et al., 2007). Another study from the Bimonte-Nelson 
laboratory also showed that E2 treatment had beneficial effects on overnight forgetting on 
the MWM task compared to vehicle control (Talboom et al., 2008). Collectively, these 
results reveal a protective role of E2 in cognitive function following the implementation of 
a delay period.  
The hormone impact was working memory-specific in the current study. For the 
spatial reference memory MWM, all treatment groups decreased in swim distance to the 
platform across all days of testing. However, there were no treatment differences in the 
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swim distance to the platform, suggesting similar spatial reference memory performance 
on this task. On the probe trial for MWM, all treatment groups swam a greater percent 
distance in the NE target quadrant, which previously contained the platform, compared to 
the opposing SW quadrant. Thus, results from the MWM task showed that all groups were 
able to effectively learn the spatial reference memory task and spatially localize to the 
platform location in a similar pattern. It is important to note that the MWM was 
administered following the WRAM. Some studies suggest that previous cognitive 
experience can impact learning and memory performance (A L Markowska, 2002; 
Talboom et al., 2014). Thus, prior learning experience may have affected learning and 
memory performance on the MWM in the present study, and may be in part contributing 
to the lack of significant treatment effects on the MWM. However, these data are consistent 
with the lack of a treatment effect for the spatial reference memory measure of the WRAM 
in the current study. 
The visible platform task tests the ability of animals to effectively perform the 
procedural components of a water-escape maze task. There were no treatment differences 
and no treatment by trial interactions on the visible platform task, indicating that all groups 
had similar capabilities required to effectively complete a water-escape maze task. 
Therefore, the interpretations of treatment effects on cognitive performance in the present 
study are not impacted by the motor and visual capabilities of the animals. 
 In the current study, E2 exposure was confirmed by showing that E2 treatment 
elevated circulating levels of E2 and its metabolite, estrone, relative to vehicle treatment, 
and by demonstrating that uterine horn weight increased with E2 treatment as compared to 
vehicle treatment. In women, the addition of a progestogen is meant to offset the uterine 
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stimulation induced by estrogen, and this has been seen in rat models (Armstrong, 1968; 
Creasy, Kafrissen, & Upmalis, 1992; S. E. Mennenga & Bimonte-Nelson, 2015). However, 
in the current study, the addition of Levo to E2 treatment did not significantly reduce E2-
induced increase in uterine horn weight. This may be explained in part by the 5:1 E2 to 
Levo ratio used in the present study, which was based on the dose of Levo that has 
previously been shown to enhance spatial learning and memory when administered alone. 
Additional investigation is warranted to address whether decreasing the E2 to Levo ratio, 
including to the 3:1 ratio used in Climara Pro, can significantly reduce uterine horn 
stimulation.  
In the frontal cortex, the present study found a relationship between working 
memory performance and activated Erk2 expression for the E2-Only group, where animals 
that tended to perform better on the WMC measure tended to have higher activated Erk2 
expression. This suggests that there is a unique relationship between working memory 
performance and activated Erk2 expression in the presence of E2 in the frontal cortex, a 
region that is heavily involved in normal working memory function (Funahashi & Kubota, 
1994). It is noteworthy that the beneficial cognitive effects of E2 in this study were specific 
to working memory, and here the activation of a signaling pathway implicated in cognitive 
function was linked particularly to E2-Only treatment and its effects in a region of the brain 
that plays a significant role in processing working memory information. In contrast to the 
relationship seen with E2-Only treatment, there was no relationship between cognitive 
performance as measured by WMC errors made and activated Erk2 expression within the 
E2 + Levo hormone combination treatment group, indicating that the addition of Levo 
obviated the E2-induced association between cognitive performance and activated Erk2 
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levels in the brain. Additionally, there was a relationship trend within the Vehicle group 
between activated Erk2 expression in the frontal cortex and WMC errors, whereby higher 
activated Erk2 levels correlated with higher WMC errors, indicating that E2-Only 
treatment may have reversed the relationship between activated Erk2 expression and 
working memory performance in the control group; this correlation was statistically 
significant before the correction, but it was not statistically significant after correcting for 
multiple correlations. Although the relationship between cognitive performance and 
activated Erk2 levels in the frontal cortex was specific to the WMC measure and the 
beneficial cognitive effects of E2-Only treatment were specific to the WMI measure, it is 
important to note that these measures of working memory performance are orthogonal and 
may be governed by different neurological pathways and brain regions. For example, a 
hippocampal lesion study found that a complete hippocampal lesion in male rats resulted 
in increased WMC errors compared to WMI errors when tested on an 8-arm radial arm 
maze, but no differences were seen between WMC errors and WMI errors in control rats 
and in rats with partial hippocampal lesions (Jarrard, Luu, & Davidson, 2012). Thus, the 
type of memory affected, and the directionality of the cognitive effect following hormone 
treatment, may be governed by the brain regions and neural pathways that are specific to 
the hormones examined. There were no treatment-induced differences in activated Erk1 
and Erk2 expression in the dorsal hippocampus, CA1/CA2 ventral hippocampus, frontal 
cortex, entorhinal cortex, or perirhinal cortex. It is important to highlight that the treatment 
regimen in this study was a chronic and cyclic low dose injection, whereas studies that 
have shown E2-induced increase of activated Erk2 expression in the dorsal hippocampus 
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are typically acute or injected at a higher or tonic dose (Fernandez et al., 2008; L. L. 
Harburger et al., 2009; Witty et al., 2013).  
The growing preclinical and clinical evidence indicates great complexity in the 
cognitive effects of ovarian hormone loss and hormone therapy. This drives the field 
toward opening new avenues of study to help scientist understand which factors play into 
this complexity in order to truly understand hormone-related impacts. Many publications 
indicate that ovarian hormone loss in women, and in rodents, is associated with changes in 
memory performance across multiple domains of memory, that subsequent E2 treatment 
can result in beneficial effects on cognitive function, and that the addition of a progestogen 
can attenuate these E2-induced cognitive benefits (Frick, 2015; Koebele & Bimonte-
Nelson, 2015; Korol & Pisani, 2015; Maki, 2012; S. E. Mennenga & Bimonte-Nelson, 
2013; Sherwin, 2006). There are notable exceptions to these outcomes, as the extent and 
direction of hormone therapy effects are sensitive to a myriad of variables. The details and 
parameters of how such factors impact outcomes are just beginning to be understood 
(Koebele & Bimonte-Nelson, 2015, 2017; Korol & Pisani, 2015). For example, age is a 
critical factor affecting the efficacy of estrogens on cognitive and brain function, with 
diminished or lost efficacy as aging ensues (L.A. Bean, Ianov, & Foster, 2014; Foster et 
al., 2003; R.B. Gibbs, 2010; Koebele & Bimonte-Nelson, 2017; Maki, 2013; S. E. 
Mennenga & Bimonte-Nelson, 2013; Talboom et al., 2008). Thus, the hormone treatment 
effects observed in the present study in middle-aged rats may be more pronounced if tested 
in young rats, and may be attenuated in aged rats.   
Several large-scale clinical studies have set out with the common goal to further 
understand the cognitive impact of menopause and hormone therapies taken by women 
  
90 
(Gleason et al., 2015; Greendale, Derby, & Maki, 2011; Karlamangla, Lachman, Han, 
Huang, & Greendale, 2017; Rapp et al., 2003; Shumaker et al., 2003). Only one human 
study thus far has specifically evaluated the impact estrogen and Levo have on cognitive 
function. In this study, the estradiol valerate plus Levo oral hormone therapy, Kilomonorm, 
was assessed; after two months, Kilomonorm improved concentration, speed of cognitive 
function, and short-term memory in peri- and post- menopausal women that either had 
received a hysterectomy (n = 6), ovariectomy (n = 14), hysterectomy plus ovariectomy (n 
= 6), or no surgical manipulations (n = 52) (Rudolph et al., 2000). In the current study, the 
cognitive effects of the estrogen plus Levo treatment in surgically menopausal rats were 
contingent on the level of cognitive demand and memory type evaluated. Thus, 
systematically designed studies of clinically-relevant hormone formulations and their 
effects in animal models of menopause are critical; information gained from such studies 
can inform future human study designs as steps are taken to further understand the complex 
interactions between hormones and various memory domains. 
In conclusion, to my knowledge, this study is the first to examine the effect of an 
E2 + Levo hormone combination treatment, as well as E2-Only and Levo-Only treatments, 
on cognitive function in a preclinical model of surgical menopause. Hormone therapy, 
which can contain only estrogens, only progestogens, or an estrogen plus progestogen 
combination, is used to decrease the onset and severity of undesired changes associated 
with menopause.  Thus, it is critical to not only examine the individual effects of hormones 
on symptoms associated with menopause, including the impact on learning and memory, 
but also how the combination of both an estrogen and a progestogen impacts these 
symptoms. Results showed that E2 and Levo each have beneficial effects on spatial 
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working memory when administered separately, replicating prior studies (Heather A. 
Bimonte-Nelson et al., 2006; Bimonte & Denenberg, 1999; B. Blair Braden et al., 2017; 
Talboom et al., 2008). However, the E2 + Levo hormone combination impaired spatial 
working memory relative to either of the hormones alone when the spatial working memory 
task was highly taxing. Furthermore, a relationship between activated Erk2 levels in the 
frontal cortex and spatial working memory following E2-Only treatment was observed. 
These findings are significant as they highlight opposing effects of an estrogen and 
progestogen hormone combination treatment, and raise further questions regarding which 
underlying neurobiological mechanisms are responsible for the individual cognitive 
enhancements of E2-Only and Levo-Only, and for the negating effects when the two 
hormones are administered together. This study illustrates that although an estrogen and a 
progestogen can be cognitively beneficial when administered alone, the clinically used 
combination of the same estrogen and progestogen does not necessarily result in added 
benefits, and can in fact yield impairments. Indeed, in the context of hormone therapy, one 
plus one does not always equal two.  
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CHAPTER 3 
17β-ESTRADIOL PLUS LEVONORGESTREL HORMONE TREATMENT: 
MEMORY IMPAIRMENTS ARE DEPENDENT ON HORMONE RATIO  
 
This chapter will be formatted and submitted for publication in Hormones and Behavior. 
 
Contribution: I am the first author of this document and was the primary graduate student 
principal investigator on this project. This study was part of an undergraduate honors 
thesis, and I mentored the student through the design, procedures, data analyses, and 
writing aspects of the project. The primary mentor on this project was Heather A. 
Bimonte-Nelson, and we received assistance from our laboratory team in carrying out the 
study.  
 
Introduction 
The average age of the United States (U.S.) population is increasing. According to 
projections by the U.S. Census Bureau, in the next several decades there will be a higher 
proportion of older people, defined as 65 years old and over, comprising the overall 
population, with an estimated increase of 9% in the number of older people from years 
2014 to 2060 (Colby & Ortman, 2015). Indeed, one in five people are predicted to be aged 
65 and over by the year 2030 (Colby & Ortman, 2015). Of note, around the average age of 
52 years, women undergo menopause and may experience associated undesired symptoms, 
including poor memory performance, poor concentration, vasomotor symptoms, 
osteoporosis, and vaginal dryness (Maki, 2012; NAMS, 2014). As the aging population 
  
93 
continues to grow, more women will be living in a menopausal state, and will do so for 
longer periods of time. Thus, in order to maintain a high quality of life for aging women, 
it is imperative to develop a complete understanding of the basic science behind the 
changes that can occur, such as with cognitive function, across the transition to menopause 
as well as post-menopause.  
Menopause, confirmed after at least one year of a lack of menses, is associated with 
a marked reduction in the circulating levels of ovarian hormones, including estrogens and 
the natural progestogen, progesterone (NAMS, 2014). Rodent models of menopause have 
been extensively utilized over the last several decades to parse out the effects of decreased 
circulating ovarian hormone levels on systemic functions, such as cognitive function, as 
well as the effects of subsequent exogenous hormone administration (Prakapenka et al., in 
review). In the clinic, multiple hormone therapy options are available for women to help 
alleviate the presence and severity of menopause-associated symptoms. Hormone therapies 
vary in type of hormone (estrogens, progestogens, or estrogen plus progestogen 
combinations), dose of hormone, as well as route of hormone administration (Prakapenka 
et al., in review). One hormone widely studied regarding its pharmacokinetics and 
pharmacodynamics in relation to cognitive function is 17β-estradiol (E2), the most potent 
endogenous estrogen in women and rodents that is often used in hormone therapy 
formulations (Frick, 2015; Koebele & Bimonte-Nelson, 2015; Korol & Pisani, 2015; Maki, 
2012; S. E. Mennenga & Bimonte-Nelson, 2013; Sherwin, 2006). In rodent models, E2 has 
been repeatedly shown to improve cognition following the loss of circulating ovarian 
hormones with ovariectomy (Ovx), the surgical removal of the ovaries, across several 
distinct behavioral paradigms, including the Morris water maze (MWM; Heather A. 
  
94 
Bimonte-Nelson et al., 2006; El-Bakri et al., 2004; Feng et al., 2004; Kiss et al., 2012; 
Lowry et al., 2010; McLaughlin et al., 2008; Talboom et al., 2008), radial-arm maze 
(Bimonte & Denenberg, 1999; Jill M. Daniel et al., 2006; Jill M Daniel et al., 1997; Fader 
et al., 1999; R. B. Gibbs & Johnson, 2008; V N Luine et al., 1998; Rodgers et al., 2010), 
object placement task (Conrad et al., 2012; Frye et al., 2007; Victoria N. Luine et al., 2003; 
McLaughlin et al., 2008), and delayed match-to-position T-maze (R. B. Gibbs, 2000; R B 
Gibbs, 1999; Robert B. Gibbs, 2007; Robert B. Gibbs et al., 2004; Robert B Gibbs, 
2002). If a woman has her uterus, estrogen-containing hormone therapy must also contain 
an opposing progestogen to reduce the risk of endometrial hyperplasia and cancer 
associated with unopposed estrogen (NAMS, 2012). Rodent studies currently suggest that 
when combined with certain progestogens, the beneficial effects of E2 on cognition can be 
attenuated (Heather A. Bimonte-Nelson et al., 2006; Lauren L. Harburger et al., 2007; 
Lowry et al., 2010; Prakapenka et al., 2018). However, there are a multitude of different 
synthetic progestogens clinically-available that differ not only by type of activity 
(progestogenic, androgenic, estrogenic, etc.) but also by potency (i.e. affinity to receptors; 
Kuhl, 2005), and many of them have yet to be evaluated for cognitive effects when 
administered alone or in combination with an estrogen in middle-aged Ovx rodents.  
We have recently shown that when administered alone, E2 and the synthetic 
progestogen, levonorgestrel (Levo) each improved spatial working memory on the water 
radial-arm maze (WRAM) relative to vehicle in middle-aged Ovx rats (Prakapenka et al., 
2018). However, the combination hormone treatment E2 plus Levo attenuated the 
beneficial cognitive effects of E2 alone and of Levo alone, and did not reduce the E2-
induced increase in uterine horn weight – a marker of E2 exposure and stimulation at the 
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uterine horns (Prakapenka et al., 2018). The E2 and Levo doses in that study were based 
on the doses from prior work in the Bimonte-Nelson laboratory that yielded enhancing 
effects on cognition by each individual hormone alone, resulting in a 5:1 E2 to Levo dose 
ratio. The clinically available Climara Pro transdermal patch that contains both E2 and 
Levo employs a 3:1 E2 to Levo dose ratio to treat symptoms associated with menopause. 
Of note, studies show that several factors can impact the direction of hormone effects on 
cognition, including the dose ratio of two hormones used in a treatment (L. L. Harburger 
et al., 2009; Koebele & Bimonte-Nelson, 2015; Jennifer J. Tuscher, Fortress, Kim, & Frick, 
2015). For instance, in a study evaluating E2 plus progesterone combination treatment in 
Ovx mice, when the E2 dose was kept constant, only the addition of the lowest tested 
progesterone dose attenuated the beneficial effects of E2 on the novel object recognition 
task, an effect that did not occur with the addition of the two higher doses of progesterone 
(L. L. Harburger et al., 2009). In fact, even though Levo is not considered to have 
estrogenic effects because it does not bind to estrogen receptors, recent in vitro work has 
shown that Levo can increase the mRNA expression for estrogen receptors in neuron 
cultures (Jayaraman & Pike, 2014; Kuhl, 2005). Thus, the clinically-utilized E2 and Levo 
hormone combination treatment must be evaluated further to determine if altering the dose 
ratio of E2 to Levo will yield cognitively enhancing effects or if the previously observed 
cognitive effects persist across a clinically relevant ratio of E2 to Levo doses.  
The aim of the present study was to examine the cognitive effects of three E2 plus 
Levo hormone combination treatments, including the combination dose ratio used in 
Climara Pro and the combination dose ratio from my prior study. I hypothesized that 
varying the dose ratios of E2 to Levo by increasing the Levo dose while keeping E2 dose 
  
96 
constant would have differential effects on cognition following a decrease in circulating 
ovarian hormone levels. To evaluate this, for the current study, middle-aged Ovx rats 
received daily subcutaneous injections of either a vehicle control, E2 alone control, or E2 
plus Levo at three different dose ratio combinations, keeping the E2 dose constant across 
all E2-containing treatments. All rats then underwent testing on a behavioral battery to 
assess spatial learning and memory, and uterine horn weight was collected at the end of the 
study to evaluate opposing effects of Levo on E2-induced stimulation at the uterine horns. 
 
Methods 
Animals 
50 11-month old Fischer-344-CDF virgin female rats were used (National 
Institute on Aging, Harlan Laboratories, Indianapolis, IN, USA). The rats were pair 
housed and received food and water ad libitum. The colony room was kept on a 12-hour 
light/dark cycle. All procedures were approved by the Institutional Animal Care and Use 
Committee and adhered to National Institutes of Health standards.  
 
Ovariectomy (Ovx) 
At 11 months old, all rats received Ovx surgery to remove their ovaries as 
previously described (B. Blair Braden et al., 2017; Prakapenka et al., 2018). Briefly, rats 
were anesthetized via isoflurane inhalation, received bilateral dorsolateral incisions in the 
skin and peritoneum, and the ovaries and tips of the uterine horns were ligatured and 
removed. Muscle and skin were then sutured closed. For pain, rats received a subcutaneous 
injection of Rimadyl (5 mg/ml/kg) and to prevent dehydration, rats received a subcutaneous 
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injection of sterile saline (2 ml).  
 
Hormone treatments 
Twenty-one days following Ovx surgery, rats received daily subcutaneous 
treatment for the rest of the study (see timeline in Figure 9). All rats were randomly 
assigned to either the Vehicle (0.1 ml sesame oil, n=10) control group, the E2 Only (0.3 μg 
E2, n=10) control group, or one of the hormone combinations groups: E2 + Low Levo (0.3 
μg E2 plus 0.06 μg of Levo, n=10), E2 + Med Levo (0.3 μg E2 plus 0.1 μg of Levo, n=10), 
or E2 + High Levo (0.3 μg E2 plus 0.6 μg of Levo). The doses for low, medium, and high 
Levo were determined based on their ratio to the constant E2 dose and prior findings, as 
summarized in Table 3. Specifically, the E2 + Low Levo dose ratio (5:1 E2 to Levo) was 
the same dose ratio previously tested within the Bimonte-Nelson laboratory (Prakapenka 
et al., 2018), the E2 + Med Levo dose ratio (3:1 E2 to Levo) was the same dose ratio as in 
the clinically used Climara Pro transdermal patch, and the E2 + High Levo dose ratio (1:2 
E2 to Levo) was obtained by using the dose of Levo treatment that has been repeatedly 
found to have beneficial cognitive effects when given alone in middle-aged Ovx rats (B. 
Blair Braden et al., 2017; Prakapenka et al., 2018).  
 
Vaginal smears 
Vaginal smears were done 16 days following treatment initiation for three 
consecutive days to confirm Ovx, as well as E2, exposure based on vaginal cytology as 
previously described (S. E. Mennenga & Bimonte-Nelson, 2015). Briefly, rats were held 
by the base of the tail and the rear end was gently lifted to expose the anogenital area. A 
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sterile cotton-tipped applicator, moistened with sterile saline, was inserted about 1 cm into 
the vaginal canal and the vaginal walls were swabbed for cell collection. The cotton swab 
was then rolled along a blank microscope slide to transfer the cells onto the slide, the cell 
types were examined under a light microscope (10x), and cell types and cycle phase were 
recorded.  
 
Water radial-arm maze (WRAM) 
Rats were tested on the water radial-arm maze (WRAM) after 21 days of treatment 
administration to assess spatial working and reference memory, as done previously (H. A. 
Bimonte-Nelson, 2015d; Bimonte & Denenberg, 1999; Prakapenka et al., 2018). The 
WRAM was an 8-armed apparatus consisting of evenly spaced arms (each arm 38.1 cm x 
12.7 cm) extending outward from a central arena. Non-toxic black paint was used to create 
opaque water, kept at 18-20°C, that filled the maze. Four out of the 8 arms contained hidden 
platforms (10 cm in diameter) that were kept submerged under water. The platform 
locations for each rat remained constant across a total of 13 days of testing, but varied 
across rats. Abundant extra-maze cues were present in the room to aid in spatial navigation. 
There were a total of four trials per day, one trial per platform, with the same drop-off 
location for each trial. Each trial was considered over when a rat either found a platform or 
3 minutes passed for the maximum allotted trial time, and the rat was then led to the nearest 
platform. When found, the rat was allowed 15 seconds on the platform and was then placed 
in a heated testing cage for an inter-trial interval (ITI) of 30 seconds. The ITI provided time 
to remove the just-found platform and clean the maze of any debris while re-distributing 
olfactory cues. The next trial began following the ITI, and the trial process was repeated 
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until all platforms had been found. In this manner, increase in working memory load within 
a day was evaluated as rats had to update the location of the platform just found, that it was 
no longer there, and remember which platform locations remained. On day 13 of WRAM 
testing, a 6-hour delay was implemented between the second and third trials for each rat to 
assess delayed memory retention. Performance on the WRAM was evaluated by scoring 
error arm entries. These error entries were further split into three orthogonal memory 
measures: reference memory (RM) error was committed when an arm that never contained 
a platform was entered, working memory incorrect (WMI) error was committed when an 
arm that never contained a platform was re-entered within a day, and a working memory 
correct (WMC) error was committed when an arm that previously contained a platform 
was entered within a day (H. A. Bimonte-Nelson, 2015d).  
 
Morris water maze (MWM) 
Spatial reference memory was evaluated on the MWM the day following WRAM 
delay, as was done previously (H. A. Bimonte-Nelson, 2015b; Prakapenka et al., 2018). 
The maze was a circular pool 188 cm in diameter in a room with abundant extra-maze cues 
to assist with spatial navigation, and the maze was filled with 18-20°C opaque water. A 
single platform (10 cm in diameter) was hidden beneath the surface of the water in the 
Northeast (NE) quadrant of the maze. The platform location remained the same for all rats 
for 4 trials per day, and 5 days of testing. The drop-off locations (North, South, West, East) 
varied across trials, and the order of the drop-off locations varied each day. Once the rat 
was released into the water, the trial started and a maximum of 60 seconds were allowed 
to find the platform. After the platform was located, or after the rat was led to it after 60 
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seconds, the rat remained on the platform for 15 seconds before being placed into a heated 
testing cage. The ITI was approximately 5-8 minutes, during which the water was cleaned 
of any debris and olfactory cues were re-distributed. MWM performance was recorded by 
a camera suspended above the maze, and EthoVision tracking system (Noldus Instruments, 
Wageningen, The Netherlands) was used to determine swim distance. On the 5th day of 
testing, a 5th trial was added as the probe trial during which the platform was removed and 
rats were dropped off from the West location, the furthest location from where the platform 
would have been located (Northeast quadrant). Each rat was allowed to swim for a full 60-
second period, and the percentage of total distance that the rats swam in the Northeast 
quadrant, the target quadrant that previously contained the platform during all other trials, 
relative to the opposite Southwest quadrant was measured to evaluate spatial localization 
to the platform.  
 
Visible platform 
The non-spatial visible platform task was administered the day after MWM was 
completed to examine motor and visual competence (H. A. Bimonte-Nelson, 2015c). The 
visible platform was a rectangular tub (100 cm x 60 cm) filled with clear water that was 
kept at a temperature of 18-20°C. A visible black platform (10 cm in diameter) was placed 
in the tub and positioned 4 cm above the water. Opaque curtains surrounded the maze, 
blocking any potential extra-maze cues. Once released at the drop-off location, each rat 
had 90 seconds to find the platform for each trial; once found, the rat remained on the 
platform for 15 seconds and was then placed into a heated testing cage for an ITI of 5-8 
minutes. Each rat was tested for 6 trials across one day. The drop-off location remained the 
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same across all trials, but the location of the platform varied semi-randomly across 3 
different locations.  
 
Uterine horn weights 
The wet weights of uterine horns were collected to confirm Ovx, E2 exposure, as 
well as potential opposing effects of Levo on E2’s uterine-stimulating effects (E. B. Engler-
Chiurazzi et al., 2012; Sarah E. Mennenga, Gerson, Koebele, et al., 2015; Prakapenka et 
al., 2018; Westerlind et al., 1998). Specifically, one day after the completion of the visible 
platform task and following treatment administration, rats underwent euthanasia under 
isoflurane anesthesia, at which point uterine horns were removed, inspected, trimmed of 
visible fat, and weighed.  
 
Statistical analyses 
Repeated measures ANOVA was used to evaluate behavioral outcomes, and alpha 
level was set at 0.05. Two animals were excluded from all behavioral analyses (one from 
the Vehicle group and one from the E2 Only group) due to pathological findings at autopsy. 
Each maze was analyzed separately. 
For the WRAM, errors made on each memory measure (WMC, WMI, and RM) 
were analyzed separately for Days 2-7, the acquisition phase, and Days 8-12, the 
asymptotic phase (H. A. Bimonte-Nelson et al., 2015; B. Blair Braden et al., 2017). For all 
analyses, planned comparisons were performed to compare Vehicle versus E2 Only, 
Vehicle versus E2 + Low Levo, Vehicle versus E2 + Med Levo, and Vehicle versus E2 + 
High Levo groups. The independent variable was Hormone and the repeated measures was 
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Trials nested within Days, and the dependent variable was Errors. If there was a significant 
Trial x Hormone interaction, the higher working memory load trials, trials 3 and 4, were 
analyzed separately using the same planned comparison groups. Additionally, linear 
regression analyses were done to assess the relationship between WMC, WMI, and RM 
errors and Levo dose. For WRAM delay, errors made on each memory measure (WMC, 
WMI, and RM) on the post-delay trial, Trial 3 on Day 13, were compared to the baseline 
trial, Trial 3 on Day 12, within each treatment group (B. Blair Braden et al., 2017). 
For the MWM maze, total swim distance across 5 days was analyzed. As was done 
for WRAM, planned comparisons were performed to compare Vehicle versus E2 Only, 
Vehicle versus E2 + Low Levo, Vehicle versus E2 + Med Levo, and Vehicle versus E2 + 
High Levo groups. The independent variable was Hormone and the repeated measures were 
distance swam on Trials nested within Days.  The probe trial was analyzed separately to 
assess spatial localization for each treatment group using a repeated measures ANOVA to 
evaluate percent swim distance in the previously platformed quadrant (Northeast; NE) 
compared to percent swim distance in the directly opposite quadrant (Southwest; SW).   
For visible platform performance, the same planned comparisons were performed 
as for the WRAM and MWM to compare Vehicle versus E2 Only, Vehicle versus E2 + 
Low Levo, Vehicle versus E2 + Med Levo, and Vehicle versus E2 + High Levo groups 
using repeated measures ANOVA. The independent variable was Hormone and the 
repeated measure was time to platform on Trials.  
Uterine horn weights were analyzed using one-way ANOVA, with Hormone as the 
independent variable and uterine horn weight as the dependent variable. Planned 
comparisons were performed to compare Vehicle versus E2 Only, Vehicle versus E2 + 
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Low Levo, Vehicle versus E2 + Med Levo, and Vehicle versus E2 + High Levo groups. 
Uterine horn weight was expected to increase with E2 treatment, and the addition of Levo 
was anticipated to decrease uterine horn weight compared to E2 alone; thus, additional 
planned comparisons were performed to examine E2 versus E2 + Low Levo, E2 versus E2 
+ Med Levo, and E2 versus E2 + High Levo groups. Two animals were excluded from all 
uterine horn weight analyses due to uterine horn pathology (e.g. cysts). 
 
Results 
Vaginal smears 
All animals receiving Vehicle treatment exhibited mostly blank smears with few 
cells present across 3 consecutive days (Figure 10), indicating lack of ovarian hormone 
stimulation and cyclicity, and confirming complete Ovx (Goldman et al., 2007; S. E. 
Mennenga & Bimonte-Nelson, 2015). All animals receiving E2 Only, E2 + Low Levo, E2 
+ Med Levo, or E2 + High Levo treatments had smears nearly identical to each other, 
containing numerous cells overall that mostly consisted of cornified cells (Figure 10). This 
confirmed the presence of circulating E2 for all hormone treatment groups, and suggests 
that the presence of Levo did not alter this measurement of vaginal cytology (Goldman et 
al., 2007; S. E. Mennenga & Bimonte-Nelson, 2015).  
 
Water radial-arm maze (WRAM) 
The WRAM evaluated spatial working and reference memory. For all memory 
measures on the acquisition phase (Days 2-7), when the rats were learning the rules of the 
task, there were no Hormone effects or Trial x Hormone interactions for any comparisons 
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(Figure 11A). For WMC errors made on the asymptotic phase (Days 8-12), there was a 
main effect of Hormone for the Vehicle versus E2 + High Levo comparison [F(1,17) = 5.504, 
p < 0.05; Figure 11B], with the E2 + High Levo group making more errors than the Vehicle 
group, suggesting that the E2 + High Levo treatment impaired working memory. There 
was a marginal effect of Hormone for the Vehicle versus E2 + Med Levo comparison 
[F(1,17) = 3.381, p < 0.1; Figure 11B], with the E2 + Med Levo group tending to make more 
WMC errors than the Vehicle group. There were no Trial x Hormone interactions between 
the Vehicle versus E2 + High Levo and Vehicle versus E2 + Med Levo comparisons for 
WMC errors. For WMC errors on the asymptotic phase for the Vehicle versus E2 + Low 
Levo and the Vehicle versus E2 Only group comparisons there were no significant effects 
of Hormone or Trial x Hormone interactions. For WMI errors made on the asymptotic 
phase, there was a main effect of Hormone for the Vehicle versus E2 + High Levo 
comparison [F(1,17) = 5.241, p < 0.05; Figure 11B], where the E2 + High Levo group made 
more errors than the Vehicle group. There was also a Trial x Hormone interaction for the 
Vehicle versus E2 + High Levo comparison [F(3,51) = 6.318, p < 0.01; Figure 11C], where 
the E2 + High Levo group made more errors than the Vehicle group on Trial 4 [t(17) = 
2.96, p < 0.01; Figure 11C], the highest working memory load trial. There was no main 
effect of Hormone for the Vehicle versus E2 + Med Levo comparison, but there was a Trial 
x Hormone interaction [F(3,51) = 3.162, p < 0.05; Figure 11C], with the E2 + Med Levo 
group making somewhat more errors than the Vehicle group on Trial 4 [t(17) = 1.834, p < 
0.1; Figure 11C], the highest working memory load trial. There were no significant main 
effects of Hormone or Trial x Hormone interactions for WMI errors made on the 
asymptotic phase for the Vehicle versus E2 + Low Levo, and the Vehicle versus E2 Only, 
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group comparisons. For RM errors, there was a marginal effect of Hormone, and no Trial 
x Hormone interaction, for the Vehicle versus E2 + High Levo comparison [F(1,17) = 3.636, 
p < 0.1; Figure 11B], where the E2 + High Levo group tended to make more errors than 
the Vehicle group. There were no significant effects of Hormone or Trial x Hormone 
interactions for RM errors on the asymptotic phase for the Vehicle versus Med Levo, 
Vehicle versus E2 + Low Levo, and Vehicle versus E2 Only comparisons.  
It was noted that as the Levo dose increased when combined with a constant E2 
dose, performance on the WRAM became progressively impaired for all memory measures 
on the asymptotic phase. This relationship between treatment group and performance was 
supported by a linear regression analysis. The linear regression analysis showed a 
significant positive linear trend across Levo dose for WMI errors [r = 0.9144; F(1,3) = 15.31, 
p < 0.05; Figure 12] and a significant positive linear trend across Levo dose for RM errors 
[r = 0.9048; F(1,3) = 13.54, p < 0.05; Figure 12]. There was also a marginal positive linear 
trend across Levo dose for WMC errors [r = 0.8755; F(1,3) = 9.85, p = 0.05; Figure 12]. 
These results indicate that, for all memory measures, the number of errors made increased 
as the dose of Levo added to a constant E2 dose increased, suggesting that higher Levo, in 
combination with E2 and with the parameters evaluated in this study, is associated with 
poorer spatial working and reference memory. 
Analysis of the 6-hour delay revealed that more WMC errors were made on the 
post-delay trial, Trial 3 on Day 13, compared to the baseline trial, Trial 3 on Day 12, by 
the E2 + Med Levo [F(1,9) = 5.444, p < 0.05; Figure 13] and by the E2 + High Levo [F(1,9) 
= 16.000, p < 0.01; Figure 13] groups, suggesting delay-induced forgetting. The E2 Only 
group [F(1,8) = 4.500, p < 0.1; Figure 13] and the E2 + Low Levo group [F(1,9) = 3.462, p < 
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0.1; Figure 13] tended to make more WMC errors on the post-delay trial compared to the 
baseline trial. The Vehicle group did not reach statistical significance in WMC errors made 
on the post-delay trial compared to the baseline trial, indicating that they did not exhibit 
delay-induced forgetting (Figure 13). There were no differences for the WMI and RM 
errors made on the post-delay trial compared to the baseline trial within each treatment 
group.  
 
Morris water maze (MWM) 
Spatial reference memory was examined on the MWM. There were no significant 
effects of Hormone, and no Hormone x Day interactions, for swim distance to the platform 
across the 5 days of testing for the Vehicle versus E2 Only, Vehicle versus E2 + Low Levo, 
Vehicle versus Med Levo, and Vehicle versus High Levo group comparisons (Figure 14A), 
suggesting that there were no differences in learning between the groups. A main effect of 
Quadrant was seen for all group comparisons for the probe trial (Figure 14B), where 
percent swim distance was greater in the target NE quadrant compared to the opposite SW 
quadrant for Vehicle [F(1,8) = 46.365, p < 0.0001], E2 Only [F(1,8) = 91.826, p < 0.0001], 
E2 + Low Levo [F(1,9) = 41.596, p < 0.0001], E2 + Med Levo [F(1,9) = 66.161, p < 0.0001], 
and E2 + High Levo [F(1,9) = 62.705, p < 0.0001] treatment groups. This indicates that all 
treatment groups were able to learn and spatially localize to the platform location by the 
end of testing.   
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Visible platform 
For Trials 1-6 of the visible platform task, there was a main effect of Trial for each 
of the planned comparisons: Vehicle versus E2 Only [F(5,80) = 2.376, p < 0.05; Figure 15], 
Vehicle versus E2 + Low Levo [F(5,85) = 3.341, p < 0.01; Figure 15], Vehicle versus E2 + 
Med Levo [F(5,85) = 2.888, p < 0.05; Figure 15], and Vehicle versus E2 + High Levo [F(5,85) 
= 2.953, p < 0.05; Figure 15], indicating that there was a decrease in latency to find the 
platform across trials. There were no main effects of Hormone for the Vehicle versus E2 
Only, Vehicle versus E2 + Low Levo, or Vehicle versus E2 + Med Levo comparisons, 
indicating that there were no treatment differences in visual and motor ability to solve a 
water escape task. There was a main effect of Hormone for the Vehicle versus E2 + High 
Levo comparison [F(1,17) = 4.785, p < 0.05; Figure 15], whereby the Vehicle group 
exhibited a greater latency to platform than the E2 + High Levo group. However, when 
only Trials 4-6 were analyzed, there was no main effect of Hormone for this comparison, 
nor was there a main effect for any of the other planned comparisons during these latter 
trials. This indicated that in the latter portion of visible platform testing, when the rats were 
expected to have learned the components of the visible platform task, there were no 
treatment differences. In fact, by the last trial, Trial 6, the mean escape time of all rats 
combined was 5.79 seconds, demonstrating that they possessed the appropriate procedural 
components necessary to solve a water escape task. 
 
Uterine horn weights 
Uterine horn weights were expected to increase with E2 treatment and decrease 
with the addition of Levo, if Levo in fact attenuated E2-induced stimulation with the tested 
  
108 
regimen (E. B. Engler-Chiurazzi et al., 2012; Sarah E. Mennenga, Gerson, Koebele, et al., 
2015; Prakapenka et al., 2018; Westerlind et al., 1998). There was a main effect of 
Hormone for the Vehicle versus E2 Only [F(1,16) = 210.607, p < 0.0001; Figure 16A], 
Vehicle versus E2 + Low Levo [F(1,18) = 145.429, p < 0.0001; Figure 16A], Vehicle versus 
E2 + Med Levo [F(1,18) = 194.697, p < 0.0001; Figure 16A], and Vehicle versus E2 + High 
Levo [F(1,18) = 420.794, p < 0.0001; Figure 16A] group comparisons, with the Vehicle 
group exhibiting lower uterine horn weights compared to each treatment group that 
contained an E2 component. These results suggest that all E2 treatments did stimulate the 
uterine horns compared to vehicle control, regardless of the presence of Levo. Interestingly, 
there was a main effect of Hormone for the E2 Only versus E2 + Med Levo comparison 
[F(1,16) = 6.305, p < 0.05; Figure 16B], and for the E2 Only versus E2 + High Levo 
comparison [F(1,16) = 5.313, p < 0.05; Figure 16B], with lower uterine horn weights seen 
with the E2 + Med Levo and E2 + High Levo treatments relative to E2 Only. This indicates 
that the medium and high doses of Levo were high enough to oppose E2’s stimulating 
effects on the uterine horns. It must be noted, however, that while the E2 + Med Levo and 
the E2 + High Levo treatments reduced uterine horn weight relative to E2 Only treatment, 
both combinations still increased uterine horn weight relative to Vehicle suggesting that 
the addition of these doses of Levo did not result in complete protection from E2-induced 
uterine stimulation. 
 
Discussion 
The two hormones evaluated in the present study, E2 and Levo, can each enhance 
spatial learning and memory when given alone in middle-aged Ovx rats (B. Blair Braden 
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et al., 2017; Prakapenka et al., 2018). Here, dose ratio-dependent cognitive and uterine 
stimulating effects of three E2 plus Levo hormone combination treatments – 5:1 (E2 + Low 
Levo), 3:1 (E2 + Med Levo), and 1:2 (E2 + High Levo) E2 to Levo dose ratios – were 
evaluated in middle-aged Ovx rats by systematically increasing the dose of Levo while 
maintaining constant E2 dose across all treatments. The combination treatments included 
the dose ratio used in the clinically-available Climara Pro as well as the combination dose 
ratio from my prior work (Prakapenka et al., 2018). Overall, I discovered that although the 
addition of the two highest Levo doses that were tested herein (E2 + Med Levo and E2 + 
High Levo) decreased E2-induced stimulation at the uterine horns, these doses impaired 
spatial learning and memory.  On the other hand, the addition of the low dose of Levo (E2 
+ Low Levo) had no impact on spatial learning and memory, and yielded no change in E2-
induced stimulation at the uterine horns, replicating prior findings (Prakapenka et al., 
2018). 
Performance on the WRAM was divided into two phases, the acquisition phase and 
the asymptotic phase, to evaluate spatial working and reference learning and memory. All 
treatment groups performed similarly during the acquisition phase of the WRAM, when 
the rules of the task were being learned, across all three memory measures (WMC, WMI, 
RM). For the asymptotic phase, when the rules of the task should have been already 
learned, the E2 + High Levo treatment group, which contained a cognitively beneficial 
dose of Levo when given alone, made more WMC and WMI errors than the Vehicle, and 
tended to make more RM errors than the Vehicle. Of note, the E2 + High Levo group made 
more WMI errors than the Vehicle when working memory was most taxed, on the highest 
working memory load trial evaluated, for the asymptotic phase of the WRAM. These 
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findings suggest that the addition of a cognitively beneficial dose of Levo to E2 in a 1:2 E2 
to Levo dose ratio impaired spatial working and reference memory. The E2 + Med Levo 
group, the dose ratio representative of the clinically available Climara Pro hormone 
therapy, tended to make more WMC errors than the Vehicle, as well as more WMI errors 
than the Vehicle when working memory was taxed, indicating a trend in impairment for 
this clinically-relevant hormone combination ratio. The E2 + Low Levo group that 
employed the same combination dose ratio as my prior study (Prakapenka et al., 2018), as 
well as the E2 Only group, did not differ in WMC, WMI, and RM errors made compared 
to the Vehicle during the asymptotic phase of the WRAM, indicating that these two 
treatment groups did not impact spatial working and reference memory. Collectively, 
results revealed that the incremental increase in Levo dose, when combined with the 
constant E2 dose, was associated with an increase in errors made for all three memory 
measures. Indeed, linear regression analyses confirmed that as Levo dose increased when 
combined with E2, animals tended to make more WMC, WMI, and RM errors on the 
asymptotic phase of the WRAM, resulting in progressively greater spatial working and 
reference memory impairment across increasing Levo dose. Furthermore, following a 6-
hour delay period, the E2 + Med Levo and E2 + High Levo groups made more WMC errors 
on the post-delay trial relative to the baseline trial, suggesting delay-induced forgetting. 
These delay findings support the detrimental cognitive effects evidenced during the 
asymptotic phase of the WRAM, with treatments containing a constant E2 dose combined 
with a medium and a high Levo dose in a 3:1 and 1:2 E2 to Levo dose ratio, respectively. 
Taken together, the WRAM results indicate a dose ratio-dependent effect of the E2 plus 
Levo combination treatment on cognition where higher Levo, in combination with E2 and 
  
111 
with the parameters evaluated in this study, was associated with poorer spatial working and 
reference memory in middle-aged Ovx rats.  
The molecular and signaling pathways in the brain are crucial players in successful 
learning and memory, as well as hormone-induced effects on learning and memory (Atkins 
et al., 1998; Frick, 2015; Koebele & Bimonte-Nelson, 2017). It is very likely that the 
cognitive effects evidenced on the WRAM in the present study are mediated by the effects 
that E2 and Levo can have on one or more of these pathways, and the dose-ratio dependent 
interaction between these effects. For instance, activated extracellular-signal regulated 
kinase 2 (Erk 2) is involved in, and required for, E2-induced beneficial memory effects (L. 
Fan et al., 2010; Fernandez et al., 2008). I have shown that activated Erk 2 expression in 
the frontal cortex of E2-treated animals positively correlated with spatial working memory, 
but that this relationship was attenuated by the addition of Levo to the E2 treatment 
(Prakapenka et al., 2018). Thus, E2 and Levo can interact to exhibit contrasting effects in 
the brain. Understanding how E2 and Levo interact in the brain, and the potential 
relationship between this interaction to cognitive outcomes, is complex. Studies have 
evaluated the role of Levo alone, as well as E2 plus Levo, on brain processes, but the 
findings from these studies are contradictory. On one hand, Levo is thought to have no 
estrogenic effects as Levo itself does not bind to the estrogen receptors (Kuhl, 2005). On 
the other hand, studies indicate that Levo may in fact yield estrogenic activity indirectly 
via the binding of its derivatives to estrogen receptors, or via its capability to increase 
estrogen receptors’ mRNA expression (Jayaraman & Pike, 2014; Santillán et al., 2001). 
This Levo-mediated estrogenic activity may be working in concert with E2 to yield the 
learning and memory changes seen in this study, particularly since the cognitively 
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beneficial effects of estrogens are dependent on both estrogen dose (more estrogen is not 
always cognitively beneficial) as well as estrogen type, which vary in binding affinity to 
estrogen receptors (Engler-Chiurazzi et al., 2012; Koebele and Bimonte-Nelson, 2015; 
Prakapenka et al., 2018, in review). In neuron culture, the addition of Levo to E2 treatment 
did not attenuate the neuroprotective effects of E2 alone, and of Levo alone, as measured 
by neuron survival, which does not support the impairing cognitive effects found in the 
present study (Jayaraman & Pike, 2014). However, another study showed that in young 
adult Ovx rats, Levo treatment increased markers of cell proliferation in the hippocampus 
when combined with E2 treatment (1:1 E2 to Levo dose ratio), but, this same E2 plus Levo 
combination treatment also increased cell apoptosis (Liu et al., 2010). In this respect, the 
increasingly impairing spatial memory effects evidenced in the present study may, in part, 
be explained by the apoptotic effects of E2 plus Levo combination treatment. In sum, 
although much research has been done to gain insight into how Levo, and Levo together 
with E2, impact brain processes, the existing evidence to date is conflicting. Future studies 
are needed with the primary focus on systematically examining the putative drivers of the 
complex effects of Levo and E2 plus Levo treatments in the brain, how these effects map 
on to cognitive measures, and the role that the ratio of E2 and Levo doses plays in both 
brain and behavioral outcomes.  
The classic water maze task to evaluate spatial reference memory, the MWM, did 
not reveal any differences between the treatment groups. For the probe trial, all treatment 
groups swam more distance in the target NE quadrant, the quadrant that previously 
contained a platform, compared to the opposite quadrant, a quadrant that never contained 
a platform, indicating that rats learned the task and spatially localized to the platform 
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location. The lack of differences between treatments on the MWM is consistent with my 
prior study evaluating E2 alone, Levo alone, and E2 plus Levo where no treatment effects 
were found on the MWM as well (Prakapenka et al., 2018). This may be in part due to the 
MWM being administered immediately after the WRAM, as the prior cognitive experience 
on the WRAM may have inadvertently impacted learning and memory effects on the 
MWM (A L Markowska, 2002; Talboom et al., 2014). There were also no treatment 
differences on the visible platform task, the control task intended to examine visual and 
motor capabilities of each treatment group to solve a water-escape task. Specifically, 
results revealed no difference in time to reach the visible platform between the vehicle and 
each treatment group during the latter three trials of testing. Indeed, all rats swam to the 
platform in under six seconds on the last trial of the task, demonstrating that the appropriate 
procedural components necessary to solve a water escape task were present across all 
treatment groups. 
It should be addressed that the E2 treatment in the present study did not show 
cognitive benefit on the WRAM and on the MWM tasks, which does not support the 
expected beneficial role of E2 on cognitive function. This finding highlights the difficulty 
in identifying the parameters of exogenous E2 exposure that can consistently yield a 
cognitive benefit in a rodent model of menopause, a topic of much discussion and debate 
in the literature (Koebele and Bimonte-Nelson, 2015; Prakapenka et al., in review). In 
fact, whether exogenous E2 treatment will yield beneficial, null, or detrimental effects on 
hippocampal-based memory in rodent models involves multiple factors, which include 
the time between Ovx and E2 administration as well as the dose, regimen, and age of E2 
administration (Barha & Galea, 2010; Heather A. Bimonte-Nelson et al., 2006; Jill M. 
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Daniel et al., 2006; Frick, 2009; R. B. Gibbs, 2000; Alicja L Markowska & Savonenko, 
2002; Talboom et al., 2008). The lack of an E2 only treatment effect on spatial learning 
and memory evaluated within this study at the examined dose and regimen parameters 
confirm E2’s complex effects on cognition.  
Uterine horn weight can be used as a marker of hormone stimulation at the uterine 
tissue in rodents (E. B. Engler-Chiurazzi et al., 2012; Sarah E. Mennenga, Gerson, Koebele, 
et al., 2015; Prakapenka et al., 2018; Westerlind et al., 1998). As predicted and previously 
reported, uterine horn weight was greater in all E2-containing treatment groups compared 
to Vehicle (Prakapenka et al., 2018). In support, vaginal cytology evaluations confirmed 
the presence of E2 in all E2-containing treatment groups, and lack of hormone stimulation 
in the Vehicle group. The addition of the low dose of Levo did not counteract E2-induced 
uterine horn weight, replicating my prior findings with the same E2:Levo dose ratio 
(Prakapenka et al., 2018). Interestingly, the addition of the medium and of the high Levo 
doses reduced uterine horn weight, albeit not back to the weight of the Vehicle group which 
can in part be due to the possible indirect estrogenic activity of Levo, such as the observed 
increase in mRNA expression for estrogen receptors with Levo treatment or the ability of 
Levo derivatives to bind estrogen receptors (Jayaraman & Pike, 2014; Santillán et al., 
2001). In the clinic, opposing uterine stimulation is the primary purpose for including the 
progestogen component in estrogen-containing hormone therapy for menopausal women. 
Here, I show that the addition of Levo doses that opposed the effects of a constant E2 dose 
on uterine horn weight also impaired spatial learning and memory. Taken together, findings 
from this study suggest that the progestogen component of hormone therapy is a critical 
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factor that must be considered for optimal results in terms of not only the progestogen’s 
uterine effects, but also its effects on brain and cognitive outcomes.  
In conclusion, the present findings provide clinically-relevant insights into the 
cognitive effects of E2 plus Levo hormone combination treatments using a rodent model 
of surgical menopause. At the evaluated doses of E2 and of Levo, long-term E2 plus Levo 
combination treatment did not provide a cognitive benefit. Furthermore, the E2 plus Levo 
hormone combination treatments with a 3:1 and 1:2 E2 to Levo dose ratio impaired spatial 
learning and memory compared to vehicle control treatment. In fact, there was a linear 
dose-response relationship, where an increasing Levo dose in combination with a constant 
E2 dose resulted in increasingly detrimental cognitive effects. Yet, the same E2 plus Levo 
hormone combination treatments of a 3:1 and 1:2 E2 to Levo dose ratio reduced E2-
induced stimulating effects at the uterine horns. Provided that women do take estrogen plus 
progestogen hormone therapy when the uterus is present, and that the addition of Levo to 
E2, a clinically available hormone combination, reduced E2-induced uterine stimulation at 
the hormone combination dose ratios that also impaired cognition, the search must continue 
for estrogen plus progestogen parameters that would yield optimal cognitive effects 
alongside uterine effects. Indeed, the progestogen is a necessity in hormone therapy in 
terms of its protection to the uterus, and additional knowledge regarding individual 
hormone and combination hormone treatments and their specific cognitive, neural, and 
uterine effects is required to harness the full potential and beneficial effects of progestogens 
as a valuable component in hormone therapy for menopausal women.  
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CHAPTER 4 
THE COGNITIVE EFFECT OF 17β-ESTRADIOL POLY (LACTIC-CO-GLYCOLIC 
ACID) NANOPARTICLE TREATMENT IN MIDDLE-AGED OVARIECTOMIZED 
RATS 
 
This chapter will be formatted and submitted to Behavior Research Methods. Included in 
this chapter are citations of a review paper that I was invited to write on the formulation 
parameters for poly (lactic-co-glycolic acid) micro- and nano- carriers, such as 
composition, molecular weight, and type of solvent used, and how they can be altered to 
systematically manipulate the pharmacokinetic and pharmacodynamic profiles of 17β-
estradiol. This review was published as part of a special edition on Reproductive tissue 
engineering in Annals of Biomedical Engineering (Prakapenka, Bimonte-Nelson, & 
Sirianni, 2017). 
 
Contribution: I am the first author of this document and was the primary graduate student 
PI on this project. Under the mentorship of Heather A. Bimonte-Nelson and Rachael W. 
Sirianni, I designed and carried out the study with the assistance of our laboratory teams.  
 
Introduction 
The use of poly (lactic-co-glycolic) acid (PLGA) nanoparticles as drug carriers to 
improve a drug’s therapeutic efficacy has been extensively investigated across a variety 
of drugs and applications over the last several decades (Chasin & Langer, 1990; Cook et 
al., 2015; Danhier et al., 2012; Fazil, Shadab, Baboota, Sahni, & Ali, 2012; Mir, Ahmed, 
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& Rehman, 2017; Prakapenka et al., 2017). The PLGA polymer is approved by the U.S. 
Food and Drug Administration (FDA) for use in the clinic and it is considered to be of 
generally low toxicity as well as biocompatible and biodegradable (J. M. Anderson & 
Shive, 1997; Chasin & Langer, 1990; Danhier et al., 2012). In fact, since as early as 
1974, PLGA-based materials – such as surgical sutures – have been used in clinical 
settings (Conn, Oyasu, Welsh, & Beal, 1974; Ulery, Nair, & Laurencin, 2011). Once a 
drug is encapsulated in PLGA nanoparticles, its activity following systemic 
administration can be modulated by modifying the release of the drug from the 
nanoparticles (Chasin & Langer, 1990; Prakapenka et al., 2017). Furthermore, the size as 
well as the surface of PLGA nanoparticles can be altered to achieve desired interactions 
between PLGA nanoparticles and tissue compartments, targeting drug activity to those 
tissue compartments (Kreuter, 2014). Indeed, there are several methods for synthesizing 
PLGA nanoparticles, and by altering various formulation parameters of the synthesizing 
process (e.g. PLGA composition, molecular weight, type of solvents used), it is possible 
to achieve specific particle size, drug loading, rate of degradation, and drug release 
(Makadia & Siegel, 2011; Mir et al., 2017; Prakapenka et al., 2017). Although a plethora 
of studies exist that evaluate and characterize both the fabrication of drug-encapsulated 
PLGA nanoparticles and how specific parameters contribute to certain desired outcome 
measures, behavior outcome measures (e.g. learning and memory) of drug-encapsulated 
PLGA nanoparticles have not been as heavily investigated. Of note, a limited number of 
studies have encapsulated the ovarian-derived hormone 17β-estradiol (E2) in PLGA 
nanoparticles, and to the best of my knowledge, no studies so far have evaluated E2 
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PLGA nanoparticle treatment effects on spatial learning and memory outcomes 
(Prakapenka et al., 2017).  
It is understood that ovarian-derived hormones, including E2, can impact learning 
and memory (Koebele & Bimonte-Nelson, 2017; Victoria N. Luine, 2014). When 
considering the estrogens found endogenously in women and in rats, E2 is the most potent 
(Kuhl, 2005). Interestingly, only roughly 1-2% of systemically circulating E2 is freely 
available to have activity, as it often appears bound to serum hormone binding globulin or 
albumin (D. C. Anderson, 1974; Kuhl, 2005). Additionally, when E2 is exogenously 
administered, it is metabolized and cleared rapidly from the system (Kuhl, 2005). 
Nevertheless, across a woman’s lifespan, E2 is heavily involved in reproductive cycle 
regulation, as well as development and maintenance of the reproductive system. At 
menopause, a woman will experience a decrease in ovarian-derived hormone levels, 
including E2, and she may experience several undesired symptoms (e.g. vasomotor 
symptoms, cognitive changes; NAMS, 2014). Hormone therapy can be prescribed to 
combat menopause-associated symptoms, and it commonly contains E2 as the estrogen 
component. In women with a uterus present, all E2-based hormone treatments must be 
accompanied by an opposing progestogen to offset undesired E2 exposure in the uterine 
tissue (NAMS, 2017). Studies evaluating learning and memory have shown that, following 
ovarian hormone loss, E2 can have a cognitively beneficial role in humans, and when 
evaluating these effects in rodent models of menopause (Frick, 2015; Koebele & Bimonte-
Nelson, 2015; Korol & Pisani, 2015; Maki, 2012; S. E. Mennenga & Bimonte-Nelson, 
2013; Sherwin, 2006). The required addition of an opposing progestogen, however, can 
attenuate the cognitively beneficial role of E2, limiting the therapeutic potential of E2 
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(Heather A. Bimonte-Nelson et al., 2006; L. L. Harburger et al., 2009; Lauren L. Harburger 
et al., 2007; Lowry et al., 2010). Thus, although E2-containing hormone therapies are FDA-
approved, safe, and efficacious, E2 delivery may be optimized to achieve greater 
therapeutic potential of the hormone, such as enhanced beneficial effects on cognition. 
Indeed, several studies have begun exploring strategies for E2 delivery optimization, and 
have characterized effective E2 encapsulation in PLGA nanoparticles, resulting in distinct 
pharmacokinetic and pharmacodynamic profiles that are different than that of free E2 
(Prakapenka et al., 2017). E2 PLGA nanoparticles can be further modified to increase E2 
delivery to the brain (Mittal, Carswell, Brett, Currie, & Kumar, 2011), and thus potentially 
maximize the beneficial cognitive effects while reducing undesired peripheral effects when 
compared to free E2. However, as the effects of E2 PLGA on spatial learning and memory 
are currently unknown, it is critical to first confirm that the beneficial cognitive effects of 
E2 when encapsulated in PLGA nanoparticles can be achieved following the loss of ovarian 
hormones, and that blank PLGA nanoparticles do not impact learning and memory, prior 
to pursuing further engineering strategies to achieve brain-targeted delivery of E2 for 
cognitive therapy. 
In the present study, E2 was encapsulated in PLGA nanoparticles and assessed for 
effects on spatial learning and memory. Specifically, middle-aged rats underwent 
ovariectomy (Ovx), whereby the ovaries were surgically removed, to achieve a blank 
circulating ovarian-derived hormone profile. Then, rats received weekly subcutaneous oil-
control, free E2, blank PLGA, or E2 PLGA treatment, and were tested on a behavioral 
battery evaluating spatial learning and memory. Uterine stimulation was determined at the 
end of the study by comparing uterine horn weights. I hypothesized that weekly delivery 
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of E2 from PLGA nanoparticles would enhance cognition in middle-aged, Ovx rats relative 
to free E2, and relative to blank PLGA nanoparticles. I did not anticipate vehicle 
differences between oil-control, the vehicle for free E2, and blank PLGA nanoparticles, the 
vehicle for E2 PLGA.  
 
Methods 
Materials 
All reagents for nanoparticle preparation and characterization, including 
dichloromethane (DCM), poly(vinyl alcohol) (PVA), methanol, phosphate buffered 
saline (PBS), and dimethyl sulfoxide (DMSO), were obtained from Sigma-Aldrich. 50:50 
poly(DL-lactide-co-glycolide) (PLGA, ester terminated) was purchased from Durect 
Corporation (Cupertino, CA, USA) and 17β-estradiol (E2) was purchased from Sigma-
Aldrich.  
 
PLGA nanoparticle preparation 
PLGA nanoparticles were prepared under endotoxin free conditions using the 
single-emulsion technique that was previously outlined by McCall and Sirianni (2013). 
Briefly, to make blank PLGA nanoparticles (blank-PLGA), 200 mg of PLGA was 
dissolved in 2 mL of DCM:methanol (4:1) and added drop-wise to 5% PVA, the aqueous 
phase, on vortex to create an emulsion. The emulsion was then ultrasonicated on ice 3 
times in 10 second intervals (40% amplitude, Fisher Scientific Model 705 Sonic 
Dismembrator), added to 84 mL of 0.3% PVA, and allowed to harden over 3 hours. 
Particles were then washed 3 times with endotoxin free water by centrifugation at 25,000 
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rcf for 20 minutes at 40C (Beckman L8-80M Ultracentrifuge, F0630 rotor). Prior to 
lyophilization and storage (at -800C), 75 mg of trehalose was added to the particles. To 
prepare E2-containing PLGA nanoparticles (E2-PLGA), 12 mg of E2 and 200 mg of 
PLGA were dissolved in 2 mL of DCM:methanol (4:1) and processed using the same 
technique as blank-PLGA.   
 
Nanoparticle characterization 
Size and morphology of blank-PLGA and E2-PLGA nanoparticles were 
determined using scanning electron microscopy (SEM, FEI XL30) following the protocol 
described by McCall & Sirianni, 2013. The average diameter of each nanoparticle batch 
was measured using ImageJ (National Institutes of Health). The hydrodynamic diameter 
and polydispersity for the nanoparticles was determined using dynamic light scatting 
(DLS, NanoBrook 90Plus Zeta particle analyzer, Brookhaven Instruments, Hotsville, 
NY).  
To calculate E2 concentration within E2-PLGA, E2-PLGA nanoparticles were 
dissolved in DMSO at 1 mg/mL and the fluorescence of the sample was compared to a 
control curve constructed using blank-PLGA nanoparticles spiked with known E2 
concentrations (280 nm/310 nm excitation/emission). E2 loading was then determined by 
dividing E2 concentration by PLGA concentration. A release profile for E2 was obtained 
by adding 10 mg/mL E2-PLGA in 1x PBS to Slide-A-Lyzer Dialysis Cassette (3,500 
MWCO) and submerging the cassette in 4 L of 370C 1x PBS release medium. For each 
time point, 20 L of E2-PLGA sample were added to 180 L of DMSO to obtain a 1 
mg/mL concentration, and the fluorescence of the samples was read in triplicate (280 
  
122 
nm/310 nm excitation/emission). The release medium was changed at 2.5, 7.5, and 21.5 
hours to assure sink conditions.  
 
Animals 
Fischer-344 CDF 11-month old virgin female rats were ordered from the National 
Institute on Aging, Harlan Laboratories (Indianapolis, IN). Food and water were ad libitum 
and a 12-hour light/dark cycle was imposed. Rats were pair-housed throughout the duration 
of the study. All procedures were approved by the Arizona State University IACUC and 
adhered to the standards set by the National Institutes of Health. Figure 18 depicts the 
timeline of experimental manipulations throughout the duration of the behavior study. 
 
Ovariectomy (Ovx) 
Ovx surgery was performed on all rats under anesthesia using acute isoflurane 
inhalation as previously done (B. Blair Braden et al., 2017; S. E. Mennenga et al., 2015; 
Prakapenka et al., 2018). Briefly, rats received dorsolateral incisions to the skin and 
muscle, each ovary was removed following ligature to the tip of the uterine horn, and the 
skin and muscle were sutured closed. All rats received a subcutaneous injection of 
Rimadyl (5 mg/mL/kg) for pain prior to start of surgery, as well as a subcutaneous 
injection of saline (2 mL) to prevent dehydration. 
 
Treatment administration 
Twenty-one days after Ovx, weekly subcutaneous treatment administration was 
initiated. Twenty rats were randomly assigned to receive 0.1 mL of either sesame oil (oil-
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control, n = 10) or 3 μg of free E2 (free-E2, n = 10) in sesame oil, and twenty rats were 
randomly assigned to receive 0.1 mL of blank-PLGA (polymer weight matched to E2-
PLGA, n = 10) suspended in saline or 3 μg of E2 encapsulated in PLGA (E2-PLGA, n = 
10) suspended in saline. The oil-control and blank-PLGA treatments served as the vehicle 
controls in this study.   
 
Behavioral assessment of cognitive function 
  Water radial-arm maze (WRAM) 
On the day of the fourth treatment administration, all animals were tested on the 
win-shift WRAM task for 13 days to evaluate spatial working and reference memory (H. 
A. Bimonte-Nelson, 2015d; Bimonte & Denenberg, 1999; B. Blair Braden et al., 2017; S. 
E. Mennenga & Bimonte-Nelson, 2015; Sarah E. Mennenga, Koebele, et al., 2015). The 
maze was located in a room that was set up with abundant spatial cues to aid in spatial 
navigation. This maze contained 8 arms, with 38.1 cm x 12.7 cm dimensions for each arm 
and was filled with opaque water kept at 18-20oC. Hidden platforms (10 cm in diameter) 
were submerged in 4 out of the 8 arms. A pre-determined set of platform locations, which 
were kept fixed throughout all 13 days of testing, were randomly assigned to each animal. 
An animal was allowed 3 minutes per trial to find a platform. The trial started when the 
animal was dropped off at the start arm location and the trial ended when the animal either 
found or was led to the platform (after 3 minutes passed). Animals were kept on the 
platform for 15 seconds after which they were placed in a heated testing cage. During the 
30 second inter-trial interval (ITI), the just-found platform was taken out of the maze and 
the water was cleaned with a fishnet to remove debris and redistribute any olfactory cues; 
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the next trial was started at the end of the ITI. In this manner, there is one trial per platform 
(4 trials per day), resulting in increased strain on the memory system with each additional 
platform that is found and removed, leading to an increase in working memory load as 
trials progress. A 6-hour delay was implemented between trials 2 and 3 on the last day of 
testing, day 13, to assess delayed memory retention. To examine performance on the 
WRAM, error arm entries were recorded and scored on orthogonal measures of reference 
and working memory. A reference memory (RM) error was defined as the first entry, 
within a day, into a non-platformed arm. A working memory incorrect (WMI) error was 
defined as re-entry, within a day, into a non-platformed arm. A working memory correct 
(WMC) error was defined as entry, within a day, into an arm that was previously 
platformed.  
 
  Morris water maze (MWM) 
MWM testing started the day following completion of WRAM testing to examine 
spatial reference memory performance, and continued for 5 days (H. A. Bimonte-Nelson, 
2015b; Talboom et al., 2014, 2008). The maze was a 188 cm in diameter circular tub 
located in a room filled with spatial cues to aid in spatial navigation. One platform (10 cm 
in diameter) was submerged in 18-20oC opaque water in the northeast quadrant of the tub; 
the platform location was kept constant for all trials across each day of testing.  There were 
four starting locations (north, south, east, or west), one per trial with a total of 4 trials per 
day. The trial started when an animal was dropped off at one of these locations and the trial 
was completed when the animal either found the platform or was led to the platform, after 
the maximum trial time of 60 seconds. Each animal was kept on the platform for 15 seconds 
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and then returned back to a heated cage. The ITI was 5-8 minutes. The Ethovision tracking 
system (Noldus Instruments, Wageningen, The Netherlands) was used to determine each 
animal’s swim distance. A probe trial was added on the last day of testing as an additional 
5th trial to examine spatial localization, during which the platform was removed and each 
animal’s swim distance in each quadrant during a total of 60 seconds was measured.   
 
  Visible platform  
The one-day visible platform task, initiated the day after MWM testing, was used 
to evaluate the motor and visual ability of each animal to complete a water-escape maze 
task (Bimonte-Nelson, 2015a; Mennenga et al., 2015a, 2015c). The maze was a 100 cm x 
60 cm rectangular tub that was filled with 18-20oC clear water, and one black platform (10 
cm in diameter) was placed in the tub so that it would be 4 cm above the surface of the 
water. All obvious spatial cues surrounding the maze were blocked using a curtain. Each 
animal was allowed 90 seconds per trial to find the platform, the location of which varied 
semi-randomly between trials, with a total of 6 trials and an ITI of 5-8 minutes. The trial 
started when an animal was dropped off from a set location and the trial ended when the 
animal either found the platform or was led to the platform after 90 seconds. Each animal 
was given 15 seconds on the platform before being placed into a heated testing cage.  
 
Confirming systemic presence of E2  
  Blood serum analysis 
Double antibody liquid-phase radioimmunoassay (Beckman Coulter, Brea, CA), 
performed by the Core Endocrinology Laboratory of the Pennsylvania State University, 
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College of Medicine, was used to determine circulating E2 and estrone, a metabolite of E2, 
levels in blood serum (Engler-Chiurazzi et al., 2012; Koebele et al., 2017; Sarah E. 
Mennenga et al., 2015c; Prakapenka et al., in review). At sacrifice, blood was collected via 
cardiocentesis following euthanasia with isoflurane on the day of the 7th treatment 
injection in the same order as behavior testing occurred. To obtain serum, blood was 
allowed to clot at 4oC (Vacutainer 367986, Becton Dickinson and Company, Franklin 
Lakes, NJ, USA) and then centrifuged for 20 minutes at 3000 rpm at 4oC. Serum was stored 
at -20oC until radioimmunoassay analysis. E2-specific antibodies were used with 125I-
labeled E2 as the tracer for the E2 assay with a functional sensitivity of 4 pg/ml. Inter-assay 
coefficients of variation at a mean level of 6 pg/ml E2 averaged 8%. Estrone-specific 
antibodies were used with 125I-labeled estrone as the tracer for the estrone assay with a 
functional sensitivity of 16 pg/ml. Inter-assay coefficients of variation for estrone at a mean 
level of 90 pg/ml averaged 11%. 
 
  Uterine horn weights 
Ovarian hormones impact uterine horn weight (E. B. Engler-Chiurazzi et al., 2012; 
Sarah E. Mennenga, Gerson, Koebele, et al., 2015; Prakapenka et al., 2018; Westerlind et 
al., 1998). To obtain uterine horn weight, uterine horns were removed and trimmed of 
visible fat at sacrifice; the wet weight of uterine horns was then used to confirm Ovx and 
to assess E2 exposure.  
 
Statistical analyses  
For all statistical analyses, alpha was set at p < 0.05.  Repeated measures ANOVA 
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was run separately to test for a main effect of Day and Treatment x Day interaction on the 
WRAM and on the MWM to determine learning. For the WRAM, each memory measure 
(WMC, WMI, and RM errors) was evaluated across days 1-12 of testing. For the MWM, 
Total Swim Distance was evaluated across days 1-5 of testing. Additionally, for the probe 
trial, each treatment group was analyzed separately using a repeated measures ANOVA to 
evaluate percent swim distance in the previously platformed quadrant (Northeast; NE) 
compared to percent swim distance in the directly opposite quadrant (Southwest; SW).  For 
the visible platform, a repeated measures ANOVA was run to test for a main effect of Trial, 
a main effect of Treatment, and a Trial x Treatment interaction to assess learning and the 
ability to perform a water-escape task for all treatment groups.  
For WRAM treatment effects, WRAM testing was split into three blocks, Block 1 
(days 2-5), Block 2 (days 6-9), and Block 3 (days 10-12). If the vehicle control groups (oil-
control and blank-PLGA) did not differ, I expected to collapse the two groups into one 
vehicle group. Thus, a planned comparison repeated measures ANOVA was run for each 
Block to directly compare oil-control and blank-PLGA treatments to evaluate vehicle 
effects. Block 3 did in fact exhibit an effect of Vehicle, and Vehicle x Trial interaction, for 
WMC and WMI measures, discussed in detail in the results section. Due to the Vehicle 
affect, additional analyses included planned comparison to only compare free-E2 to its 
respective vehicle control (oil-control) and E2-PLGA to its respective vehicle control 
(blank-PLGA) for WMC, WMI, and RM errors made on each Block of testing. In the case 
of a significant Treatment x Trial interaction, Trial 3 and Trial 4 were analyzed separately 
to evaluate performance on the moderate and high working memory load trials, 
respectively. For all analyses, Vehicle or Treatment were the independent variables and 
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Trials nested within Days were the repeated measures. For WRAM delay, errors made on 
the WMC, WMI, and RM memory measures on the post-delay trial, Trial 3 on Day 13, 
were compared to the baseline trial, Trial 3 on Day 12, within each treatment group as was 
done previously (B. Blair Braden et al., 2017). For MWM, planned comparisons were done 
to analyze Total Swim Distance between free-E2 and oil-control as well as E2-PLGA and 
blank-PLGA across the 5 days of testing. Treatment was set as the independent variable 
and Trials nested within Days were set as the repeated measures.  
Planned comparison one-way ANOVAs were used separately for E2 and estrone 
blood serum levels and uterine horn weights to directly compare blank-PLGA and oil-
control (vehicle effect), free E2 and oil-control, E2-PLGA and blank-PLGA, as well as 
E2-PLGA and free E2. Treatment was set as the independent variable and E2 Level, 
Estrone Level, and Uterine Horn Weight were set as the dependent variables. 
 
Results 
Nanoparticle characterization 
E2 loading in PLGA nanoparticles was 4.45%. SEM image analysis revealed that 
the blank-PLGA and E2-PLGA nanoparticles were spherical with an average diameter of 
175  34 nm and 158  30 nm, respectively (Figure 17A). DLS analysis revealed that the 
average hydrodynamic diameter for blank-PLGA and E2-PLGA nanoparticles was 232  
2.1  nm and 256  2.3 nm, respectively, and the polydispersity index, a measure of 
molecular mass distribution, for blank-PLGA and E2-PLGA nanoparticles was 0.105  
0.04 and 0.158  0.02, respectively (Figure 17C). All measurements are expressed as mean 
 standard deviation. The surface charge for both batches of nanoparticles was close to 
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neutral, -1.91 for blank-PLGA and -0.59 for E2-PLGA (Figure 17C). The release profile 
of E2 from PLGA nanoparticles exhibited a rapid release of E2 within the first 8 hours 
(~80% of E2 released), followed by a slow sustained release. Completed release of E2 was 
observed after about 48 hours of incubation (Figure 17B).  
 
Behavioral assessment of cognitive function 
  Water radial-arm maze (WRAM) 
The WRAM measures spatial working and spatial reference memory. For each 
memory measure, there was a main effect of Day, indicating learning of the WRAM as 
illustrated by a decrease in WMC [F(11,36) = 5.676, p < 0.0001; Figure 19], WMI [F(11,36) = 
9.840, p < 0.0001; Figure 19], and RM [F(11,36) = 7.816, p < 0.0001; Figure 19] errors across 
days 1-12 of testing. There were no significant Treatment x Day interactions for each 
memory measure, demonstrating that WRAM learning for all days of testing did not differ 
based on treatment groups.  
First, performance on Blocks 1, 2, and 3 of the WRAM was evaluated between the 
two vehicle control groups, oil-control and blank-PLGA, across the three memory 
measures, WMC, WMI, and RM. No main effects of Vehicle, or Vehicle x Trial 
interactions, were seen for WMC, WMI, and RM errors made on Blocks 1 and 2. However, 
results for the WMC measure on Block 3, the asymptotic phase evaluating memory 
retention, revealed a significant main effect of Vehicle [F(1,18) = 8.170, p < 0.05; Figure 
20A] and a Vehicle x Trial interaction [F(2,36) = 7.803, p < 0.01; Figure 20A], where the 
oil-control group made more errors than the blank-PLGA group. Further analyses indicated 
that this Vehicle effect was particularly pronounced on Trial 4 [p < 0.01], the highest 
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working memory load trial evaluated on this version of the WRAM. For the WMI measure 
on Block 3, there was a marginal effect of Vehicle [F(1,18) = 4.296, p = 0.05; Figure 20B] 
and a significant Vehicle x Trial interaction [F(3,54) = 4.056, p < 0.05; Figure 20B] where 
the oil-control group tended to make more errors than the blank-PLGA group, and this 
effect was significant on the highest working memory load trial, Trial 4 [p < 0.05]. There 
was no significant effect of Vehicle and no Vehicle x Trial interaction for the RM measure 
on Block 3 (Figure 20C). Taken together, the two control vehicles exhibited significantly 
different effects on spatial working memory on Block 3, the asymptotic phase of the 
WRAM when rules of the task should be learned.  
Following analysis of vehicle effects, planned comparisons were performed only to 
evaluate E2-PLGA versus its vehicle (blank-PLGA) as well as free E2 versus its vehicle 
(oil-control). This analysis revealed no main effect of Treatment, but a significant 
Treatment x Trial interaction, for WMC errors on Block 1 of testing [F(2,36) = 4.486, p < 
0.05; Figure 21A], or the acquisition phase during which the rules of the task were being 
learned, between E2-PLGA and blank-PLGA groups where the E2-PLGA group made 
fewer WMC errors on Trial 3, the moderate working memory load trial, compared to the 
blank-PLGA group [p < 0.05; Figure 21B]. There were no Treatment differences and no 
Treatment x Trial interactions on Blocks 2 and 3 for WMC measures (data not shown), as 
well as Blocks 1, 2 and 3 for WMI and RM measures, between E2-PLGA and blank-PLGA 
groups (see Figure 21A for Block 1 Treatment x Trial interactions). There were no 
Treatment differences and no Treatment x Trial interactions on Blocks 1, 2, and 3 for 
WMC, WMI, RM measures between free E2 and oil-control groups (data not shown). Thus, 
a main effect of vehicle was observed where the blank PLGA nanoparticle group improved 
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spatial working memory compared to the sesame oil group. Additionally, data suggest that 
the E2-PLGA treatment did enhance spatial working memory compared to its blank-PLGA 
control during the acquisition phase (Block 1) of the WRAM, but only when working 
memory load was moderate.  
On day 13 of WRAM, a 6-hour delay was implemented between Trials 2 and 3. 
Errors made on the baseline trial, Trial 3 on Day 12, were compared errors made on the 
post-delay trial, Trial 3 on Day 13, within each treatment group. For WMC errors, oil-
control [F(1,9) = 6.612, p < 0.05; Figure 22], free E2 [F(1,9) = 18.447, p < 0.01; Figure 22], 
E2-PLGA [F(1,9) = 6.688, p < 0.05; Figure 22] treatment groups made errors on the delay 
trial compared to the baseline trial, indicating delay-induced forgetting. The blank-PLGA 
group appeared to make more WMC errors on the delay trial compared to the baseline trial, 
although this did not reach statistical significance. For WMI and RM errors, there were no 
differences within each treatment group between errors made on the delay trial compared 
to the baseline trial (data not shown).  
 
  Morris water maze (MWM) 
Analysis of spatial reference memory performance across the five days of testing 
on the MWM revealed a main effect of Day, with decreasing Total Swim Distance scores 
across days [F(4,36) = 78.929, p < 0.0001; Figure 23A]. The groups had a similar learning 
profile across days as there was no Day x Treatment significant effect. Planned 
comparisons revealed a marginal effect of treatment, and no Treatment x Day interaction, 
across the 5 days of testing between the blank-PLGA group and the E2-PLGA group [F(1,18) 
= 3.181, p < 0.1; Figure 23B], suggesting that there was a trend for the E2-PLGA group to 
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swim a shorter distance to the platform than the blank-PLGA group. There was no effect 
of Treatment and no Treatment x Day interaction across the 5 days of testing between the 
oil-control and free E2 groups. For the probe trial, oil-control [F(1,9) = 61.563, p < 0.0001], 
free E2 [F(1,9) = 14.357, p < 0.01], blank-PLGA [F(1,9) = 69.291, p < 0.0001], and E2-PLGA 
[F(1,9) = 108.477, p < 0.0001] groups swam a greater percent distance in the target northeast 
quadrant where the platform was previously located compared to the opposite southwest 
quadrant that never contained the platform, suggesting that each treatment group was able 
to spatially localize to the platform location (data not shown). 
 
  Visible platform 
The visible platform task was used to confirm visual and motor capability to 
complete a water-escape maze task. Across all six trials, there was a main effect of Trial 
[F(5,36) = 3.225, p < 0.01], and the average latency to platform for all subjects across the six 
trials was 8.9 seconds (data not shown). There was no significant Trial x Treatment 
interaction and a marginal Treatment effect for all six trials [F(3,36) = 2.658, p < 0.1]. No 
Treatment effect was seen for the last three trials tested, suggesting that all groups exhibited 
similar ability to perform on a water-escape maze task, especially by the latter half testing.  
 
Confirming systemic presence of E2  
  Blood serum analysis 
Blood serum levels of E2 and estrone were obtained to determine circulating levels 
of free E2 and its ability to be metabolized following weekly subcutaneous administration. 
Specifically, blood serum was collected in order of behavior testing the day of the 7th 
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weekly treatment administration. Planned comparison analyses revealed a main effect of 
Treatment for E2 levels between blank-PLGA and E2-PLGA groups [F(1,18) = 6.475, p < 
0.05; Figure 24A] as well as a main effect of Treatment for E2 levels between oil-control 
and free E2 groups [F(1,18) = 6.316, p < 0.05; Figure 24A], where the E2-PLGA and free 
E2 groups had higher E2 levels than their respective controls. There was a main effect of 
Treatment for estrone levels between blank-PLGA and E2-PLGA groups [F(1,18) = 20.451, 
p < 0.001; Figure 24B] and a main effect of Treatment for estrone levels between oil-
control and free E2 groups [F(1,18) = 11.153, p < 0.01; Figure 24B], where the E2-PLGA 
and free E2 groups had higher estrone levels than their respective controls. There were no 
Treatment effects between the E2-PLGA and free E2 groups in E2 levels or in estrone 
levels, suggesting that there was no difference in circulating free E2, or in its metabolism 
to estrone, between free versus nanoparticle encapsulated weekly subcutaneous 
administration of E2. 
 
  Uterine horn weight 
Uterine horn weights were obtained the same day as blood serum as a marker for 
uterine stimulation as a function of treatment. There was a main effect of Treatment 
between the blank-PLGA and E2-PLGA groups [F(1,18) = 9.52, p < 0.01; Figure 25] as well 
as a main effect of Treatment between oil-control and free E2 groups [F(1,18) = 31.458, p < 
0.0001; Figure 25], where the E2-PLGA and free E2 groups had higher uterine horn 
weights than their respective controls. Interestingly, there was also a main effect of 
Treatment between the E2-PLGA and free E2 groups [F(1,18) = 6.230, p < 0.05; Figure 25], 
where the E2-PLGA group had higher uterine horn weights than the free E2 group, 
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indicating that E2 encapsulated in nanoparticles resulted in greater uterine horn stimulation 
than free E2. 
Discussion 
The present study evaluated the cognitive and uterine effects of E2 PLGA 
nanoparticle treatment relative to free E2, as well as blank PLGA nanoparticle treatment 
in middle-aged, Ovx rats. E2 encapsulation in PLGA nanoparticles enhanced spatial 
working memory on the WRAM, and exhibited a trend for enhanced spatial reference 
memory on the MWM compared to blank PLGA nanoparticles. Interestingly, there was a 
vehicle effect, whereby the blank PLGA nanoparticle group made fewer errors than the oil-
control group, suggesting that either the blank PLGA nanoparticle treatment improved 
memory or the oil-control group impaired memory on the WRAM. The experiment as 
designed cannot determine which interpretation of the vehicle effect is supported; however, 
future research could decipher which interpretation of the vehicle effect would be 
supported. Consequently, E2 PLGA nanoparticle versus free E2 treatment effects on 
learning and memory could not be directly evaluated in this study. It is important to note 
that all groups performed similarly on the control visible platform task, with an average 
time to platform across all six trials of 8.9 seconds. When peripheral exposure to E2 was 
assessed, both E2-treated groups exhibited increased uterine horn weight compared to their 
respective vehicle controls, and E2 PLGA nanoparticle treatment had greater uterine horn 
weight than free E2 treatment, indicating potentially increased or sustained exposure of E2 
at the uterine horns with nanoparticle encapsulation. 
The WRAM is often used within the Bimonte-Nelson laboratory’s behavioral 
battery to evaluate hormone effects on spatial working and reference memory in middle-
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aged, Ovx rats (Acosta et al., 2010; B. Blair Braden et al., 2017; Prakapenka et al., 2018). 
In the present study, all rats learned the task and their learning trajectories across the 12 
days of testing did not differ by treatment. WRAM performance was further evaluated 
across Blocks 1 (days 2-5), 2 (days 6-9), and 3 (days 10-12) of testing. Intriguingly, a 
vehicle effect was observed on Block 3 of testing, the asymptotic phase evaluating spatial 
memory retention. This effect revealed that blank PLGA nanoparticle treatment, the 
vehicle for E2 PLGA nanoparticle treatment, resulted in fewer WMC and WMI errors 
made compared to the oil-control treatment, the vehicle for free E2 treatment; the vehicle 
effect was primarily driven by performance on Trial 4, when working memory demand 
was highest. Following a 6-hour delay, analyses revealed that all treatment groups 
exhibited delay-induced forgetting on the WMC measure, although the blank PLGA 
treatment group did not reach statistical significance on the delay trial compared to the 
baseline trial, further supporting vehicle-specific differences on spatial working memory. 
The vehicle effect was surprising, as I did not anticipate the blank PLGA nanoparticles, 
suspended in sterile saline, to impact spatial learning and memory differently from the 
sesame oil. For instance, cholesterol can be neuroprotective against corticosterone-induced 
reduction in apical dendritic branching in the CA3 region of the hippocampus in 
gonadectomized male and female rats and sesame oil can reduce cholesterol levels, 
suggesting potential impairing effects of sesame oil (Ortiz et al., 2013; Satchithanandam et 
al., 1996). However, a thorough literature search indicated that on spatial memory 
measures, saline and sesame oil did not differ in effects and were typically combined as 
one control group for treatment comparisons (Abdulla, Calaminici, Stephenson, & Sinden, 
1993; Tarbali & Khezri, 2016). Assuming similar effects of saline and sesame oil on 
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learning and memory, the PLGA characteristics may be the ones at play in the distinct 
vehicle effects on memory evidenced in the present study. Indeed, following systemic 
administration, PLGA degrades into lactic acid and glycolic acid, and recent studies 
suggest that lactic acid plays a critical role in long-term memory formation, spatial working 
memory, as well as neuroplasticity (Newman, Korol, & Gold, 2011; S. Sun, Li, Chen, & 
Qian, 2017; Suzuki et al., 2011; Yang et al., 2014). Additionally, PLGA nanoparticles may 
elicit a foreign body immune response following administration (Fournier, Passirani, 
Montero-Menei, & Benoit, 2003; Semete et al., 2010), and the immune system is involved 
in maintaining spatial learning and memory (Yirmiya & Goshen, 2011; Ziv et al., 2006). 
However, future studies are needed to systematically address these hypotheses. Existing 
studies evaluating drug-encapsulated PLGA nano- and micro-particle effects on learning 
and memory that included both saline as well as blank nanoparticle control groups revealed 
no vehicle effects on cognitive performance on the passive-avoidance task (Khalin et al., 
2016; Wang et al., 2007). A recent study that included both saline and blank PEGylated 
poly(anhydrite) nanoparticle control groups on the spatial MWM did not report statistical 
analyses for the vehicle comparison even though the learning curves between the saline 
and blank nanoparticle groups do appear to be different (Moreno et al., 2018). Importantly, 
many of the studies that evaluated drug-encapsulated nanoparticle effects on learning and 
memory did not include both a saline and a blank nanoparticle control group; thus, based 
on these studies it cannot be definitively concluded whether or not the addition of the blank 
nanoparticle impacts memory differently from the saline control (Chu, Tian, Liu, Li, & Li, 
2007; S. Fan et al., 2018; Joshi, Chavhan, & Sawant, 2010; Sánchez-López et al., 2018; D. 
Sun et al., 2016; Tiwari et al., 2014). Taken together, findings from the present study 
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underscore the critical importance of including proper controls and statistical analyses 
when evaluating novel delivery systems as it is possible that the addition of a seemingly 
inert carrier may indeed influence learning and memory outcomes on its own.  
Due to the exhibited vehicle effects, WRAM performance was further evaluated 
only to compare E2 PLGA treatment relative to its control, as well as free E2 treatment 
relative to its control. On Block 1 of testing – the acquisition block, when rats were learning 
the rules of the task – a trial by treatment interaction revealed that E2 PLGA nanoparticle 
treatment resulted in fewer WMC errors relative to blank PLGA nanoparticle treatment on 
Trial 3, when working memory load was moderate. These findings are consistent with 
literature, and support a cognitively beneficial role of E2 following a decrease in circulating 
levels of ovarian-derived hormones (Bimonte & Denenberg, 1999; Jill M. Daniel et al., 
2006; Jill M Daniel et al., 1997; Fader et al., 1999; R. B. Gibbs & Johnson, 2008; V N 
Luine et al., 1998; Prakapenka et al., 2018; Rodgers et al., 2010). Interestingly, free E2 
treatment did not differ from its control on any of the three memory measures evaluated 
across the three blocks of WRAM testing. Although due to the exhibited differences in 
vehicles, E2 PLGA and free E2 treatments could not be directly compared for cognitive 
outcomes on the WRAM, the findings overall indicate that E2 encapsulation in PLGA 
nanoparticles did enhance the hormone’s beneficial effects on cognition when a weekly 
subcutaneous treatment regimen was implemented, as E2 PLGA improved spatial working 
memory compared to its control whereas free E2 did not differ from its control, supporting 
my hypothesis that weekly delivery of E2 from PLGA nanoparticles will enhance cognition 
in middle-aged, Ovx rats relative to blank PLGA nanoparticles, and relative to free E2. 
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 The second learning and memory task implemented within the behavioral battery 
of the present study, the MWM, evaluated spatial reference memory. Once again, all rats 
learned the task and exhibited a similar learning trajectory across all days of testing. 
Additionally, probe trial evaluation indicated that all treatment groups spatially localized 
to the platform location. There was a trend for the E2 encapsulated PLGA treatment group 
to swim a shorter distance to the platform across the 5 days of testing relative to its control, 
although the effect did not reach statistical significance. The free E2 treatment did not differ 
in swim distance to platform relative to its control. Overall, MWM data suggest that weekly 
subcutaneous E2 PLGA treatment tended to improve spatial reference memory, whereas 
weekly subcutaneous free E2 treatment did not. In Ovx rats, higher levels of circulating E2 
correlate with better performance on the MWM task (Talboom et al., 2008). Thus, the 
moderate beneficial effects of E2-PLGA treatment on the MWM in the present study may 
in part be due to a greater presence of the hormone in cognitively-involved brain regions 
than free E2, as circulating E2 levels did not differ (discussed below), and postulate that 
additional investigation of E2 PLGA treatment as a function of treatment regimen as well 
as E2 dose may result in strengthened cognitive effects of E2 PLGA treatment. 
Our overarching goal of optimizing the delivery of E2 for cognitive therapy was to 
enhance E2-mediated memory effects while minimizing exposure of the hormone to 
peripheral tissue. Following E2 PLGA and free E2 treatments, circulating levels of E2 and 
of estrone, a metabolite of E2, were higher relative to each treatment’s respective controls, 
confirming the presence of E2 and its metabolite in the periphery. E2 and estrone 
circulating levels did not differ between E2 PLGA and free E2 treatment groups, indicating 
that E2 encapsulation in PLGA nanoparticles did not impact circulating levels of E2 or of 
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the hormone’s metabolism to estrone. In terms of uterine stimulation, both E2 PLGA and 
free E2 increased uterine horn weight compared to their respective controls, confirming E2 
exposure at the uterine horns as estrogen exposure was expected to increase uterine horn 
weight in Ovx rats (Prakapenka et al., 2018; Westerlind et al., 1998). Further, E2 PLGA 
increased uterine horn weight compared to free E2, suggesting prolonged exposure of the 
uterine horns to E2 following its delivery when encapsulated in PLGA nanoparticles. Thus, 
uterine stimulation findings from the current study indicate that E2 encapsulated in PLGA 
nanoparticles increased the hormone’s uterine effects compared to free E2. 
In sum, despite an apparent effect of vehicle on spatial working memory, the 
implementation of PLGA nanoparticles for E2 delivery enhanced the cognitively-
beneficial effects of the hormone. Indeed, weekly E2 PLGA treatment resulted in improved 
spatial working memory on the WRAM task, and showed a trend in improved spatial 
reference memory on the MWM task, relative to control whereas free E2 did not impact 
spatial learning and memory relative to control. However, E2 PLGA treatment also resulted 
in enhanced effects of the hormone on uterine stimulation relative to free E2, suggesting 
that the use of PLGA nanoparticles, at least in a non-modified formulation, is not ideal for 
use in cognitive therapy. Nevertheless, the established baseline of cognitive and uterine 
effects following E2 PLGA treatment versus free E2 treatment provided within this study 
sets the stage for future work focused on modifying E2 PLGA formulations to target E2 
delivery to the brain, and to indirectly decrease circulating levels and uterine horn exposure 
to the hormone once a lower treatment dose yielding the same cognitive outcomes as free 
E2 is achieved. And, importantly, I have shown that the evaluation of vehicle controls when 
implementing novel drug delivery platforms or outcome measures is critical, and can 
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impact interpretation of results, as the carrier itself may exhibit effects on evaluated 
outcome measures. In consideration of improving E2 treatment for potential use as a 
cognitive therapy, alternate drug delivery strategies must also be evaluated, such as 
addition of a specific targeting moiety, route of administration, or use of other drug carrier 
types. Undeniably, the merging of behavioral neuroendocrinology with biomedical 
engineering is an exciting, and still novel, avenue that can yield hormone therapy options 
optimized for desired therapeutic efficacy, such as treatment of a specific symptom with 
minimized peripheral burden, and will ultimately lead to improved quality of life for 
women across their lifespans. 
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CHAPTER 5 
COGNITIVE EFFECTS OF INTRANASAL 17β-ESTRADIOL-CYCLODEXTRIN 
TREATMENT IN MIDDLE-AGED OVARIECTOMIZED RATS 
 
This chapter will be formatted and submitted as a manuscript for publication to a peer-
reviewed journal.  
 
Contribution: I am the first author of this document and was the primary graduate student 
PI on this project. Under the mentorship of Heather A. Bimonte-Nelson and Rachael W. 
Sirianni, I designed and carried out the study with the assistance of our laboratory teams.  
 
Introduction 
Transitional menopause is a natural aspect of aging in women and occurs at an 
average age of 52 years (NAMS, 2014). Surgical menopause occurs following the 
surgical removal of reproductive tissues (e.g., the ovaries). The onset of either transitional 
or surgical menopause is associated with an overall decrease in circulating ovarian 
hormone levels, including two of the endogenously present steroid hormone classes, 
estrogens and progestogens. With menopause and the associated changes in circulating 
hormone milieu, several undesired symptoms may be present, such as changes in 
cognitive functions as well as vaginal atrophy, hot flashes, and osteoporosis (Maki, 2012; 
NAMS, 2014). Multiple hormone therapy options are available for women to decrease 
the presence and severity of some of these symptoms, and these therapies are often 
administered by oral or transdermal routes (Kuhl, 2005; Prakapenka et al., in review). 
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The two main components in hormone therapy are estrogens and progestogens. The type 
of hormone, the dose ratios of hormone combinations, as well as type and length of 
hormone administration can all vary when prescribed for hormone therapy (Kuhl, 2005; 
Prakapenka et al., in review). Thus, it is imperative to understand how menopause-
associated changes in ovarian hormone milieu, as well as subsequent exogenous hormone 
therapy treatments, impact women’s health, including brain health, and to explore 
alternate delivery platforms that may ultimately capitalize and improve on the therapeutic 
efficacy of hormone therapies.  
One extensively studied ovarian hormone within the field of behavioral 
neuroendocrinology is 17β-estradiol (E2). E2 is the most potent natural estrogen in 
women and in rodents, it is a common estrogenic component in hormone therapy, and it 
can exhibit beneficial cognitive effects following a decrease in endogenously circulating 
ovarian hormones (Frick, 2015; Koebele & Bimonte-Nelson, 2015; Kuhl, 2005; Maki, 
2012; S. E. Mennenga & Bimonte-Nelson, 2013; NAMS, 2012; Prakapenka et al., 2018). 
Through extensive evaluations, it is now understood that a myriad of factors, such as 
route of administration, regimen, dose, and background circulating hormone profile, can 
influence whether E2 will have beneficial, neutral, or even detrimental cognitive effects 
(Koebele & Bimonte-Nelson, 2015; Prakapenka et al., in review). The ovariectomy (Ovx) 
rodent model, whereby ovaries are surgically removed, has been instrumental in 
systematically controlling for and examining these factors as well as the corresponding 
observed changes in cognitive function (S. E. Mennenga & Bimonte-Nelson, 2013; 
Prakapenka et al., in review). For instance, I have recently showed that a daily 
subcutaneous injection of E2 enhanced spatial working memory on the water radial arm 
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maze (WRAM) in middle-aged, Ovx rats, and increased uterine horn weight, a marker of 
uterine exposure to estrogens (Prakapenka et al., 2018). Of note, although this specific E2 
treatment regimen was cognitively-beneficial, its administration yielded increased 
peripheral uterine stimulation – an undesired effect. In the clinic, estrogen-only hormone 
therapy is associated with an increase in the risk for developing endometrial hyperplasia 
and cancer; thus, minimal uterine exposure to estrogens when administered alone is 
desired (NAMS, 2014). Although progestogens can and are used in the clinic to oppose 
these estrogen-associated risks in women that have an intact uterus, Ovx rodent models 
indicate that the addition of a progestogen can also oppose the cognitively-beneficial 
effects of estrogens (Heather A. Bimonte-Nelson et al., 2006; Lauren L. Harburger et al., 
2007; Lowry et al., 2010; Maki, 2012; NAMS, 2012). Indeed, when evaluating a 
clinically relevant estrogen plus progestogen hormone combination, I found that the 
addition of a cognitively-beneficial synthetic progestogen, levonorgestrel (Levo), to a 
cognitively-beneficial dose of E2 at a 5:1 E2 to Levo dose ratio attenuated the beneficial 
effects of E2 and of Levo when each were given alone (Prakapenka et al., 2018). This 
hormone combination treatment did not decrease uterine horn weight compared to E2 
alone treatment (Prakapenka et al., 2018). Further analyses revealed that the addition of 
Levo at a 3:1 and a 1:2 E2 to Levo dose ratio did in fact decrease uterine horn weight 
compared to E2 alone treatment; yet, these two hormone combination treatments also 
impaired spatial working and reference memory (Chapter 3). Taken together, existing 
studies posit value in developing a targeted delivery platform that can achieve an 
increased uptake of estrogen in regions of the brain involved in cognitive function, while 
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minimizing estrogen exposure at the uterus, as it would maximize the beneficial role of 
estrogens, such as E2, in learning and memory.  
The intranasal route of administration can achieve greater delivery to the brain 
versus peripheral tissue compared to several other routes of administration (Nonaka et al. 
2008). In regard to E2 delivery, a clinically available intranasal spray of E2, Aerodiol, 
was designed for menopausal hormone therapy but was discontinued for industrial 
reasons, with no severe side effects reported (Pelissier et al., 2001; Studd et al., 1999). 
Indeed, clinical evaluations of Aerodiol concluded that a daily administration of Aerodiol 
was well tolerated and effective at reducing symptoms associated with menopause in 
women (Pelissier et al. 2001; Studd et al. 1999). Further, intranasal E2 can circumvent 
first-pass E2 metabolism as compared to oral administration, as well as can achieve 
cyclic E2 circulating levels, a hormone profile that more closely represents the natural 
fluctuations in circulating E2 levels in both women and female rodents (M. E. Davis & 
Brewster, 2004; Studd et al., 1999). To the best of my knowledge, the cognitive effects of 
E2 following intranasal administration have not yet been evaluated, and additional 
assessments are needed to better understand the peripheral burden of intranasally 
administered E2, particularly at the uterine tissue, in order to help determine whether it 
could have an overall efficacious profile as a hormone therapy.  
A major limitation in administering E2 via the intranasal route is the hormone’s 
low solubility. In Aerodiol, E2 was solubilized with the addition of randomly methylated 
β-cyclodextrin. Cyclodextrins (CDs) are a group of compounds composed of sucrose 
molecules bound together in a ring, forming a hydrophobic core and a hydrophilic 
surface. Due to this donut-shape structure, CDs are commonly used in drug delivery to 
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solubilize hydrophobic compounds, such as E2, by creating a drug-inside-CD complex. 
CDs differ based on the number of sucrose chains (6-, 7-, and 8- chains), and their 
properties can be altered to enhance desired CD characteristics, such as increased 
solubility. For instance, the 2-hydroxypropyl β-CD is used to produce a commercially 
available ‘water-soluble E2’ (Sigma-Aldrich). Of note, this E2-CD complex has been 
previously utilized in behavioral rodent paradigms to assess the role of E2 in cognitive 
function (Fernandez et al., 2008; L. L. Harburger et al., 2009; Sinopoli, Floresco, & 
Galea, 2006). Furthermore, intranasal rodent studies suggest that the addition of CDs can 
enhance uptake of hydrophobic agents in the brain (e.g. ~2-fold for I-GALP, a galanin-
like peptide) as well as impact regional brain distribution as a function of CD type (N 
Nonaka et al., 2008; Naoko Nonaka et al., 2012). Thus, based on prior studies evaluating 
intranasal delivery as well as the role of CDs in intranasal delivery to the brain, the 
combination of intranasal administration plus the addition of a CD is a promising avenue 
that may be utilized to achieve increased E2 uptake in the brain, minimal peripheral E2 
exposure, and even targeted delivery to specific regions in the brain. Particularly, the 
brain regions of interest are the frontal cortex and the dorsal hippocampus; these two 
regions are heavily involved in learning and memory and are necessary for E2-induced 
beneficial cognitive effects (L. Fan et al., 2010; Fortress, Fan, Orr, Zhao, & Frick, 2013; 
Prakapenka et al., 2018). Here, I propose to evaluate a potentially novel delivery platform 
– intranasal delivery of E2 as a function of CD type – for E2-based hormone therapy 
targeted for greater cognitive effects and lower uterine effects.  
In the present work, I tested the overarching hypothesis that intranasal 
administration of an E2-CD complex targeting estrogen delivery to the frontal cortex and 
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to the dorsal hippocampus in middle-aged Ovx rats will result in enhanced cognitive 
function and minimal uterine horn stimulation compared to vehicle control and compared 
to free E2. In Study 1, the brain-distribution and biodistribution profiles of radiolabeled 
E2, alone or complexed with CDs, in middle-aged, Ovx rats following intranasal 
administration was determined. I predicted that varying the CD type in the E2-CD 
complex formulations would differentially impact E2 uptake in specific regions of the 
brain following intranasal administration. Next, in Study 2, daily intranasal 
administration of free E2 and of an E2-CD combination that yielded greatest E2 delivery 
to cognitively-involved brain regions were evaluated on a behavioral battery assessing 
spatial working and spatial reference memory in middle-aged, Ovx rats. At the 
completion of the study, uterine horn weights were collected to assess E2-induced effects 
on uterine stimulation based on treatment type. I predicted that the E2-CD complex 
would improve spatial learning and memory, and have minimal uterine stimulation, 
relative to vehicle, and relative to free E2.   
 
Methods - Study 1: Brain-distribution and biodistribution of free E2 and of E2-CD 
complexes following intranasal administration 
Animals 
Sixty-two female Fischer-344 CDF virgin rats were ordered from the National 
Institute on Aging, Harlan Laboratories (Indianapolis, IN). The ages ranged from 9-11 
months old due to limited availability of ages at the NIA colony. Once arrived, rats were 
pair-housed, kept on a 12-hour light/dark cycle, and provided food and water ad libitum. 
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All procedures were approved by the Arizona State University IACUC and adhered to the 
standards set by the National Institutes of Health. See Figure 26 for the study timeline. 
 
Ovariectomy (Ovx) 
All rats received Ovx surgery under acute isoflurane anesthesia, as previously 
described (B. Blair Braden et al., 2017; S. E. Mennenga et al., 2015; Prakapenka et al., 
2018). Specifically, following dorsolateral incisions to the skin and muscle, the tip of 
each uterine horn was ligatured, and the ovaries plus the tip of the uterine horns were 
excised. Muscle and skin were then sutured and stapled closed, respectively. 
Subcutaneous Rimadyl (5 mg/mL/kg) was given for pain, and subcutaneous saline (2 
mL) was given to prevent dehydration. One rat died due to surgical complications. 
 
Treatments 
 Approximately three weeks following Ovx surgery (20 ± 2 days after Ovx), 59 
rats were randomly assigned to receive a single intranasal administration of one of the 
five treatment formulations outlined in Table 4. Two rats did not receive treatment and 
served as background radioactivity controls for later tissue processing. The five 
treatments were administered to each rat at 0.04 mCi of tritiated E2 per kg body weight. 
The formulations included free E2 (Treatment A), E2-randomly methylated β-CD 
complex (Treatment B), E2-2-hydroxypropyl β-CD complex (Treatment C), E2-β-CD 
complex (Treatment D), and E2-γ-CD complex (Treatment E). All treatments were 
solubilized in 0.9% saline with the exception of Treatment A, which was solubilized 
using 20% PEG solution in 0.9% saline; the pH was kept at 5.5 for all treatments to 
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match the pH range of a rat’s nasal cavity and to minimize irritation following intranasal 
administration in awake rats (A. Singh, Singh, & Madhav, 2012). Tritiated E2, dissolved 
in ethanol, was purchased from American Radiolabeled Chemicals (cat # ART 0820). 
Treatment A served as the free E2 comparison, without the addition of a CD carrier. 
Treatment B utilized the CD that was used in the clinically available Aerodiol intranasal 
spray (Pelissier et al., 2001; Studd et al., 1999); tritiated E2 was combined with the CD 
that was dissolved in 96% ethanol at a 1:2 E2 to CD molar ratio. Treatment C utilized the 
CD that has been evaluated in behavioral studies of E2’s effects on learning and memory, 
as well as neuromolecular mechanisms (Fernandez et al., 2008; L. L. Harburger et al., 
2009; Sinopoli et al., 2006); tritiated E2 was combined with the CD that was dissolved in 
96% ethanol at a 1:2 E2 to CD molar ratio. Treatment D utilized the base β-CD of the 
two CD derivatives from Treatments B and C; tritiated E2 was combined with the CD 
that was dissolved in 50% ethanol at 500C at a 1:4 E2 to CD molar ratio and sonicated for 
30 minutes. Treatment E utilized γ-CD, which has a greater internal cavity size than that 
of β-CD (M. E. Davis & Brewster, 2004); tritiated E2 was combined with the CD that 
was dissolved in 50% ethanol at 500C at a 1:5 E2 to CD molar ratio and sonicated for 30 
minutes. After the five treatment formulations were generated, each formulation was 
aliquoted, ethanol was evaporated, and treatments were stored at 40C. On the day of 
treatment administration, each rat was weighed, gently wrapped in a towel while 
exposing the nostrils, and administered 5 l of a treatment per nostril for a total of 10 l  
at 0.04 mCi/kg tritiated E2, while gently holding onto the jaw area of the rat’s head to 
immobilize it. For three days prior to treatment administration, all rats were habituated to 
being handled for intranasal administration (but not administered anything). 
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Tissue collection 
At 0.5, 2, or 6 hours following intranasal administration (n = 3-4 rats per 
treatment per time point), isoflurane was used to anesthetize the rat, whole blood was 
collected from the right atrium of the heart and frozen (-200C), and the rat was perfused 
with heparinized 1x PBS (10 units of heparin per ml of 1x PBS) through the left ventricle 
of the heart. Following perfusion, the brain was rapidly excised and dissected to collect 
the olfactory bulbs, trigeminal nerves, frontal cortex, cingulate cortex, basal forebrain, 
striatum, dorsal hippocampus, hypothalamus, amygdala, entorhinal cortex, perirhinal 
cortex, and the CA1/CA2 region of the ventral hippocampus.  The tissue was weighed 
and stored at -200C until later processing. Uterine horns were removed from the body 
cavity, trimmed of visible fat, weighed, and stored at -200C until later processing. All 
samples were collected as a whole area for each region and tissue of interest and then 
processed for radioactivity detection using the liquid scintillation technique to obtain the 
desired radioactivity levels per mg of sample. Of note, alternate methods of radioactivity 
detection are available, such as film radiography of a section or slice of a region or tissue 
of interest, which can allow for more accurate spatial representation of radioactivity 
levels within a sample (e.g. region or cell localization) rather than the overall 
radioactivity level as a function of sample weight. For the purpose of this study, the goal 
was to determine and compare E2 delivery in areas of interest which differed in size (e.g., 
dorsal hippocampus versus uterine horns), and the homogenization plus liquid 
scintillation technique allowed for such comparisons.   
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Tissue processing 
Solvable Solution (PerkinElmer) was used to homogenize whole blood, brain 
tissue, and uterine horns. For brain tissue, 0.005 ml of Solvable per mg of tissue was 
added to each sample and then incubated overnight at 500C. The next day, 0.2 ml of 30% 
hydrogen peroxide was added to each sample and incubated for 30 min at 500C for de-
colorization. Then, Hionic-Fluor scintillation cocktail (PerkinElmer) was added to each 
sample and allowed 1 hour for light and temperature to adjust prior to reading the 
radioactivity of each sample in triplicate on the LS 6500 Multi-Purpose Liquid 
Scintillation Counter. For whole blood, 0.005 ml of Solvable per mg of whole blood was 
added to each sample and then incubated overnight at 500C. The next day, 0.2 ml of 30% 
hydrogen peroxide was added in 50 l increments to minimize foaming to 500 l of each 
sample and incubated for 30 min at 500C for de-colorization. Next, Hionic-Fluor 
scintillation cocktail (PerkinElmer) was added to each sample and allowed 1 hour for 
light and temperature to adjust prior to reading the radioactivity of each sample in 
triplicate. For uterine horns, each uterine horn was finely minced, weighed, and 0.005 ml 
of Solvable per mg of tissue was added to each sample and then incubated overnight at 
500C. The next day, 0.2 ml of 30% hydrogen peroxide was added in 100 l increments to 
minimize foaming to 500 l of each sample and incubated for 30 min at 500C for de-
colorization. Hionic-Fluor scintillation cocktail (PerkinElmer) was then added to each 
sample and allowed 1 hour for light and temperature to adjust prior to reading the 
radioactivity of each sample in triplicate. The tissue and whole blood from the rats that 
did not receive any treatment was processed in the same exact way and radioactivity was 
read at the same time as the respective samples were processed. All data were expressed 
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as CPM/mg of tissue after subtracting the background CPM/mg obtained from the control 
rats (rats that received no treatment).   
 
Methods - Study 2: Cognitive evaluation of daily intranasal E2-CD treatment relative to 
free E2 and vehicle 
Animals 
Forty female Fischer-344 CDF virgin rats were ordered from the National Institute 
on Aging, Harlan Laboratories (Indianapolis, IN). Ages ranged from 9-10 months old. All 
rats were pair-housed and kept on a 12-hour light/dark cycle for the duration of the study. 
Food and water were provided ad libitum. All procedures were approved by the Arizona 
State University IACUC and adhered to the standards set by the National Institutes of 
Health. See Figure 26 for the study timeline. 
 
Ovariectomy (Ovx) 
Ovx surgery was performed on all rats following the same procedure as outlined 
in Study 1 methods.  The first body weight measurement was collected immediately prior 
to Ovx, and body weight was monitored on a weekly basis for the rest of the study to 
monitor animal health as well to confirm Ovx and E2 exposure; body weight was 
expected to increase following Ovx and to be greater with vehicle control treatments 
compared to E2-containing treatments (Diz-Chaves et al., 2012; Prakapenka et al., 2018; 
Rogers, Perfield, Strissel, Obin, & Greenberg, 2009). 
 
 
  
152 
Treatment administration 
Three weeks following Ovx surgery, all rats were randomly assigned to receive 
daily intranasal administration of one of four treatments that continued for the duration of 
the study (Figure 26). Treatments were counter-balanced so that 20 rats received 
intranasal administration from 7:10 - 7:30 am every day and 20 rats received intranasal 
administration at 9:10 - 9:30 am every day to account for future behavioral battery 
assessments which were estimated to take about 1 hour for 20 rats to complete (using 2 
behavioral rooms). In this manner, all rats were behaviorally tested 0.5 - 1.5 hours 
following treatment administration, capitalizing on the treatment brain-distribution 
effects observed in Study 1. The four treatments followed the same synthesis and 
administration procedures as outlined in Study 1, and utilized non-radioactive E2 
purchased from Sigma-Aldrich. The treatments included saline-PEG (20% PEG solution 
in saline) as the vehicle control for free E2, 1 g/rat free E2, saline-CD (saline with 2-
hydroxypropyl β-CD) as the vehicle control for the E2-CD complex, and 1 g/rat E2-CD 
(E2-2-hydroxypropyl β-CD complex). 2-hydroxypropyl β-CD was chosen as the CD for 
the E2-CD complex treatment due to its greatest delivery of E2 to the dorsal 
hippocampus relative to free E2, as observed in Study 1 and discussed in more detail in 
the Results section; the amount of CD in saline-CD and in E2-CD vehicle groups were 
matched. The dose of E2 was determined to be 1 g/rat/day based on the lowest dose of 
E2 in Aerodiol that effectively alleviated symptoms of menopause in women, adjusted 
for difference in body weight between women and rats (Studd et al. 1999). 
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Water radial-arm maze (WRAM) 
On the fourth week of treatment administration, all rats started behavioral testing. 
The first task, the win-shift WRAM, tested spatial working and reference memory (H. A. 
Bimonte-Nelson, 2015d; Bimonte & Denenberg, 1999; B. Blair Braden et al., 2017; S. E. 
Mennenga & Bimonte-Nelson, 2015; Sarah E. Mennenga, Koebele, et al., 2015). The maze 
had 8 arms, with 38.1 cm x 12.7 cm dimensions for each arm, and the room had abundant 
spatial cues set up to aid in spatial navigation. The maze was filled with opaque water, and 
the temperature of the water was 18-20oC. Four out of the 8 arms contained hidden 
platforms that were 10 cm in diameter, and the location of which was fixed throughout all 
days of testing for a rat, but varied across rats and within treatment groups. For each trial, 
there was a maximum time of 3 minutes allotted to solve the task by locating one of the 
platforms. To start a trial, a rat was dropped off at the same start arm location each time 
and the trial continued until the rat either found or was led to the platform (after 3 minutes 
passed). After 15 seconds on the platform, the rat was placed back into a heated testing 
cage. The inter-trial interval (ITI) was 30 seconds, during which the just-located platform 
was removed and a fishnet was used to clean the maze and redistribute olfactory cues. After 
the ITI, the next trial was started and the task continued until there were no more platforms 
left to find, resulting in four trials total per day for each rat. With each trial, the task became 
increasingly harder to solve as working memory demand was increasingly taxed as trials 
progressed. After 12 days of testing, on day 13, a delay period of 6 hours was added 
between trials 2 and 3 to evaluate delayed memory retention.  
Performance on the WRAM was scored by recording and scoring number of error 
arm entries. Error entries were further divided into 3 memory measures evaluating 
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reference and working memory. A reference memory (RM) error was made when a rat 
entered a non-platformed arm within a day. A working memory incorrect (WMI) error was 
made when a rat re-entered a non-platformed arm within a day. A working memory correct 
(WMC) error was made when a rat entered a previously platformed arm within a day.  
 
Visible platform  
To confirm procedural components (e.g. visual, motor) to solve a water-escape task 
are present, the visible platform task was implemented on the last day of behavioral testing 
(Bimonte-Nelson, 2015a; Mennenga et al., 2015a, 2015c). Specifically, a rectangular tub, 
100 cm x 60 cm, was set up in a room with all spatial cues blocked using a curtain around 
the maze. The maze contained 18-20oC clear water with one black platform (10 cm in 
diameter) that was kept 4 cm above the water surface. The maximum trial time to find the 
platform was 90 seconds, with 6 trials total. The platform location was semi-randomly 
varied between trials, and the ITI was 5-8 minutes. The trial started when a rat was dropped 
off from a set location and the trial ended when the rat either found the platform or was led 
to the platform after 90 seconds. Once found, each rat was given 15 seconds on the platform 
before being placed into a heated testing cage. Performance on the visible platform task 
was measured as time, in seconds, to platform. 
 
Uterine horn weights 
Uterine horn weight served as a marker of uterine stimulation as it is well known 
that ovarian hormones impact uterine horn weight and can be effectively used to confirm 
Ovx and to assess E2 exposure (E. B. Engler-Chiurazzi et al., 2012; Sarah E. Mennenga, 
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Gerson, Koebele, et al., 2015; Prakapenka et al., 2018; Westerlind et al., 1998). The wet 
weight of uterine horns was collected at sacrifice after the uterine horns were excised and 
all visible fat was removed.  
 
Statistical analyses  
For Study 1 and Study 2 statistical analyses, alpha was set at p < 0.05. Study 1 
analyses included one-tailed Student’s t-tests to evaluate the hypothesis that the addition 
of a CD would increase the delivery of E2 to the dorsal hippocampus and to the frontal 
cortex relative to free E2 within each time point that was collected. An outlier was excluded 
from all analyses and figure representations as it was 5-fold greater than the next highest 
value within that treatment group (0.5 hr timepoint for Treatment B), although the 
interpretation of statistical outputs did not depend on whether the outlier was included or 
not in the analyses.   
To evaluate changes in body weight across the 10 weeks of Study 2, a repeated 
measures ANOVA was run for Weeks 1-4, the weeks prior to treatment initiation, and 
Weeks 5-10, the weeks during treatment administration. The independent variable was 
Treatment, and the repeated measures were Weeks. Fisher’s post hoc analyses were run 
when there was a significant main effect of Treatment. 
For the WRAM, each memory measure (WMC, WMI, and RM errors) was 
evaluated separately on days 2-7, the acquisition phase, and on days 8-12, the asymptotic 
phase, as done previously (Hiroi et al., 2016; Sarah E. Mennenga, Gerson, Koebele, et al., 
2015). A 2 x 2 factorial repeated measures ANOVA was used to evaluate performance, 
with Estrogen Treatment (No E2 or E2) and Vehicle Type (saline-PEG or saline-CD) as 
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factors. In the case of a significant main effect of Estrogen, main effect of Vehicle, or 
Estrogen x Vehicle interaction, additional repeated measures ANOVAs were conducted to 
directly evaluate Treatment effects for the appropriate two group comparison. A significant 
Trial x Estrogen, Trial x Vehicle, or Trial x Estrogen x Vehicle interaction led to further 
analyses on the highest working memory load trial that was evaluated on this version of 
the WRAM, Trial 4. For all analyses, Estrogen, Vehicle, or Treatment were set as the 
independent variables and Trials nested within Days were the repeated measures. For the 
WRAM delay, total errors made (WMC, WMI, and RM memory measures combined) on 
the post-delay trials (Trials 3 and 4 on Day 13) were compared to the baseline trials (Trials 
3 and 4 on Day 12) within each treatment group to evaluate delayed memory retention.  
For the visible platform, a repeated measures ANOVA was run to test for a main 
effect of Trial, a main effect of Treatment, and a Trial x Treatment interaction to assess 
simple learning and the ability to perform the procedural components of a water-escape 
task across treatment groups. Treatment was the independent variable and the repeated 
measures were Trials. A one-way ANOVA was run for uterine horn weights, and Fisher’s 
post hoc analyses were used in the case of a significant Treatment effect. Treatment was 
the independent variable and Uterine Horn Weight was set as the dependent variable. 
 
Results – Study 1: Brain-distribution and biodistribution of free E2 and of E2-CD 
complexes following intranasal administration 
 Representative spatial heat maps were created to illustrate the distribution of E2, 
as a function of CD type, across the examined brain regions and time (Figures 27-30). 
The evaluated brain regions included olfactory bulbs, trigeminal nerves, frontal cortex, 
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cingulate cortex, basal forebrain, striatum, dorsal hippocampus, hypothalamus, amygdala, 
entorhinal cortex, perirhinal cortex, and the CA1/CA2 region of the ventral hippocampus. 
In general, the greatest E2 delivery to each brain area was observed at the earliest time 
point collected, 0.5 hr, followed by a rapid decrease for each treatment formulation. Of 
note, there was strong variability in the data within a treatment formulation across each 
time point, as can be visualized by the quantitative graphs for each region (Figure 31), 
and at times resulted in a single point driving the overall average concentration (e.g. peak 
average concentration at the 2 hr time point rather than the 0.5 hr time point in the 
trigeminal nerve following intranasal free E2 administration). E2 concentration in the 
trigeminal nerves, one of the potential pathways for agent uptake into the brain with 
intranasal delivery, tended to have slower clearance across the three evaluated time points 
as compared to the olfactory bulbs, another potential pathway for agent uptake into the 
brain with intranasal delivery. Focusing on the two regions of interest, E2 payload in the 
dorsal hippocampus 0.5 hr following Treatment C administration was significantly 
greater than that of Treatment A - free E2 (p < 0.05). Furthermore, when comparing 
dorsal hippocampus to uterine horn E2 delivery, Treatment A resulted in ~2-fold 
increased E2 levels in dorsal hippocampus relative to uterine horns whereas Treatment C 
resulted in ~4-fold increased E2 levels in dorsal hippocampus relative to uterine horns 
(Figure 33 B). Interestingly, E2 levels in the dorsal hippocampus following Treatment A 
(free E2) did not exhibit rapid clearance across the collected time points as seen with 
Treatment C. No statistically significant differences in E2 delivery to the dorsal 
hippocampus were observed with the other three Treatment formulations, and at the other 
collected time points for all Treatment formulations, relative to free E2. There were no 
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statistically significant differences in E2 delivery to the frontal cortex with any E2-CD 
Treatment formulations relative to free E2.   
 E2 levels in whole blood were greatest at the 0.5 hr time point following 
intranasal administration for each Treatment group and cleared rapidly across time 
(Figures 32 and 33A). Although uterine horn E2 levels also were greatest at the 0.5 hr 
time point following intranasal administration for each Treatment group, the E2 levels 
did not exhibit as rapid clearance of E2 and were retained across the collected time points 
(Figure 32 and 33A). These findings are consistent with prior biodistribution studies 
evaluating the fate of exogenously administered tritiated E2, where E2 appeared to be 
retained for longer periods of time in estrogen-responsive tissues (Green, Luttge, & 
Whalen, 1969; Jehan, Srivasta, Akhlaq, Ahmad, & Setty, 1982; Jensen, 1963).  
 
Results – Study 2: Cognitive evaluation of daily intranasal E2-CD treatment relative to 
free E2 and vehicle 
Body weight 
 Average body weights were monitored for the duration of the study across each 
treatment group as a marker of health, and as a general marker of E2 presence 
(Prakapenka et al., 2018; Figure 34A). Across the first 4 weeks of the study, prior to the 
initiation of daily intranasal treatment, there was no main effect of Treatment for average 
body weight (Figure 34B). For the latter 6 weeks of the study, when daily intranasal 
treatment was administered, there was a main effect of Treatment for average body 
weight [F(3,36) = 4.276, p < 0.05; Figure 34B], with free E2 and E2-CD exhibiting 
significantly lower body weights relative to their respective vehicle controls (p < 0.05), 
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confirming the presence of E2. Body weight between free E2 and E2-CD treatment 
groups was not significantly different. 
 
Water radial-arm maze (WRAM) 
The WRAM evaluated spatial working and spatial reference memory. The 12 days 
of testing were divided into the acquisition phase, days 2-7, when the rats were learning 
the rules of the task, and the asymptotic phase, days 8-12, after the rats should have learned 
the rules of the task. On the acquisition phase, a main effect of Estrogen was seen [F(1,36) = 
5.161, p < 0.05; Figure 35A], whereby the groups with E2 made fewer RM errors than the 
groups with no E2. Additionally, there was a marginal Estrogen x Vehicle interaction 
[F(1,36) = 3.303, p < 0.1] for RM errors made on the acquisition phase (data not shown). 
Further analyses revealed that these effects were driven by a main effect of Treatment 
between saline-PEG and free E2 [F(1,18) = 8.452, p < 0.01; Figure 35B], where the free E2 
group made fewer RM errors than the saline-PEG group. Further, there was a marginal 
Treatment effect between free E2 and E2-CD [F(1,18) = 3.349, p < 0.1], where the free E2 
group tended to make fewer RM errors than the E2-CD group. Thus, on the acquisition 
phase, the free E2 treatment improved RM relative to its respective control, and tended to 
improve RM relative to the E2-CD treatment. There was a significant Estrogen x Vehicle 
interaction for WMI errors made on the asymptotic phase [F(1,36) = 5.414, p < 0.05; Figure 
36A], as well as a significant Trial x Estrogen x Vehicle interaction [F(3,108) = 3.522, p < 
0.05; Figure 36C]. Further analyses for WMI errors collapsed across all four trials revealed 
a main effect of Treatment between E2-CD and saline-CD [F(1,18) = 9.885, p < 0.01; Figure 
36B], as well as between E2-CD and free E2 [F(1,18) = 4.449, p < 0.05; Figure 36B], where 
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the E2-CD group made more WMI errors compared to the saline-CD group and compared 
to the free E2 group. Additionally, on Trial 4, the highest working memory load trial 
evaluated on the WRAM in the present study, there was a significant Estrogen x Vehicle 
interaction for WMI errors [F(1,36) = 4.766, p < 0.05; Figure 36C]. Further analyses for 
WMI errors made on Trial 4 alone revealed a main effect of Treatment between E2-CD 
and saline-CD [F(1,18) = 6.047, p < 0.05; Figure 36D] and a marginal effect of Treatment 
between E2-CD and free E2 [F(1,18) = 3.157, p < 0.1; Figure 36D], where the E2-CD group 
made more WMI errors than the saline-CD group and tended to make more WMI errors 
than the free E2 group. Together, these data indicate that the E2-CD treatment impaired 
working memory on the asymptotic phase of the WRAM, particularly at the high working 
memory demand. For the WRAM delay, there was no difference for total errors made 
(WMC, WMI, and RM memory measures combined) on the post-delay trials, Trials 3 and 
4 on Day 13, compared to the baseline trials, Trials 3 and 4 on Day 12, for each treatment 
group, suggesting that no treatment group exhibited delay-induced forgetting following a 
6-hour delay period (data not shown).   
 
Visible platform task 
The visible platform task assessed whether motor and visual abilities to complete a 
water-escape task were present across treatment groups. There was no main effect of 
Treatment and no significant Trial x Treatment for Latency to Escape, but there was a main 
effect of Trial [F(5, 180) = 7.770, p < 0.0001], suggesting that each treatment group had a 
similar procedural capability to learn and complete a water-escape task. In fact, each 
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treatment group’s average latency to platform across all 6 trials was under 9 seconds 
indicating strong performance. 
 
Uterine horn weight 
To evaluate the uterine effects of the E2 regimens tested here, uterine horn weight 
was examined across treatments. A main effect of Treatment was seen [F(3,36) = 58.043, p 
< 0.0001; Figure 37], where both of the E2-treated groups had significantly higher uterine 
horn weights than their respective vehicle control groups (p < 0.0001). Additionally, the 
E2-CD group had greater uterine horn weight relative to the free E2 group (p < 0.01), 
suggesting that E2 did have uterine stimulating effects with both E2 treatments, and that 
these effects were more pronounced with the addition of the CD.  
 
Discussion 
 The present work evaluated cognitive and uterine effects of free E2 and an E2-CD 
complex utilizing an intranasal administration in middle-aged, Ovx rats. In Study 1, I 
evaluated the distribution of tritiated E2 as a function of CD type in comparison to free E2 
in the brain as well as in the periphery. Next, in Study 2, daily intranasal treatments of free 
E2 and of the E2-CD complex that resulted in greatest E2 uptake in the dorsal hippocampus 
were evaluated for cognitive and uterine effects. I originally hypothesized that intranasal 
administration of an E2-CD complex targeting estrogen delivery to the frontal cortex and 
to the dorsal hippocampus in middle-aged Ovx rats would result in enhanced cognitive 
function and minimal uterine horn stimulation compared to vehicle control and compared 
to free E2. Findings from Study 1 did not indicate a significant difference in E2 delivery to 
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the frontal cortex between free E2 and E2-CD complex formulations, but there was an 
increase observed in E2 delivery to the dorsal hippocampus when E2 was complexed with 
2-hydroxypropyl β-CD relative to free E2 half an hour following intranasal administration. 
Thus, in Study 2, I evaluated whether intranasal administration of the E2-CD complex 
targeting estrogen delivery to the dorsal hippocampus in middle-aged Ovx rats would result 
in enhanced cognitive function and minimal uterine horn stimulation compared to vehicle 
control and compared to free E2. Intriguingly, Study 2 findings revealed that intranasally 
administered free E2 enhanced learning and memory on the WRAM but that the E2-CD 
complex, which was shown to exhibit greater E2 delivery to the dorsal hippocampus than 
free E2, impaired learning and memory. Furthermore, although both E2-containing 
treatment groups, free E2 and E2-CD complex, increased uterine horn weight relative to 
the respective vehicle control treatment groups, the E2-CD complex resulted in greater 
uterine horn weight than free E2, suggesting increased uterine stimulation by E2 with the 
addition of CD.  
Although Study 1 evaluated E2 delivery across multiple regions in the brain, the 
primary focus was on E2 delivery across time to the frontal cortex and to the dorsal 
hippocampus as a function of CD type, as these regions are impacted by E2 and are 
associated with the cognitively-beneficial E2 effects (L. Fan et al., 2010; Fortress et al., 
2013; Prakapenka et al., 2018; Meharvan Singh, Meyer, Millard, & Simpkins, 1994). 
Results showed that the E2-2-hydroxypropyl β-CD complex formulation increased E2 
delivery to the dorsal hippocampus relative to free E2 half an hour following intranasal 
administration. E2 was rapidly cleared when delivered via the E2-2-hydroxypropyl β-CD 
complex whereas free E2 resulted in a more sustained presence of E2 in the dorsal 
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hippocampus over time. In relation to E2 levels in the uterine horns, free E2 resulted in 
~2-fold greater dorsal hippocampus E2 levels and E2-2-hydroxypropyl β-CD complex 
resulted in ~4-fold greater dorsal hippocampus E2 levels. Furthermore, although E2 
levels in whole blood and in the uterine horns were greatest at the half an hour time point 
following intranasal administration with both free E2 and the E2-2-hydroxypropyl β-CD 
complex, E2 levels in whole blood appeared to be cleared rapidly across time whereas E2 
levels in uterine horns appeared to be retained and not cleared as rapidly across the 
collected time points. These findings support prior studies that suggest that E2 is retained 
for longer periods of time in estrogen-responsive tissues such as the uterine horns 
compared to circulating levels (Green et al., 1969; Jehan et al., 1982; Jensen, 1963). No 
differences were observed in frontal cortex E2 levels between free E2 and E2-CD 
complex formulations across the three collected time points; thus, this portion of the 
overarching hypothesis was not tested for cognitive outcomes. 
Behavioral outcomes from Study 2 evaluating spatial working and reference 
memory on the WRAM revealed that when the rats were learning the rules of the task, 
during the acquisition phase, daily free E2 treatment improved reference memory 
performance relative to vehicle. The daily free E2 treatment group also tended to make 
fewer RM errors than the E2-CD complex group during the acquisition phase. On the 
WRAM, the RM measure is always capped at a maximum of four possible errors that can 
be made within a day as four out of the eight available arms never contain a platform, and 
a RM error entry is defined as a first entry into a non-platformed arm. Therefore, even 
with the inherent ceiling effect, the impact of the free E2 daily intranasal treatment on the 
reference memory measure was robust enough to reveal a significant beneficial effect. 
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The cognitively-beneficial effect of the intranasal free E2 treatment is consistent with 
prior literature that evaluated the effects of E2 treatments on tasks evaluating spatial 
reference memory (Bimonte-Nelson et al., 2006; El-Bakri et al., 2004; Feng et al., 2004; 
Kiss et al., 2012; Lowry et al., 2010; McLaughlin et al., 2008; Talboom et al., 2008). On 
the asymptotic phase, when the rules of the WRAM should have been learned, an 
estrogen by vehicle interaction was observed. Specifically, the E2-CD complex treatment 
impaired spatial working memory whereby the E2-CD complex group made more WMI 
errors than the CD vehicle control as well as than free E2, and this effect was present 
when working memory load was taxed (on the highest working memory load trial of the 
task). This finding contradicts my hypothesis, as I predicted that greater E2 delivery to 
the dorsal hippocampus would result in cognitively-beneficial effects that would be 
stronger than those of the free E2 treatment. It is possible that the E2 concentrations 
achieved with daily E2-CD complex treatment in the dorsal hippocampus may be too 
high to achieve beneficial effects of E2 on spatial learning and memory. Indeed, a recent 
study in naturally cycling women found that when E2 levels were supraphysiological, the 
effects of E2 on hippocampal activity exhibited an inverted-U shape, suggesting that 
there is a sweet spot for E2 levels in the hippocampus that would yield a desired 
outcome, at least in terms of hippocampal activity, and E2 levels less or greater than that 
sweet spot may in fact yield the opposite outcome (Bayer, Gläscher, Finsterbusch, 
Schulte, & Sommer, 2018). In support of this notion, rodent studies evaluating different 
doses of E2 treatment have shown cognitive impairments with higher doses of E2, while 
lower doses of E2 exhibited cognitive improvements (Barha et al., 2010; Heather A. 
Bimonte-Nelson et al., 2006). Taken together, the cognitive outcomes of the present 
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study provide a baseline for the evaluation of intranasally administered E2 on spatial 
learning and memory and warrant additional investigation into the dose of free E2, as 
well as E2-CD complexes, that could yield optimal beneficial cognitive effects following 
intranasal administration. It is also important to note that the visible platform task 
revealed that all treatment groups were able, and exhibited similar abilities, to complete a 
water-escape task, indicating that the treatment paradigms within the study were not 
detrimental to performance on a water-escape task.  
Complete Ovx procedure and the presence of E2 in Study 2 were confirmed via 
body weight, as well as uterine horn weight, measurements. Following Ovx, all treatment 
groups exhibited rapid increases in average body weights that did not differ from each 
other, confirming successful Ovx as rodents tend to gain weight rapidly following the 
removal of both ovaries (Prakapenka et al., 2018; Rogers et al., 2009). After daily 
intranasal treatment initiation, which continued for the rest of the study, both of the E2-
containing treatments continued to exhibit weight gain but at a lower rate than the two 
vehicle control groups, resulting in significantly lower average body weight with E2-
containing treatments compared to their respective vehicle controls, and no difference in 
body weight between free E2 and E2-CD complex treatments. This E2-induced 
separation in body weight between free E2 and its vehicle control and E2-CD complex 
and its vehicle control was expected based on prior work and confirmed the presence of 
E2 following intranasal administration (Prakapenka et al., 2018). However, change in 
body weight is not a direct marker of peripheral E2 exposure, as studies have shown that 
estrogen receptors in the hypothalamus can mediate the observed changes in body weight 
(Xu et al., 2011). A more direct measure of peripheral exposure to E2 are uterine horn 
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weights, which are expected to decrease with Ovx and increase with E2 exposure (E. B. 
Engler-Chiurazzi et al., 2012; Sarah E. Mennenga, Gerson, Koebele, et al., 2015; 
Prakapenka et al., 2018; Westerlind et al., 1998). Indeed, in the present study, uterine 
horn weight was greater with free E2 and E2-CD complex treatments relative to their 
respective vehicle controls, confirming Ovx as well as E2 presence at the uterine tissue. 
Interestingly, uterine horn weights were greater with E2-CD complex treatment relative 
to free E2 treatment, suggesting potentially greater or longer exposure of the uterine 
tissue to E2 when the estrogen was complexed with the CD compared to without. 
Together, the uterine horn weight results indicate that the cognitively-beneficial daily free 
E2 intranasal treatment had lower uterine stimulation relative to the cognitively-impairing 
daily E2-CD complex treatment. 
In conclusion, daily intranasal administration of the E2-CD complex that yielded 
the greatest E2 uptake in the dorsal hippocampus impaired spatial working memory and 
had the greatest effect on uterine stimulation in middle-aged, Ovx rats. However, daily 
intranasal free E2 treatment improved spatial reference memory and yielded lower 
uterine stimulation than E2-CD complex treatment. Thus, here, I identified a novel 
approach to evaluate the cognitive effects of E2 by implementing the previously 
clinically available intranasal route of administration, wherein daily E2 intranasal 
treatment improved memory in a low circulating ovarian hormone background. This 
work sets up the cognitive baseline for further evaluation of intranasally administered E2 
in a rodent model of surgical menopause, such as varying the dose of intranasal E2 
treatments as well as evaluating intranasal versus subcutaneous E2 treatments on both 
cognitive and uterine measures. In the clinic, intranasal E2 was effective at reducing 
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common symptoms of menopause (e.g, hot flashes) prior to discontinuation, however, its 
effects on cognition have not been assessed at that time (Dooley, Spencer, & Ormrod, 
2001; Studd et al., 1999). The data in the present study suggest that intranasal E2 therapy 
should be re-visited for clinical effects, particularly focusing on its potential therapeutic 
effects on cognition in concert with treatment of other common symptoms of menopause 
(e.g. hot flashes). Additionally, the cognitively-beneficial effects of intranasal E2 provide 
novel avenues for further assessment of clinically-available estrogen plus progestogen 
combinations for cognitive therapy; indeed, the cognitive and uterine effects of 
combination hormone treatments where the estrogen is administered intranasally whereas 
the progestogen is administered either subcutaneously or locally (i.e. intrauterine devices) 
are currently unexplored. Combining and taking advantage of the inherent 
pharmacokinetic properties of different routes of administration may yield the optimal 
delivery platform for menopausal hormone therapy, whereby the beneficial cognitive 
effects of estrogens are maximized and the undesired uterine stimulation effects are 
minimized. Continuing the evaluation of the cognitive effects of intranasal E2 treatment, 
and the varying factors surrounding it, is critical as the information gained can lead to 
developments in hormone therapy formulations that could target particular symptoms, 
such as altered cognitive function, in menopausal women. 
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CHAPTER 6 
GENERAL SUMMARY AND DISCUSSION 
 
The introduction and conclusion sections of this chapter were adapted from an editorial 
that was written, and accepted, for an invited submission to the journal Aging based on 
the published findings from Chapter 2. The editorial was titled:  
Memory and menopause: an unsolved puzzle 
A.V. Prakapenka, H.A. Bimonte-Nelson 
 
 
Contribution: The invited editorial was co-authored by Heather Bimonte-Nelson and me. 
I am the primary author of this chapter, and I received feedback on it from both of my 
mentors, Rachael Sirianni and Heather Bimonte-Nelson. 
 
 
Menopause is a natural part of life that impacts every woman as aging ensues. 
Clinically, menopause in women is defined by a halt in menses for at least one year, 
during which time ovarian function and ovulation are attenuated (NAMS, 2014). The 
road to menopause can be transitional and natural, or surgical, if a woman undergoes 
surgical removal of parts of her reproductive system (e.g., ovaries, uterus). In both 
transitional and surgical menopause, there is ultimately a marked decrease in ovarian-
derived circulating hormone levels. These steroid hormones, including estrogens and the 
natural progestogen, progesterone, not only maintain and support reproductive function, 
but also play key roles in numerous other bodily functions and systems, including brain-
mediated functions such as cognition (Frick, 2015; Koebele & Bimonte-Nelson, 2017; 
Prakapenka et al., in review). Indeed, these two classes of steroid hormones are present, 
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and can even be synthesized, in the brain, as are respective receptors (Foster, 2012; Kretz 
et al., 2004; Micevych & Sinchak, 2008; Mitra et al., 2003). With menopause, a woman 
can experience a variety of symptoms that impact quality of life. Exogenously 
administered hormone therapy can be clinically used to prevent many undesirable 
menopause symptoms (e.g., vasomotor and sleep disturbances, vaginal and vulvar 
atrophy, osteoporosis). However, hormone therapy is not currently approved or 
recommended for aiding cognitive symptoms associated with menopause. Clinical data 
available to date do not definitively support hormone therapy benefits on cognition or 
dementia outcomes (NAMS, 2017). Amid the collection of imperfectly-fitting puzzle 
pieces that represent the uncertainty regarding whether hormone therapy yields positive 
cognitive effects, there have been exciting and illuminating scientific discoveries that 
have guided the direction of the field, allowing sections of the completed puzzle picture 
to emerge. If scientists think across bodily systems in an interdisciplinary fashion, if 
scientists think creatively, and if basic scientists, engineers, and physicians work 
together, the drive forward will continue with an escalating momentum, the puzzle will 
yield a more complete picture, and marked enrichments in the standard of care for 
women on the path to menopause, in menopause, and in post-menopause will ensue.  
Studies over the last several decades indicate that estrogens and progestogens can 
impact learning and memory and related brain substrates, although behavioral 
neuroendocrinologists are still left with missing puzzle pieces of information regarding the 
optimal hormone milieu parameters that yield consistent and predictable beneficial impacts 
on brain and cognitive health. On numerous occasions, the Bimonte-Nelson laboratory and 
others have shown that the potent E2 can, but does not always, enhance cognition, and that 
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the addition of a progestogen can reverse the cognitive benefits and brain changes induced 
by E2 treatment (Heather A. Bimonte-Nelson et al., 2006; Frick, 2015b; L. L. Harburger 
et al., 2009; Koebele & Bimonte-Nelson, 2015; Prakapenka et al., 2018). Currently, 
available estrogen-containing treatment in the clinic must include an opposing progestogen 
for a woman that has her uterus to offset the estrogen-associated risk for endometrial 
hyperplasia and cancer (NAMS, 2014). Thus, although both efficacious and safe, hormone 
therapy formulations remain to be optimized, particularly in the domain of cognitive 
therapeutic effects. The present dissertation work strived to combine tools from behavioral 
neuroendocrinology with tools from biomedical engineering in an interdisciplinary fashion 
to develop a 17-estradiol (E2) delivery platform for improved cognitive effects of E2 
treatment while minimizing peripheral E2 burden. Specifically, the overarching goal of this 
dissertation work was to approach optimization of E2 treatment utilizing three distinct 
hormone delivery strategies - 1) combining E2 with a cognitively-beneficial progestogen, 
2) encapsulating E2 in polymeric nanoparticles for subcutaneous administration, and 3) 
solubilizing E2 in cyclodextrin for intranasal administration. The rat model of surgical 
menopause, the surgical removal of the ovaries, or ovariectomy (Ovx), was implemented 
across all studies, and the same timeline between Ovx, treatment, and behavioral battery 
initiation was utilized.  
 
Approach 1: Evaluation of estrogen plus progestogen hormone combination treatment 
that contained the cognitively-beneficial E2 plus a cognitively-beneficial progestogen. 
In Chapters 2 and 3, the impact of a daily subcutaneous administration of E2 plus 
a cognitively-beneficial progestogen on spatial learning and memory, as well as on uterine 
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stimulation, was evaluated.  The cognitively-beneficial progestogen was levonorgestrel 
(Levo), a synthetic progestogen used in the clinic for both hormone therapy and 
contraceptive purposes. In the first study, I replicated the beneficial cognitive effects of E2 
and of Levo when administered alone in middle-aged, Ovx rats (Heather A. Bimonte-
Nelson et al., 2006; Bimonte & Denenberg, 1999; B. Blair Braden et al., 2017; Talboom et 
al., 2008). Interestingly, I found that the E2 plus Levo hormone combination, at a 5:1 E2 
to Levo dose ratio, attenuated the beneficial effects of E2 alone and Levo alone on spatial 
learning and memory. Indeed, this particular E2 plus hormone combination impaired 
spatial working memory relative to the individual E2 and Levo treatments when the 
working memory load was high. Furthermore, I observed a distinct relationship within the 
E2 alone treatment group between working memory performance and activated Erk2 
expression in the frontal cortex. This E2-specific relationship was mitigated by the addition 
of Levo to the E2 treatment. When evaluating peripheral burden, it was found that uterine 
horn weight, which was used as a marker of uterine stimulation, was increased following 
treatments with E2 - both with E2 alone and E2 plus Levo treatment groups. The addition 
of Levo did not oppose E2-specific effects on uterine stimulation. The clinically available 
hormone therapy patch that contains both E2 and Levo combines the two hormones in a 
3:1 E2 to Levo dose ratio. Thus, in the second study, I addressed how altering E2 to Levo 
dose ratios, by increasing Levo dose and keeping E2 dose constant, would impact both 
cognition and uterine stimulation. Specifically, dose ratio-dependent cognitive and uterine 
effects were evaluated following daily subcutaneous treatment with either a 5:1, 3:1, or 1:2 
E2 to Levo dose ratio combinations. Results replicated findings from the first study, where 
the 5:1 E2 to Levo dose ratio combination treatment had no cognitive effects relative to 
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vehicle and did not oppose E2-specific uterine stimulation. The 3:1 and 1:2 E2 to Levo 
dose ratio combination treatments did decrease E2-specific uterine stimulation, but these 
two treatments impaired spatial learning and memory. Indeed, a significant linear 
relationship between memory and Levo dose was observed, where the addition of 
increasing Levo dose to E2 treatment tended to increase memory impairments. Taken 
together, findings from this translational approach to E2 delivery for optimized cognitive 
therapeutic effects indicated that even with the selection of a cognitively-beneficial 
progestogen, the beneficial cognitive effects of E2 alone are reversed when progestogen is 
added and can even result in impairment in combination formulations that oppose E2’s 
effects at the uterine tissue.  
 
Approach 2: E2 encapsulation in polymeric nanoparticles in order to harness the delivery 
advantages of nanoparticles, including sustained release, decreased metabolism, and 
potential for tissue-specific targeting. 
Polymeric nanoparticles comprised of poly (lactic-co-glycolic) acid (PLGA) can be 
engineered to alter the activity and delivery of encapsulated agents. Chapter 4 aimed to 
evaluate the cognitive effects of weekly subcutaneous E2 encapsulated PLGA nanoparticle 
treatment in comparison to the blank PLGA nanoparticle and free E2 treatment, as well as 
the effects of these treatment formulations on uterine exposure to E2. Due to an observed 
vehicle effect between blank PLGA and sesame oil, the vehicle for free E2, I was not able 
to directly compare the effects of E2 PLGA to free E2 on spatial learning and memory. 
Results did show that E2 PLGA treatment improved learning and memory relative to its 
vehicle control, and free E2 did not differ in learning and memory relative to its vehicle 
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control. Additionally, although both of the E2-containing treatments increased uterine horn 
weight in respect to their vehicle controls, the cognitively enhancing E2 PLGA treatment 
exhibited greater uterine horn weight compared to free E2. Thus, the second delivery 
approach of this dissertation work underscored the critical importance of including proper 
controls in behavioral study design and revealed that E2 encapsulation in PLGA 
nanoparticles can have beneficial learning and memory effects following a treatment 
regimen when free E2 did not. Yet, E2 encapsulation in PLGA did increase E2 exposure 
at the uterine horns compared to free E2, suggesting that additional modifications to PLGA 
nanoparticles or an implementation of alternate delivery routes would be beneficial to 
achieve more optimal E2 presence in the brain and uterine horns to achieve desired 
cognitive therapeutic effects. 
 
Approach 3: Intranasal administration of E2, combined with an agent carrier to solubilize 
E2, to target the delivery of E2 to the brain but minimize its delivery to the uterine horns. 
 The intranasal route of administration is thought to exhibit direct nose-to-brain 
agent delivery and can achieve greater agent uptake in the brain relative to peripheral 
tissues as compared to alternate routes of administration (Dhuria, Hanson, & Frey, 2010; 
Lochhead & Thorne, 2012; N Nonaka et al., 2008). The aim of the third approach was to 
determine the cognitive and uterine effects of daily intranasal E2 treatment. To solubilize 
E2 and to achieve greater E2 uptake in the brain, particularly in cognitive brain regions, 
four different cyclodextrins (CD) were evaluated as carriers for intranasal E2 delivery and 
compared to delivery of free E2 (solubilized in a 20% PEG saline solution). Brain-
distribution data showed that E2 complexation with 2-hydroxypropyl β-CD increased 
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uptake of E2 in the dorsal hippocampus, an area involved in spatial learning and memory, 
half an hour following intranasal administration when compared to free E2. Interestingly, 
when evaluated for cognitive outcomes, the E2-2-hydroxypropyl β-CD complex impaired 
spatial learning and memory, even though this formulation was shown to have greater 
uptake in the dorsal hippocampus as opposed to free E2 and was therefore hypothesized to 
improve cognitive performance. On the other hand, the free E2 intranasal treatment 
improved spatial learning and memory, suggesting that E2 concentration in the brain, 
specifically in regions of the brain that are heavily involved in learning and memory, is a 
critical factor for E2’s cognitive outcomes. Uterine horn weight data indicated that both 
free E2 and the E2-2-hydroxypropyl β-CD complex increased uterine horn weight relative 
to their vehicle controls, and that the cognitively impairing E2-2-hydroxypropyl β-CD 
complex formulation resulted in greater uterine horn weight as compared to the cognitively 
enhancing free E2. Together, these findings suggest that the intranasal route of 
administration is a promising delivery strategy for obtaining optimal cognitive therapeutic 
effects of E2 while minimizing peripheral burden. However, there are still a myriad of 
factors, including E2 treatment dose, that need to be evaluated in order to develop a better 
understanding of how these factors can impact the directionality of E2’s cognitive effects 
following intranasal administration.  
 
Conclusions 
Developing estrogen-containing hormone therapy formulations that can yield 
beneficial, or at least neutral, effects on the brain and its functioning, with minimal 
undesired effects at the uterine tissue, could immensely expand the breadth of clinically-
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available hormone-based treatment options across a wide variety of needs. This potential 
significance spans not only hormone therapy but also contraceptive use and treatment for 
hormone-related health conditions. The present dissertation work combined biomedical 
engineering with behavioral neuroendocrinology scientific approaches to evaluate three 
separate delivery strategies aimed at capitalizing on the beneficial cognitive effects of E2 
while minimizing peripheral burden in a rodent model of menopause. Findings from the 
studies detailed here are comprehensively visualized in Figure 38, where the graph depicts 
uterine horn weights, a marker of uterine stimulation used across the studies, as a function 
of the evaluated E2 formulations. For each uterine horn weight bar, the green check-mark 
indicates improved spatial learning and memory relative to vehicle control, the brown null 
sign indicates neutral effects on spatial learning and memory relative to vehicle control, 
and the red ‘x’ denotes impaired spatial learning and memory relative to vehicle control. 
For the vehicle controls for each E2 formulation, the average uterine horn weights ranged 
from 0.135 – 0.184 g (data not shown in the figure); based on prior studies in the Bimonte-
Nelson laboratory, uterine horn weights for ovary-intact middle-aged rats, on average, can 
range from 0.6 g to 0.9 g. Overall, lower stimulating effects at the uterine horns while 
maintaining cognitively-beneficial effects of E2 treatment following a decrease in 
circulating ovarian hormone levels were achieved by incorporating the intranasal route of 
administration for daily E2 treatment and by encapsulating E2 in polymeric nanoparticles 
for weekly subcutaneous administration. Additionally, several E2 formulations were 
identified that yielded impairing cognitive effects alongside lower uterine horn stimulation 
as well as impairing cognitive effects alongside greater uterine horn stimulation. For 
example, the addition of Levo to E2 treatment resulted in neutral or impairing cognitive 
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effects. At the 3:1 and the 1:2 E2 to Levo dose ratio treatment formulations, the addition 
of Levo reduced uterine horn weight compared to free E2 treatment although the weights 
remained greater than those of the vehicle control group. The greater uterine horn 
stimulation with E2 plus Levo treatments as compared to vehicle control could in part be 
explained by the ability of Levo to yield estrogenic activity indirectly via its capability to 
increase estrogen receptors’ mRNA expression or the binding of its derivatives to estrogen 
receptors (Jayaraman & Pike, 2014; Santillán et al., 2001). Taken together, data from the 
present dissertation work can serve as the backbone for research in targeted E2 delivery 
aimed at optimizing the cognitive therapeutic effects of E2 in the context of menopause 
while minimizing peripheral burden.  
The spatial working memory findings across the studies evaluated within this 
dissertation differ based on the phase of testing, acquisition or asymptotic, and on the trials, 
moderate working memory load (Trial 3) or highest working memory load (Trial 4) trials, 
during which E2 treatment effects were observed, which may confound the interpretation 
as well as the translational impact of the beneficial, neutral, or impairing cognitive effects. 
When analyzing WRAM data, working memory performance was initially evaluated 
across all 4 trials within the 12 days of testing with the goal of assessing the learning curve 
as well as potential trends in performance. Then, performance was blocked into specific 
phases (e.g., acquisition, asymptotic) of the learning curve such that the reported findings 
would reflect consistent trends in performance rather than isolation of a single effect. 
Further, the distinction in treatment effects observed on the moderate working memory 
load trial versus the highest working memory load trial within this dissertation highlights 
the ability to evaluate treatment effects that are dependent on working memory complexity 
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as evaluated by increase in working memory demand on the WRAM. For instance, a switch 
in working memory performance of a particular treatment group from Trial 3 to Trial 4 
suggests that the increase in 1 unit of information in working memory was sufficient to 
alter the animals’ performance in relation to their performance on the previous trial (Trial 
3) as well as in relation to the other treatment groups on Trials 3 and 4. Indeed, in an 8-arm 
WRAM with 7 platformed arms, with the maximum highest working memory load of 7 
information units (in contrast, a 4 information unit WRAM design was utilized within this 
dissertation), ovary-intact rats, low E2 dose treated Ovx rats, and moderate E2 dose treated 
Ovx rats exhibited improved working memory when the load contained 1 – 4 units of 
information, and only the moderate E2 dose treatment exhibited improved working 
memory when the load contained 6 units of information, indicating a working memory load 
impact on treatment effects as trials progressed and as the units of information within the 
working memory domain increased (Bimonte & Denenberg, 1999). Thus, in the context of 
the studies conducted within this dissertation, the difference in spatial working memory 
performance on Trial 3, the moderate working memory load trial, compared to the 
difference in spatial working memory performance on Trial 4, the highest working memory 
load trial, as a function of treatment yield impactful translational interpretations. These 
subtle changes in treatment effects within a particular working memory load and across an 
increase in working memory load can represent the difference in effect of a hormone 
therapeutic on executive function at moderate cognitive demand versus high cognitive 
demand in menopausal women.  
It is important to note some limitations to the interpretation and translational 
application of data from this dissertation, which warrant additional investigations. For one, 
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the cognitive and uterine effects in the present studies were all evaluated within a rat model 
of surgical menopause, with the ovaries being surgically removed. However, most women 
undergo transitional menopause where ovaries remain intact, resulting in a different 
circulating ovarian hormone background profile. Studies show that type of menopause 
model in rats can indeed impact the directionality of a hormone’s effects on cognitive 
outcomes (Acosta, Mayer, Talboom, Tsang, et al., 2009). Additionally, although uterine 
horn weight was used as a marker of uterine stimulation across all studies, it must be noted 
that the desired weight of the uterine horn weights for exogenous estrogen administration 
is not known. In fact, uterine horn weight can naturally fluctuate across a typical 
reproductive cycle in response to changes in endogenous circulating hormone milieu 
(Nequin, Alvarez, & Schwartz, 1979). Thus, it would be beneficial to determine an 
additional marker of uterine stimulation that could aid in the translational interpretation of 
E2-induced uterine stimulation. Furthermore, this dissertation focused on the delivery of 
E2, the most potent endogenous estrogen in women and in rodents (Kuhl, 2005). However, 
there are a multitude of different estrogens that still remain to be evaluated for their 
potential as a cognitive therapeutic, as they can differ in both brain activity as well as 
cognitive outcomes (E. B. Engler-Chiurazzi et al., 2012; Hiroi et al., 2016; Kuhl, 2005; 
Sarah E. Mennenga, Gerson, Koebele, et al., 2015; Prakapenka et al., in review). Indeed, 
additional alternate delivery strategies focused on targeted estrogen delivery, to achieve 
greater appropriately-regimented estrogen activity in the brain than in the periphery, and 
greater appropriately-regimented progestogen activity in the uterus than in the brain, must 
be explored. To be most efficacious, scientific strategies should be armed with knowledge 
regarding where and when during a lifetime hormone exposure is optimal, as well as what 
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type and concentration of hormone is most beneficial given specific hormonal historical 
contexts. Identifying the particular impactful components of these complex interactions is 
necessary to fill in the missing pieces of the menopause and memory puzzle, and can help 
scientists and clinicians optimize women’s health across a lifetime.  
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Table 1.  
U.S. FDA approved hormone therapy for treatment of symptoms associated with 
menopausea. 
Estrogen-only hormone therapy, which needs an opposing progestogen if the uterus is 
present 
Brand Name Hormone type 
Route of 
administration 
Alora Estradiol Patch 
Cenestin Synthetic Conjugated Estrogens Pill 
Climara Estradiol Patch 
Delestrogen Estradiol Valerate Injection (Shot) 
Divigel Estradiol Gel 
Elestrin Estradiol Gel 
Enjuvia Synthetic Conjugated Estrogens Pill 
Esclim Estradiol Patch 
Estrace Estradiol Pill 
Vaginal Cream 
Estraderm Estradiol Patch 
Estrasorb Estradiol Skin Cream (Emulsion) 
Estring Estradiol Vaginal Insert 
EstroGel Estradiol Gel 
Evamist Estradiol Skin Spray 
(Transdermal) 
Femring Estradiol Acetate Vaginal Ring 
Femtrace Estradiol Acetate Pill 
Menest Esterified Estrogen Pill 
Menostar (only 
used to prevent 
osteoporosis) 
Estradiol Patch 
Minivelle Estradiol Patch 
Ogen Estropipate Pill 
Vaginal Cream 
Ortho-Est Estropipate Pill 
Premarin Conjugated Estrogens Pill 
Vaginal Cream 
Injection (Shot) 
Vagifem Estradiol Vaginal Tablet 
Vivelle Estradiol Patch 
Vivelle-Dot Estradiol Patch  
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Progestogen-only hormone therapy, which can also be taken in combination with 
estrogen-only therapy 
Prometrium Micronized Progesterone Pill 
Provera Medroxyprogesterone Acetate Pill 
Estrogen-progestogen combination hormone therapy 
 
Activella Estradiol / Norethindrone Acetate Pill 
Angeliq Estradiol / Drospirenone Pill 
Climara Pro Estradiol / Levonorgestrel Patch 
Combipatch Estradiol / Norethindrone Acetate Patch 
Femhrt 
Ethinyl Estradiol / Norethindrone 
Acetate Pill 
Prefest Estradiol / Norgestimate Pill 
Prempro 
Conjugated Estrogen / 
Medroxyprogesterone Acetate Pill 
 
aAdapted from U.S. FDA Menopause: Medicines to Help You (U.S. FDA’s Office of 
Women’s Health, 2015). 
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Table 3.  
Summary of treatment groups. 
Group Dose (μg) 
Dose Ratio  
(E2:Levo) Rationale for treatment 
Vehicle 
E2: none 
Levo: none 
___ 
Vehicle control for all hormone 
treatments 
E2 only 
E2: 0.3 μg 
Levo: none 
___ 
E2 only control for combination 
hormone treatments 
E2 + Low Levo 
E2: 0.3 μg 
Levo: 0.06 μg 
5:1 
E2:Levo dose ratio used in my prior 
study (Chapter 2) 
E2 + Med Levo 
E2: 0.3 μg 
Levo: 0.1 μg 
3:1 
E2:Levo dose ratio used in the 
clinically-available hormone therapy 
transdermal patch, Climara Pro 
E2 + High 
Levo 
E2: 0.3 μg 
Levo: 0.6 μg 
1:2 
E2:Levo dose ratio with a Levo dose 
that has been repeatedly shown to 
improve cognition when given alone 
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Table 4.  
Summary of treatment groups for Study 1. 
Treatment Formulation 
E2:CD 
molar ratio Rationale for CD 
A 
free E2 – dissolved in 20% 
PEG saline solution 
___ ___ 
B 
E2-randomly methylated β-
CD 
 – dissolved in saline 
1:2 
CD derivative found in 
Aerodiol intranasal spray 
C 
E2-2-hydroxypropyl β-CD 
 – dissolved in saline 
1:2 
CD derivative used in 
behavioral studies 
evaluating estrogen effects 
on the brain 
D E2-β-CD – dissolved in 
saline 
1:4 
base CD for the derivatives 
used in treatments B and C 
E 
E2-γ-CD – dissolved in 
saline 
1:5 
CD with a larger inner 
cavity than β-CD 
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Figure 1. The reproductive cycle. 
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Figure 2. Rodent models of menopause. 
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Figure 3.  Study timeline and trajectory of rat body weight throughout the span of 
the study. (A) Study timeline depicts time periods between Ovx, start of treatment 
injections, and order of behavioral testing. (B) Changes in body weight accurately represent 
expected fluctuations as a result of Ovx, type of treatment, and maze testing.  
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Figure 4. Water radial-arm maze (WRAM) performance. A) Learning curve for WMI 
errors, collapsed across trials for Blocks 1, 2, and 3. B) WMI Block 1 only, summed across 
trials, depicting a decrease in WMI errors for E2-Only and Levo-Only treatment groups 
relative to the Vehicle group. C) WMI errors across Trials 1-4 for Block 1 of testing. D) 
WMI errors on Trial 3 only, the moderate working memory load trial, for Block 1 of testing, 
illustrating that all hormone treatment groups made fewer WMI errors relative to the 
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Vehicle group. E) WMI errors on Trial 4 only, the high working memory load trial, for 
Block 1 of testing, depicting that the E2+Levo group made more WMI errors relative to 
E2-Only and Levo-Only groups. F) Treatment x Trial interaction, representing WMI errors 
made on the moderate and high working memory load trials (Trials 3 and 4, respectively) 
and Treatment (Vehicle and E2+Levo) for Block 1 of testing. The impact of E2 + Levo 
treatment on WMI performance was dependent on working memory demand. All errors 
are expressed as mean ± SEM. #p < 0.1, *p < 0.05, **p < 0.01. 
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Figure 5. Water radial-arm maze (WRAM) performance following a 6-hour delay. 
Top graph shows WMC errors made on baseline trials (T3+4 on Day 12 of WRAM) and 
post-delay trials (T3+4 on Day 13 of WRAM) for all treatment groups. Bottom graphs 
illustrate WMC errors made on baseline trials and post-delay trials split by treatment group. 
All errors are expressed as mean ± SEM. *p < 0.05. 
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Figure 6. Morris water maze (MWM) performance. A) Swim distance to the platform 
for the 5 days of testing, illustrating that all treatment groups learned the task as depicted 
by the decrease in swim distance across days. B) Percent swim distance in the northeast 
(NE) quadrant that previously contained the platform compared to the opposing southwest 
(SW) quadrant that never contained a platform on the probe trial, confirming spatial 
localization of the platform by animals from all treatment groups. All measurements are 
expressed as mean ± SEM. ***p < 0.0001 
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Figure 7. Circulating E2 and estrone levels and uterine horn weights. (A) E2 blood 
serum levels were increased in the E2-Only and E2+Levo treatment groups compared to 
the Vehicle group and compared to the Levo-Only group. (B) Estrone blood serum levels 
were elevated in the E2-Only and E2 + Levo treatment groups relative to the Vehicle group 
and relative to the Levo-Only group. (C) Uterine horn weight increased for the two E2 
treated groups (E2-Only, and E2 + Levo) relative to the Vehicle group and relative to the 
Levo-Only group. All measurements are expressed as mean ± SEM. ***p < 0.0001 
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Figure 8. Pearson r correlations between Block 1 WMC errors and activated Erk2 
expression in the frontal cortex. For each treatment group, a single sample was chosen 
to provide a representative image of the blots for phosphorylated Erk1 and Erk2 as well as 
total Erk1 and Erk2 in the frontal cortex. (A) Block 1 WMC errors did not correlate with 
activated Erk2 expression within the Vehicle group. (B) Block 1 WMC errors correlated 
with activated Erk2 expression within the E2-Only group. (C) Block 1 WMC errors did not 
correlate with activated Erk2 expression within the Levo-Only group. (D) Block 1 WMC 
errors did not correlate with activated Erk2 expression within the E2+Levo group. Of note, 
the false discovery rate-corrected statistics (Q) are reported here to account for multiple 
correlations. *Q < 0.1. Activated Erk2 expression is expressed as phosphorylated 
Erk2/total Erk2. 
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Figure 9. Study timeline. The study timeline illustrates the timing between Ovx, 
treatment initiation, vaginal smears, and the implemented behavioral battery. 
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Figure 10. Representative images of vaginal cytology for each treatment group. The 
Vehicle group had mostly blank smears that contained few cells, confirming Ovx and 
lack of hormone stimulation. All E2-containing treatment groups had lots of cells in the 
smear that mostly consisted of cornified cells, a marker of E2 exposure. The addition of 
Levo to E2 did not appear to impact vaginal cytology.  
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Figure 11. Errors made on the water radial-arm maze split by acquisition phase 
(days 2-7) and asymptotic phase (days 8-12). (A) There were no treatment differences 
for WMC, WMI, and RM errors made on the acquisition phase, when rules of the task 
were being learned. (B) On the asymptotic phase, when rules of the task should be 
learned, the E2 + High Levo group made more WMC and WMI errors than the Vehicle, 
and tended to make more RM errors than the Vehicle. The E2 + Med Levo group tended 
to make more WMC errors than the Vehicle. (C) A Trial x Hormone interaction for WMI 
errors revealed that the E2 + High Levo group made more WMI errors than the Vehicle 
group on Trial 4, the highest working memory load trial evaluated on the asymptotic 
phase of the WRAM. The E2 + Med Levo group tended to make more WMI errors than 
the Vehicle group on Trial 4 on the asymptotic phase of the WRAM. Data are presented 
as mean ± SEM. #p < 0.1, *p < 0.05, **p < 0.01. 
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Figure 12. Linear regression analyses between Levo dose and errors made on the 
asymptotic phase of the water-radial arm maze. For WMC measure, errors tended to 
increase linearly as the Levo dose, in combination with the constant E2 dose, increased. 
For both WMI and RM measures, errors increased linearly as the Levo dose, in 
combination with the constant E2 dose, increased. Data are presented as mean ± SEM. #p 
< 0.1, *p < 0.05. 
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Figure 13. Effect of a 6-hour delay period on WMC errors made on the water radial-
arm maze. The E2 + Med Levo and E2 + High Levo groups made more WMC errors on 
the post-delay (Delay) trial, Trial 3 on Day 13, compared to the baseline (Baseline) trial, 
T3 on Day 12, indicating delay-induced forgetting. The E2 Only and E2 + Low Levo 
groups tended to make more WMC errors on the Delay trial compared to the Baseline trial, 
and the Vehicle group did not statistically differ in WMC errors made on the Delay trial 
compared to the Baseline trial suggesting that these three treatment groups were not as 
impacted by the delay period. Data are presented as mean ± SEM. #p < 0.1, *p < 0.05, **p 
< 0.01. 
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Figure 14. Morris water maze performance. (A) There were no treatment differences 
in distance to platform. (B) On the probe trial, all treatment groups swam a greater 
percent distance in the target NE quadrant, the quadrant that previously contained a 
platform, compared to the opposite SW quadrant, suggesting that all groups were able to 
spatially localize to the platform location. Data are presented as mean ± SEM. ****p < 
0.0001. 
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Figure 15. Visible platform performance. (A) All treatment groups decreased in time to 
platform across all 6 trials of testing. (B) No treatment differences were seen on the last 3 
trials of testing, indicating that all treatment groups could perform and solve a water escape 
task in a similar manner. Data are presented as mean ± SEM. 
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Figure 16. Uterine horn weights as a marker of uterine stimulation. (A) The E2 Only, 
E2 + Low Levo, E2 + Med Levo, and E2 + High Levo groups had greater uterine horn 
weight than the Vehicle group, suggesting E2-induced stimulation at the uterine horns 
(B) The addition of the medium and high Levo doses, the E2 + Med Levo and the E2 + 
High Levo groups, resulted in lower uterine horn weights than the E2 Only group, 
indicating opposing effects of Levo on E2-induced uterine stimulation at these E2:Levo 
dose ratio combinations. Data are presented as mean ± SEM. ***p < 0.0001, *p < 0.05. 
 
 
 
 
  
230 
 
Figure 17. Blank-PLGA and E2-PLGA characterization. (A) Representative SEM 
images of blank-PLGA and E2-PLGA nanoparticles; scale bar is 200 nm. (B) E2 release 
profile from PLGA nanoparticles, n = 4 per time point. (C) Table summarizing the size, 
polydispersity, and zeta potential of each nanoparticle formulation. Data are presented as 
mean  standard deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
zeta potential of each nanoparticle formulation. Data are presented as mean  standard 
deviation. 
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Figure 18. Study timeline. The study timeline illustrates the timing between Ovx 
surgery and initiation of weekly treatment injections, as well as between treatment 
initiation and behavior testing on the water radial-arm maze (WRAM), Morris water 
maze, and visible platform task.  
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Figure 19. Water radial-arm maze learning curves for each memory measure. 
WMC, WMI, and RM errors made on each day of testing, collapsed across trials and 
treatment groups, are shown to visualize the learning curve for each memory measure. 
The days of weekly injection administration are noted. Data are presented as mean ± 
SEM. 
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Figure 20. Water radial-arm maze: vehicle effect on the asymptotic phase. (A) WMC 
errors on Block 3 of testing, the asymptotic phase, where the blank-PLGA made fewer 
WMC errors than the oil-control group. The trial by vehicle graph illustrates that the 
blank-PLGA made fewer WMC errors than oil-control on Trial 4, the highest working 
memory load trial. (B) WMI errors on Block 3 of testing where the blank-PLGA tended 
to make fewer WMI errors than the oil-control group. The trial by vehicle graph 
illustrates that the blank-PLGA made fewer WMI errors than oil-control on Trial 4, the 
highest working memory load trial. (C) RM errors on Block 3 of testing, where no 
differences between the two vehicle control groups were observed. Data are presented as 
mean ± SEM. **p < 0.01, *p < 0.05, #p < 0.1. 
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Figure 21. Water radial-arm maze: acquisition phase. (A) Trial by treatment graphs 
for WMC, WMI, and RM errors made on Block 1, the acquisition phase, for blank-PLGA 
and E2-PLGA. For WMC, there was a treatment x trial interaction, and further analyses 
revealed that on Trial 3, the moderate working memory load trial, E2-PLGA made fewer 
WMC errors than blank-PLGA, shown in (B). Data are presented as mean ± SEM. *p < 
0.05. 
 
  
235 
 
Figure 22. WMC errors made after a 6-hour delay on the water radial-arm maze. 
WMC errors made on the Delay trial, Trial 3 on Day 13, and WMC errors made on the 
Baseline trial, Trial 3 on Day 12, for each treatment group. Oil-control, free E2, and E2-
PLGA groups made more WMC errors on the Delay trial relative to the Baseline trial, 
suggesting delay-induced forgetting. Differences in WMC errors made on the Delay trial 
relative to the Baseline trial by the blank-PLGA group did not reach statistical 
significance. Data are presented as mean ± SEM. **p < 0.01, *p < 0.05. 
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Figure 23. Morris water maze performance. (A) Distance to platform for each day of 
testing, collapsed across trials, depicting learning of the task by each treatment group. 
The day of treatment injection is noted on the x-axis. (B) Distance to platform collapsed 
across days and trials, noting that the E2-PLGA group tended to swim a shorter distance 
to platform than the blank-PLGA group. Data are presented as mean ± SEM. #p < 0.1. 
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Figure 24. E2 and estrone blood serum levels. (A) E2 blood serum levels collected 
following the 7th treatment injection, with free E2 and E2-PLGA exhibiting greater E2 
levels than oil-control and blank-PLGA, respectively. (B) Estrone blood serum levels 
collected following the 7th treatment injection, with free E2 and E2-PLGA exhibiting 
greater estrone levels than oil-control and blank-PLGA, respectively. Data are presented 
as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05. 
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Figure 25. Uterine horn weights. Free E2 and E2-PLGA treatments increased uterine 
horn weight relative to oil-control and blank-PLGA, respectively, indicating E2-induced 
uterine stimulation. E2-PLGA had greater uterine horn weight compared to free E2, 
suggesting greater E2 exposure with the E2-PLGA treatment formulation. Data are 
presented as mean ± SEM. ****p < 0.0001, **p < 0.01, *p < 0.05. 
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Figure 26. Study 1 and Study 2 timeline. The timeline highlights the similarities and 
distinctions between Study 1 and Study 2 in regards to Ovx, treatment, and tissue 
collection versus behavioral testing. 
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Figure 27. Spatial distribution of tritiated free E2 and E2-CD complex formulations 
in the brain across time – Part 1. Representative spatial heat maps illustrating the 
distribution of E2 across time and as a function of treatment formulation in the olfactory 
bulbs, trigeminal nerves, frontal cortex, and cingulate cortex. 
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Figure 28. Spatial distribution of tritiated free E2 and E2-CD complex formulations 
in the brain across time – Part 2. Representative spatial heat maps illustrating the 
distribution of E2 across time and as a function of treatment formulation in the striatum 
and basal forebrain. 
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Figure 29. Spatial distribution of tritiated free E2 and E2-CD complex formulations 
in the brain across time – Part 3. Representative spatial heat maps illustrating the 
distribution of E2 across time and as a function of treatment formulation in the dorsal 
hippocampus, amygdala, and hypothalamus. 
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Figure 30. Spatial distribution of tritiated free E2 and E2-CD complex formulations 
in the brain across time – Part 4. Representative spatial heat maps illustrating the 
distribution of E2 across time and as a function of treatment formulation in the perirhinal 
cortex, entorhinal cortex, and ventral CA1/CA2 hippocampus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
244 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 O lfa c to r y  B u lb
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
 
 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 T r ig e m in a l N e r v e
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
  
245 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 F r o n ta l C o r te x
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
ti
s
s
u
e
 
   
 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 C in g u la te  C o r te x
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
  
246 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 S tr ia tu m
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 B a sa l F o r e b r a in
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
  
247 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 D o r s a l H ip p o c a m p u s
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
ti
s
s
u
e
 
 
  
 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5
H y p o th a la m u s
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
 
  
248 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 A m y g d a la
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 V e n tr a l C A 1 /C A 2  H ip p o c a m p u s
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
ti
s
s
u
e
 
 
 
  
249 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 E n to r h in a l C o r te x
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
A
, 
0
.5
h
r
A
, 
2
h
r
A
, 
6
h
r
B
, 
0
.5
h
r
B
, 
2
h
r
B
, 
6
h
r
C
, 
0
.5
h
r
C
, 
2
h
r
C
, 
6
h
r
D
, 
0
.5
h
r
D
, 
2
h
r
D
, 
6
h
r
E
, 
0
.5
h
r
E
, 
2
h
r
E
, 
6
h
r
0
5
1 0
1 5
2 0
2 5 P e r ir h in a l C o r te x
T r e a tm en t  G r o u p
C
P
M
 p
e
r
 m
g
 o
f 
t
is
s
u
e
 
 
Figure 31. Brain distribution of tritiated free E2 and E2-CD complex formulations 
across time. Quantitative representation of E2 distribution across time and as a function 
of treatment formulation in the olfactory bulbs, trigeminal nerves, frontal cortex, 
cingulate cortex, basal forebrain, striatum, dorsal hippocampus, hypothalamus, amygdala, 
entorhinal cortex, perirhinal cortex, and the CA1/CA2 region of the ventral hippocampus. 
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Figure 32. Biodistribution of tritiated free E2 and E2-CD complex formulations 
across time. Quantitative representation of E2 distribution across time and as a function 
of treatment formulation in whole blood and uterine horns. 
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Figure 33. Tritiated E2 distribution in whole blood and uterine horns. (A) Tritiated 
E2 distribution across time in whole blood and uterine horns with Treatment A (free E2) 
and Treatment C formulations. E2 appears to be rapidly cleared from whole blood but 
sustained at the uterine horns with both treatments (B) Tritiated E2 distribution across 
time in frontal cortex, dorsal hippocampus, and uterine horns with Treatment A (free E2) 
and Treatment C formulations. E2 uptake in dorsal hippocampus is greater relative to 
uterine horns 0.5 hr following intranasal administration with Treatment C as compared to 
Treatment A. Data are presented as mean ± SEM. 
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Figure 34. Weekly body weights. (A) Average weekly body weight for each treatment 
group throughout the duration of the study. Ovx, treatment initiation, and behavior 
initiation are noted on the graph. (B) Average body weight for weeks 1-4 of the study, 
prior to treatment initiation. (C) Average body weight for weeks 5-10 of the study, after 
treatment initiation, where E2-containing treatment groups exhibited lower average body 
weight than respective vehicle control groups. Data are presented as mean ± SEM. *p < 
0.05.  
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Figure 35. Water radial-arm maze performance on the acquisition phase. (A) RM 
errors made on the acquisition phase between E2-containing treatment groups and groups 
that did not contain E2, showing a main effect of E2. (B) RM errors made on the 
acquisition phase across the four treatment groups, where the free E2 group made less 
errors than its vehicle control, saline-PEG. Data are presented as mean ± SEM. **p < 
0.01, *p < 0.05.  
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Figure 36. Water radial-arm maze performance on the asymptotic phase. (A) 
Estrogen by vehicle interaction for WMI errors made on the asymptotic phase. (B) 
Estrogen by vehicle interaction separated into four graphs, showing that the E2-CD group 
made more WMI errors than the free E2 group and than the saline-CD group. (C) Trial by 
estrogen by vehicle interaction for WMI errors made on the asymptotic phase, where an 
estrogen by vehicle interaction was observed on Trial 4, the highest working memory 
load trial evaluated on the task. (D) Trial 4 estrogen by vehicle interaction separated into 
four graphs, showing that the E2-CD group tended to make more WMI errors than free 
E2 group and made more WMI errors than saline-CD group. Data are presented as mean 
± SEM. **p < 0.01, *p < 0.05, #p < 0.1.  
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Figure 37. Uterine horn weights. Free E2 and E2-CD treatment had greater uterine horn 
weight than their respective vehicle controls, saline-PEG and saline-CD, confirming E2 
presence at the uterine horns. E2-CD had increased uterine horn weight relative to free 
E2, suggesting greater uterine horn exposure to E2 with the addition of the CD carrier. 
Data are presented as mean ± SEM. ****p < 0.0001, **p < 0.01.  
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Figure 38. Summary of cognitive and uterine effects across the E2-containing 
formulations evaluated in the present dissertation. Uterine horn weight for each E2-
containing formulation across all chapters – Chapter 2 (green bars), Chapter 3 (orange 
bars), Chapter 4 (blue bars), and Chapter 5 (pink bars). The dose of E2, regimen and type 
of treatment administration, as well as dose of Levo and type of vehicle are depicted on 
the x-axis. Above the bar for each E2-containing formulation, a green check-mark 
indicates improved spatial learning and memory relative to vehicle control, a brown null 
sign indicates neutral effects on spatial learning and memory relative to vehicle control, 
and a red ‘x’ denotes impaired spatial learning and memory relative to vehicle control. 
For reference, average uterine horn weights for all evaluated vehicle controls were 
between 0.135 – 0.184 g. Data are presented as mean ± SEM. 
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APPENDIX A 
 
ESPRESSO MARTINI 
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ESPRESSO MARTINI 
Ingredients 
1 shot Vodka 
¼ shot Simple syrup 
¼ shot Kahlua 
½ shot espresso 
Garnish: coffee bean 
 
Instructions 
Combine the ingredients, shake with ice, and strain into a cocktail glass. Place a coffee 
bean on top as garnish. 
